| Date |
Subject |
Media |
| 2026-06-01 |
Gene on Link Partners with California’s RFC to Advance Precision Reproductive Testing
|
Economic Daily News |
| 2026-06-01 |
TTY Biopharm Hits Record Highs in 2025 with EPS of NT$6.28
|
Investor |
| 2026-06-01 |
IBMI Marks 30th Anniversary: Expanding into a Strategic Investment Platform for Biotech
|
Economic Daily News |
| 2026-06-01 |
UnicoCell Advances into Southeast Asia: Exosomes Secure Cosmetic Notification in the Philippines
|
Economic Daily News |
| 2026-06-01 |
Inventec Medical Subsidiary "Inventec Appliances" Identifies Three Growth Pillars in Smart Healthcare
|
MoneyDJ |
| 2026-06-01 |
ScinoPharm Receives TFDA Approval for Multiple Myeloma Drug Bortezomib
|
Economic Daily News |
| 2026-06-01 |
Lotus Pharma Completes Asset Transfer for 4 Products in Vietnam; Sales to Commence in Q1 2026
|
Economic Daily News |
| 2026-05-28 |
NTU Hospital Yunlin Branch Launches High-End Hybrid OR to Drive Regional Medical Upgrading
|
Economic Daily News |
| 2026-05-28 |
Pet Pharm Biotech to Invest NT$1.5B in New Miaoli Radiopharmaceutical Plant
|
Economic Daily News |
| 2026-05-28 |
Orient Europharma Partners with Japan’s Dermatology Leader Maruho to Target Hyperhidrosis Market
|
Investor |
| 2026-05-28 |
Bora Pharmaceuticals Secures US FDA Approval for Restasis® Generic; USL to Lead Launch
|
Commercial Times |
| 2026-05-28 |
AI-Driven Transformation: BioMed Firms Accelerate Drug Discovery and Aesthetics
|
Economic Daily News |
| 2026-05-28 |
Balancing Industrial Growth with Health Equity: Lessons for Taiwan’s Healthcare Strategy
|
United Daily News (Taiwan) |
| 2026-05-28 |
NCCN Grants Category 1 Status to PharmaEssentia’s Ropeg for Essential Thrombocythemia (ET)
|
Commercial Times |
| 2026-05-28 |
StemCyte Receives US Government Grant Extension Through 2027 for Multi-Ethnic Cord Blood Program
|
Investor |
| 2026-05-28 |
Ministries of Environment and Health Convene Joint Committee to Protect Vulnerable Populations
|
Economic Daily News |
| 2026-05-28 |
TaiGen Biopharmaceuticals Licenses Flu Candidate Pixavir to Boryung for South Korean Market
|
Economic Daily News |
| 2026-05-28 |
Formosa Pharmaceuticals to Relaunch Ophthalmic New Drug BICOVI in the US; Targets 50% Market Share
|
Investor |
| 2026-05-28 |
HealthConn Advances Microbial Diagnostics with New "Reflex" Laboratory in Taichung
|
Investor |
| 2026-05-26 |
Lin BioScience (Belite Bio) Completes Enrollment for LBS-008 Phase II/III DRAGON II Trial for Stargardt Disease
|
Economic Daily News |
| 2026-05-26 |
SciVision Biotech Secures Kuwaiti Sales License for Hyaflex™ Joint Injections
|
Economic Daily News |
| 2026-05-26 |
Gongwin Biopharm Reports Breakthrough Clinical Results for Equine Oncology at WEVA 2026
|
Commercial Times |
| 2026-05-26 |
Taiwan Extends Hospital Accreditation Validity to 6 Years; Smart Healthcare and Workplace Quality to be Integrated
|
China Times |
| 2026-05-26 |
Microbiome Breakthrough: Gut Metabolite "Acetate" Predicts Liver Cancer Immunotherapy Success
|
The Liberty Times |
| 2026-05-26 |
Synmosa to Launch Japan’s First-in-Class IBAT Inhibitor for Chronic Constipation in Q2
|
Economic Daily News |
| 2026-05-26 |
NTU Hospital Yunlin and NHRI Establish "Southern Bio-Innovation Base" for Medical Resilience
|
Economic Daily News |
| 2026-05-26 |
Bora Pharmaceuticals Triggers "Triple Engine" Growth Strategy for 2026
|
Investor |
| 2026-05-26 |
T-E PHARMA Targets 2026 Emerging Stock Listing with 5 Major Clinical Milestones
|
Commercial Times |
| 2026-05-26 |
Diamond Biotechnology Recognizes €2M Milestone; 2026 Set as "Harvest Year" for Global Expansion
|
Investor |
| 2026-05-25 |
Heron Neutron Medical and Siemens Healthineers Partner to Build AI-Driven "Theranostics" Platform for AB-BNCT
|
Economic Daily News |
| 2026-05-25 |
EverFortune.AI Secures World’s First FDA PCCP Approval for Radiotherapy AI "Seg Pro V3"
|
Commercial Times |
| 2026-05-25 |
Flat Medical Achieves European Breakthrough: EpiFaith® Secures UK NHS Tender and Entry into France’s Largest Hospital System
|
National Innovation Award |
| 2026-05-25 |
TaiRx Biopharma Advances to "Operating 3.0"; IPO Application Set for H2
|
MoneyDJ |
| 2026-05-25 |
Taiwan’s Biotech Sector Sees Three-Pronged Growth Driven by Key Market Themes
|
Commercial Times |
| 2026-05-25 |
Allogeneic CAR-T and Exosomes Drive Growth: Ever Supreme Bio Tech Reports Strong FY2025 Earnings
|
Commercial Times |
| 2026-05-25 |
Cross-Border Collaboration: Tucheng & Linkou Chang Gung Hospitals Sign MOU with Hanyang University (Korea)
|
Commercial Times |
| 2026-05-25 |
Ever Fortune.AI (EFAI) to Increase Stake in EverBot Technology; FDA Milestone Achieved
|
Economic Daily News |
| 2026-05-25 |
NTU Cancer Center Leadership Transition: Liver Transplant Authority Wu Yao-ming Assumes Presidency
|
United Daily News (Taiwan) |
| 2026-05-25 |
PharmaEssentia Invests NT$1.45 Billion in Puerto Rico Plant to Bolster U.S. Supply Chain
|
Commercial Times |
| 2026-05-25 |
Abnova’s RNA Platform Targets Nipah Virus (NiV) Vaccine Development
|
Commercial Times |
| 2026-05-25 |
Taipei VGH and Philips Taiwan Expand Strategic Clinical Innovation Framework
|
Economic Daily News |
| 2026-05-25 |
SECOM and Taipei VGH Launch AI Medical Resilience Initiative
|
anue |
| 2026-05-25 |
StemCyte-KY Targets H1 Listing Driven by Three Major Catalysts
|
Commercial Times |
| 2026-05-25 |
OBI Pharma Reports Clinical Trial Setback for Hematologic Cancer Drug
|
Economic Daily News |
| 2026-05-25 |
Intech Biopharm Partners with Top 10 Global Generic Giant for U.S. MDI Market
|
Economic Daily News |
| 2026-05-25 |
aetherAI Pursues Platform Strategy in Pathology AI; CEO Yeh Highlights Institutional Maturity as Key to Commercialization
|
Commercial Times |
| 2026-05-25 |
Second-Generation CAR-T Expected for NHI Coverage in 2026; MOHW Evaluates Advancing to Second-Line Therapy
|
PTS NEWS |
| 2026-05-25 |
Anji Technology Cuts into Military and Medical 3D Printing via NCSIST Technology Licensing
|
MoneyDJ |
| 2026-05-22 |
BRIM Biotechnology Reports Major Clinical Progress; Breakthrough Success in Compassionate Use Cases
|
Economic Daily News |
| 2026-05-22 |
TWi Biotechnology’s AC-203 Clears Interim Analysis; DSMB Recommends Full Enrollment for Rare Skin Disease Trial
|
Commercial Times |
| 2026-05-22 |
PharmaEssentia Reports Near 50% YoY Revenue Growth in January
|
Commercial Times |
| 2026-05-22 |
TCI Co. Revenue Up 12%; Subsidiary Maxigen Biotech Grows by 7.9%
|
Economic Daily News |
| 2026-05-22 |
Chlitina-KY Reports 117% Revenue Jump; Cautiously Optimistic for 2026
|
Economic Daily News |
| 2026-05-22 |
Strong Market Demand Drives "January Surge" for Biotech Stocks
|
Commercial Times |
| 2026-05-22 |
NT$50 Billion "Healthy Taiwan" Initiative Launches: Medical AI Providers Secure Five-Year Order Backlog
|
Economic Daily News |
| 2026-05-22 |
Oncology Authority Dr. Yen Chia-jui Appointed Deputy Director-General of the NHIA
|
China Times |
| 2026-05-22 |
Grape King Bio Sets January Record with 58.65% Growth in Contract Manufacturing
|
Commercial Times |
| 2026-05-22 |
Contact Lens "Big Three" Report Strong January Revenue; Vizionfocus Sets New Record
|
Investor |
| 2026-05-22 |
Advantech Accelerates Edge AI and Server Deployment to Drive Vertical Applications in Healthcare and Robotics
|
MoneyDJ |
| 2026-05-22 |
CMUH and Ever Supreme Launch "EXO 001" In Vivo CAR-T Platform
|
Economic Daily News |
| 2026-05-22 |
TaiMed Biologics Advances Long-Acting HIV Trials and Enters US$400 Billion Autoimmune Market
|
Commercial Times |
| 2026-05-22 |
Catcher Technology Reports Growth Driven by Medical Segment; Strategic Expansion into Vietnam
|
Commercial Times |
| 2026-05-21 |
Mixed January Performance Among Pharmaceutical "Big Three": Bora, Lotus, and PharmaEssentia
|
Commercial Times |
| 2026-05-21 |
AcadeMab Biomedical Enters Critical Phase for AM-928; Plans Phase II Combination Therapy
|
Commercial Times |
| 2026-05-21 |
Catcher Technology Invests in Niche Biomedical to Expand into Neuromodulation
|
Economic Daily News |
| 2026-05-21 |
Heron Neutron Medical Secures TFDA Approval for F18 FBPA Clinical Trial and Joins MSCI Small Cap Index
|
Investor |
| 2026-05-21 |
Formycon and Lotus Pharmaceutical Ink Exclusive Licensing Deal for FYB206 to Target Asia-Pacific Market
|
Commercial Times |
| 2026-05-21 |
XTALPI Delivers Multi-Million RMB Robotic AI Laboratory to South Korea’s JW Pharmaceutical
|
PR Newswire |
| 2026-05-19 |
NTUH Plans Transition to "Same-Day Surgery" Models for Specialized Procedures to Minimize Overnight Nursing Burdens
|
United Daily News (Taiwan) |
| 2026-05-19 |
Intai Technology Advances Surgical Robotics Validation; Significant Progress Anticipated in H2 2026
|
MoneyDJ |
| 2026-05-19 |
Compal Subsidiary Aco Healthcare Partners with NTUH to Deploy Handheld Ultrasound, Slashing Diagnostic Lag by 1,353 Minutes
|
MoneyDJ |
| 2026-05-19 |
Massive Shake-Up in Q1 2026 Biopharma EPS Rankings: Contact Lens Leaders Dominate as Legacy CDMO Giants Drop Out of Top 10
|
Economic Daily News |
| 2026-05-19 |
Gut-Brain Axis Innovation: Drosophila-Based Screening Platform Paves Way for Neuroprotective Probiotics
|
National Innovation Award |
| 2026-05-19 |
Biotech IPO Wave Peaking in Q2 2026; Over 20 Listings Expected This Year Driven by Favorable Policy
|
Economic Daily News |
| 2026-05-19 |
Taiwan Activates 23 "Core Care Hospitals" to Reconstruct Epidemic Resilience and Triage Infrastructure
|
United Daily News (Taiwan) |
| 2026-05-19 |
Bora Pharmaceuticals Secures Multibillion-New-Taiwan-Dollar Manufacturing Pact with Top 20 Global Pharma; US Maple Grove Facility to Lead Production
|
Investor |
| 2026-05-19 |
JelloX Biotech Penetrates U.S. Healthcare Core with "3D Digital Pathology"
|
United Daily News (Taiwan) |
| 2026-05-19 |
Foresee Pharmaceuticals Reports Dual Success: CAMCEVI Global Expansion and FP-001 Phase III Victory
|
Commercial Times |
| 2026-05-19 |
Institutional Investors Bullish on Global Life Sciences Outlook Driven by Three Core Engines
|
Commercial Times |
| 2026-05-19 |
Hanchor Bio’s HCB101 Granted U.S. FDA Orphan Drug Designation for Gastric Cancer
|
Economic Daily News |
| 2026-05-19 |
Oneness Biotech’s Bonvadis Receives Marketing Authorization in Colombia
|
Economic Daily News |
| 2026-05-19 |
Japan MHLW Approves PharmaEssentia’s High-Dose Ropeg Regimen
|
Economic Daily News |
| 2026-05-19 |
2026: The
|
China Times |
| 2026-05-19 |
GlycoNex to Launch New Biosimilar Project in Q2 Targeting Psoriasis and Autoimmune Markets
|
Investor |
| 2026-05-19 |
Formosa Pharmaceuticals Partners with Arrotex to Enter Australia and New Zealand Ophthalmic Markets
|
Economic Daily News |
| 2026-05-19 |
Anxo Pharmaceutical Transfers Five Drug Licenses to Synmosa for Upfront and Milestone Payments
|
Economic Daily News |
| 2026-05-19 |
Bora Pharmaceuticals Upgrades Chungli Plant to Bonded Factory Status to Boost CDMO Export Momentum
|
Commercial Times |
| 2026-05-19 |
Genomics Leader Genomics BioSci Receives TWSE Approval for Innovation Board Listing
|
Economic Daily News |
| 2026-05-19 |
Health2Sync Integrates with Korean Giants iSens and Handok to Deepen Digital Health Footprint
|
Economic Daily News |
| 2026-05-19 |
Lotus Pharma (Alvogen) Secures Global Rights for Solaxa’s SCA27B Orphan Drug in $95M Deal
|
Investor |
| 2026-05-19 |
Standard Chemical & Pharmaceutical Group Maintains Dominance as Taiwan’s Most Profitable Pharma Conglomerate
|
Commercial Times |
| 2026-05-19 |
AVerMedia Expands "Physical AI" to Humanoid Robotics for Commercial Deployment
|
Investor |
| 2026-05-12 |
TaiMed Biologics: Trogarzo Exports from South Korea Remain Duty-Free Amid U.S. Tariff Shifts
|
Commercial Times |
| 2026-05-12 |
Lotus Pharmaceutical Submits U.S. NDA for Oncology 505(b)(2) Candidate LP757
|
Commercial Times |
| 2026-05-12 |
Intech Biopharm Secures First Nasal Spray Drug License in Taiwan for Fixed-Dose Combination
|
Investor |
| 2026-05-12 |
WeLeader Biomedical Reports Record Financial Growth Amid Diagnostic Sector Expansion
|
Commercial Times |
| 2026-05-12 |
NTU Hospital Unveils AI Liquid Biopsy for Pancreatic Cancer with Over 93% Accuracy
|
United Daily News (Taiwan) |
| 2026-05-12 |
PharmaEssentia Files for South Korean ET Drug License; Eyes Five-Country Launch by 2026
|
Economic Daily News |
| 2026-05-12 |
Orient Pharma and Generic Giant Cipla Ink Commercial Deal to Launch Third P4 Drug in the U.S.
|
Economic Daily News |
| 2026-05-12 |
Ever Supreme Bio Technology Reports Steady Revenue Growth and Clinical Breakthroughs in CAR-T and Exosomes
|
Economic Daily News |
| 2026-05-12 |
Chlitina-KY (CHLITINA) Posts EPS of $7.13; Proposes 8.8% Cash Dividend Yield
|
The Liberty Times |
| 2026-05-12 |
StemCyte Launches Global Expansion of Innovative "Public Bank Protection Service" in the U.S. Market
|
IBMI |
| 2026-05-11 |
PharmaEssentia Reports Record Earnings: 2025 EPS Hits $13.64 with Landmark Dividend Payout
|
Commercial Times |
| 2026-05-11 |
NaviFUS Deploys in Europe to Accelerate Brain Tumor Clinical Translation
|
Commercial Times |
| 2026-05-11 |
Center Laboratories Hits 7-Year High with EPS of $12.33; Focuses on High-Barrier Manufacturing
|
NOWNEWS |
| 2026-05-11 |
Bonraybio Reports Record EPS of $4.13; Pivots to "AI-Powered Fertility Science"
|
Commercial Times |
| 2026-05-11 |
IBMI Elects 8th Board of Directors: Academician Pan-Chyr Yang Succeeds Chi-Huey Wong as President
|
Economic Daily News |
| 2026-05-11 |
Meribank Biotech Partners with AHEAD Intelligence and Apexcella Biomedical to Standardize Allogeneic NK Cell Therapy
|
anue |
| 2026-05-11 |
Grape King Posts 2025 EPS of $8.22; Strong OEM/ODM Momentum Offsets Retail Headwinds
|
Commercial Times |
| 2026-05-10 |
StemCyte-KY Enters China Market via Hainan Pilot to Accelerate REGENECYTE Commercialization
|
Investor |
| 2026-05-07 |
Google Partners with NHIA to Launch World-First "AI Health Network" in Taiwan
|
Economic Daily News |
| 2026-05-07 |
Tanvex-KY Completes CDMO Integration; Revenue Jumps 10-Fold Post-Bora Merger
|
Commercial Times |
| 2026-05-07 |
PharmaEssentia Revenue Surges 56% in February; Ropeg Poised for Multi-Country ET Approval
|
Economic Daily News |
| 2026-05-07 |
TCM Biotech Int’l to Launch $132 IPO; Pivots to Non-Antibiotic Treatment for Recurrent UTI
|
NOWNEWS |
| 2026-05-07 |
Taiwan Cabinet to Bolster Drug Resilience; MOEA Proposes 25% Tax Credit for Essential Medicine
|
Economic Daily News |
| 2026-05-07 |
Taiwan Biotech Accelerates Global Anti-Epidemic and AI Diagnostic Footprint
|
Commercial Times |
| 2026-05-07 |
Savior Lifetec Challenges for Global Leadership in Ertapenem; Targets 20% Growth in 2026
|
Economic Daily News |
| 2026-05-07 |
Bioteque Reaches New Heights in 2025; TPU Catheter Margins Hit 70%
|
Investor |
| 2026-05-06 |
Taiwan Biotech Posts Strong 2025 Earnings; "Eye-Sector" and Standard Chemical & Pharmaceutical Group Emerge as Top Performers
|
Commercial Times |
| 2026-05-06 |
"Beauty Economy" Resilient: Chlitina-KY Revenue Surges 23% on Franchise and Digital O2O Success
|
Commercial Times |
| 2026-05-06 |
BioGend Therapeutics Receives Class II Medical Device License for "Stromal Vascular Fraction" System
|
Investor |
| 2026-05-06 |
StemCyte Expands "Public Bank Protection Plan" into Southeast Asia via Malaysia Partnership
|
IBMI |
| 2026-05-06 |
Bora Pharmaceuticals Secures $264 Million Order Book; Recovery Underway After Temporary Dip
|
Commercial Times |
| 2026-05-06 |
Foresee Pharmaceuticals Revenue Jumps 111% on CAMCEVI Royalties and Supply Growth
|
Commercial Times |
| 2026-05-06 |
Elixiron Immunotherapeutics Partners with CUORiPS to Optimize iPSC Regenerative Medicine
|
Commercial Times |
| 2026-05-06 |
Lotus Pharmaceutical Reports 132% Revenue Surge in February Following Alvogen Integration
|
Economic Daily News |
| 2026-05-05 |
President Lai Hosts 28th National Biotechnology and Medical Care Quality Awards; RBMP Pushes for SNQ Global Alignment
|
IBMI |
| 2026-05-05 |
Johnson Chemical Posts EPS of $1.19; Moves Closer to Acquisition of Genovate Biotechnology
|
Investor |
| 2026-05-05 |
Synmosa Reports Record Profits; Targets Double-Digit Growth via "Triple-Track" Strategy
|
Investor |
| 2026-05-05 |
Bora Pharmaceuticals Posts 2025 EPS of $23.90; CDMO Revenue Surges 53%
|
Economic Daily News |
| 2026-05-05 |
Qisda Deepens Medical and AI Integration to Accelerate High-Value Transformation
|
MoneyDJ |
| 2026-05-05 |
TaiDoc Reports EPS of $15.12; Board Authorizes NT$450 Million Share Buyback
|
Investor |
| 2026-05-04 |
Lotus Pharmaceutical Posts 2025 EPS of $18.14; Seven Consecutive Years of Double-Digit Growth
|
Economic Daily News |
| 2026-05-04 |
Global Expansion Milestone: Oneness Biotech’s "Bonvadis" Secures CE Mark for All 27 EU Member States
|
IBMI |
| 2026-05-04 |
M&A Bombshell: Easywell Biomedicals to Acquire Genovate Biotechnology via Share Swap, Creating a Taiwan-US Dual-Base Powerhouse
|
Commercial Times |
| 2026-05-04 |
InnoCare Optoelectronics Hits 3-Year Profit Peak; EPS Reaches $3.84 on Global "Glocalization"
|
Economic Daily News |
| 2026-05-04 |
Handa Pharmaceuticals Profits Double in 2025; EPS Hits Record High of $4.85
|
Investor |
| 2026-05-04 |
The Next "Biotech Gold Mine": Taiwan’s Radiopharmaceutical Supply Chain Targets $55.8 Billion Global Market
|
Commercial Times |
| 2026-05-04 |
Medeon Biodesign Secures US FDA Approval for Urocross; Sets Sights on $1 Billion Licensing Deal
|
Economic Daily News |
| 2026-04-27 |
Obigen Pharma Advances: OBI-858 Completes Phase III Enrollment Ahead of Schedule
|
Economic Daily News |
| 2026-04-27 |
Taiwan Mobile Partners with Lydsec and Biomdcare to Deploy AI SOAP Systems at Changhua Hospital
|
Economic Daily News |
| 2026-04-27 |
IEAT, IBMI, and FETA Sign Landmark MOU to Forge New Biomedical Export Platform
|
ETtoday |
| 2026-04-27 |
IBMI: Building an Integrated Platform for Medicine, Industry, and Capital to Accelerate Global Innovation
|
Economic Daily News |
| 2026-04-27 |
TCM Biotech’s "CatCHimera" Platform Granted US FDA Breakthrough Device Designation
|
Commercial Times |
| 2026-04-27 |
Medigen Vaccine Biologics Secures Vietnam’s First EV71 Vaccine Approval; Sets Export Milestone
|
Commercial Times |
| 2026-04-27 |
Formosa Pharmaceuticals Receives Canadian Approval for APP13007 to Treat Post-Operative Inflammation
|
Economic Daily News |
| 2026-04-27 |
EirGenix Launches Breast Cancer Biosimilar EG12014 in Europe; Slovakia Named First Commercial Market
|
Investor |
| 2026-04-27 |
Shin Kong Security Partners with Shinsoft to Secure Digital Healthcare Environments
|
The Liberty Times |
| 2026-04-27 |
Formosa Laboratories Hits Milestone: First ANDA Approval Marks Entry into US Finished Dose Market
|
Commercial Times |
| 2026-04-27 |
Lotus Pharmaceutical Targets 65-80% Revenue Surge Driven by Alvogen Synergy and New Launches
|
Investor |
| 2026-04-27 |
Breakthrough in Nursing Education: Tri-Service General Hospital Debuts "Smart Sensing Arm" with AI Precision Monitoring
|
National Innovation Award |
| 2026-04-26 |
ScinoPharm Advances "Triple-Core" Strategy; Focuses on High-Value Drug-Device Combinations
|
Commercial Times |
| 2026-04-26 |
T-E Pharma Debuts Sublingual GLP-1 Breakthrough; A New Weapon in Global Weight Management
|
Economic Daily News |
| 2026-04-26 |
Easywell Biomedicals & Genovate Biotechnology Merger: Chairman Predicts Revenue Doubling Within 5 Years
|
MoneyDJ |
| 2026-04-26 |
Bora Pharmaceuticals: Global M&A Market Rebounds; CDMO Giant Ready for New Acquisitions
|
MoneyDJ |
| 2026-04-26 |
Taichung Veterans General Hospital Innovates "Protect & Warm" Mittens to Enhance Geriatric Pulse Oximetry Accuracy
|
National Innovation Award |
| 2026-04-26 |
YesChain Launches "Pharmacy 5.0" to Build Next-Gen Community Health Hubs
|
Commercial Times |
| 2026-04-26 |
TaiMed Biologics Reports Accelerated Enrollment for HIV Long-Acting Combo TMB-365/380
|
Investor |
| 2026-04-26 |
Creative Life Science Hits 3-Year Profit High; Targets 2026 IPO Listing
|
Investor |
| 2026-04-14 |
AP Biosciences Set for IPO Application; Core Assets Enter Critical Licensing Phase
|
Investor |
| 2026-04-14 |
Heron Neutron Medical Establishes Southeast Asia’s First Accelerator-Based BNCT Research Center
|
Economic Daily News |
| 2026-04-14 |
TaiGen Biopharmaceuticals Partners with Insilico Medicine for AI-Driven CKD Anemia Drug
|
China Times |
| 2026-04-14 |
EirGenix/Sandoz Trastuzumab Biosimilar Faces Setback in U.S. Due to Manufacturing Defects
|
Investor |
| 2026-04-14 |
TCI Co., Ltd. Invests NT$830 Million to Deepen North American Manufacturing
|
Commercial Times |
| 2026-04-14 |
National "Biomedical Data Team" to Form on Dec 20; Yang Pan-chyr Appointed Chairman
|
Economic Daily News |
| 2026-04-14 |
TaiGen’s Pixavir Fluromarboxil Approved in China; Targets RMB 10 Billion Market
|
Economic Daily News |
| 2026-04-14 |
CHC Healthcare Group Sees Strong Q4 Performance Driven by Equipment Cycles
|
China Times |
| 2026-04-14 |
TSH Biopharm Aims to Double Annual Revenue via Four Strategic Engines
|
Commercial Times |
| 2026-04-11 |
Lotus Pharmaceutical Reports 14% Growth in Asian Operations Despite FX Headwinds
|
NOWNEWS |
| 2026-04-11 |
Super-Aged Society: Focus on AI to Drive "Healthy Taiwan"
|
Commercial Times |
| 2026-04-11 |
Milestone Payment Secured as Licensing Partner Completes GMP Validation for Anya Biopharm
|
MoneyDJ |
| 2026-04-11 |
Localization of BNCT: Heron Neutron Medical Partners with Canada’s ACSI for Technology Transfer
|
Investor |
| 2026-04-11 |
InnoZone Special Exhibit: 130 Biomedical Research Achievements Drive Industrial Linkage and Commercialization
|
National Innovation Award |
| 2026-04-11 |
Microsoft Fabric Integrates with Local Data Centers; TBMC Builds Real-World Data Platform
|
TechNews |
| 2026-04-11 |
PharmaEssentia Completes First FDA Meeting for ET; On Track for 2026 Approval
|
Commercial Times |
| 2026-04-11 |
Bora Pharmaceuticals Subsidiary Expands Footprint in Mainland China
|
Commercial Times |
| 2026-03-31 |
Adimmune Subsidiary Enimmune Partners with Thermo Fisher for Allergy Markets
|
Economic Daily News |
| 2026-03-31 |
Taipei Veterans General Hospital (TVGH) Showcases AI and Robotics: Mapping the Future Healthcare Blueprint
|
Health Media Now |
| 2026-03-31 |
Pharmosa BiopharmInitiates Global Phase 3 for L606: Superior Data Accelerates Dual Indications
|
Commercial Times |
| 2026-03-31 |
Handa Pharmaceuticals to List on Mainboard Dec 23; Dual Engines Drive Profit Growth
|
Investor |
| 2026-03-31 |
Immunwork Completes Clinical Trial for Obesity Drug: Demonstrates Safety and Efficacy
|
Commercial Times |
| 2026-03-31 |
Taiwan Healthcare+ Expo Integrates with Global Markets
|
Commercial Times |
| 2026-03-31 |
Taiwan’s SNQ Certification Goes Global, Setting Asia-Pacific Standards with ICHOM
|
IBMI |
| 2026-03-31 |
Gongwin-KY Becomes First Taiwan-Listed Firm in China’s Commercial Insurance Innovative Drug Catalog
|
Economic Daily News |
| 2026-03-31 |
OBI Pharma’s OBI-902 Secures Second U.S. FDA Orphan Drug Designation for Gastric Cancer
|
Investor |
| 2026-03-31 |
Taiwan’s "AI Medical Team" Debuts: 35 Hidden Champions from Three National Science Parks
|
Sanlih E-Television News |
| 2026-03-24 |
ASUS Unveils "Maestro" Command Center: Shaping the Healthcare 4.0 Ecosystem
|
MoneyDJ |
| 2026-03-24 |
NCKU Hospital: A Strategic Roadmap for Smart Inpatient and Senior Care
|
ETtoday |
| 2026-03-24 |
BenQ/Qisda "Medical Fleet": Leading the Silver Economy with AI
|
MONEY LINK |
| 2026-03-24 |
President Lai: Three Strategic Pillars Mark the Golden Age for Taiwan's Medical Technology
|
Economic Daily News |
| 2026-03-24 |
Chairman Wong Chi-huey: AI and Robotics to Lead the Next Wave of Global Healthcare
|
Commercial Times |
| 2026-03-24 |
Historic Czech Procurement: NT$7.4 Billion Deal Signed at Healthcare+ Expo
|
Economic Daily News |
| 2026-03-24 |
MEDTEX Forum: Global VCs Converge on Taiwan’s Biotech Pipeline
|
Commercial Times |
| 2026-03-24 |
NYCU Hospital Unveils Smart Precision Medicine Achievements at Healthcare+ Expo
|
United Daily News (Taiwan) |
| 2026-03-23 |
Hualien Tzu Chi Hospital Shares "East-West Integrated Precision Health" Milestones
|
yam.com |
| 2026-03-23 |
Beiley biofund to List on Emerging Stock Market: A Specialized "Active ETF" for Biotech
|
The Liberty Times |
| 2026-03-23 |
BenQ Medical Launches AI-Integrated Rehabilitation System (IQMR)
|
MoneyDJ |
| 2026-03-23 |
ASUS Scales Smart Healthcare: Building an AI Robotics Ecosystem
|
Commercial Times |
| 2026-03-23 |
Bora Pharmaceuticals Targets U.S. Rare Disease and Epilepsy Markets
|
Economic Daily News |
| 2026-03-23 |
Belite Bio’s Lead Candidate Tinlarebant Succeeds in Phase 3; NDA Expected in H1 2026
|
Commercial Times |
| 2026-03-23 |
PSMC Founder Frank Huang Backs BGM-2121: World-First PTHrP Target Enters Ph1 Trials
|
Economic Daily News |
| 2026-03-08 |
Taiwan Healthcare+ Expo Reaches Record Scale: Medical Robotics and AI Take Center Stage
|
Commercial Times |
| 2026-03-08 |
Medigen Vaccinology (United Biopharma) Expands HIV Drug into Russian Market
|
Economic Daily News |
| 2026-03-08 |
EMS Giants Flex "Smart Healthcare" Muscles: Foxconn, Quanta, and Compal Target Multi-Billion Market
|
Commercial Times |
| 2026-03-08 |
GBC (General Biologicals) Accelerates Dual Engines: 2026 Revenue Growth Projected at 20%
|
Commercial Times |
| 2026-03-08 |
United Orthopedic Chairman Lin Yen-sheng: 2024 Revenue Projected to Grow 20%; Kaohsiung Plant II Project Initiated
|
Economic Daily News |
| 2026-03-08 |
AUO to Showcase "Beyond 3D, Precision AI" at 2025 Taiwan Healthcare+ Expo
|
Economic Daily News |
| 2026-03-08 |
Heron Neutron Medical Collaborates with Europe’s Cosylab to Drive Global AB-BNCT Expansion
|
Economic Daily News |
| 2026-03-08 |
Acer Medical Secures TFDA Approvals for Three AI Innovations Ahead of Healthcare Expo
|
Investor |
| 2026-03-08 |
President Lai Outlines Three Pillars for a "Healthy Taiwan"
|
Commercial Times |
| 2026-03-08 |
Lotus Pharmaceutical: 2025 Targets Intact; Alvogen US Acquisition to Close by Year-End
|
Investor |
| 2026-03-08 |
TTY Biopharm’s "Three Arrows" Strategy Drives Double-Digit Growth Forecast
|
Economic Daily News |
| 2026-03-08 |
Pegavision: 2026 Revenue to Challenge Double-Digit Growth
|
Economic Daily News |
| 2026-03-08 |
Mycenax Biotech Partners with Three Major Japanese Firms to Secure Domestic Biologics Supply Chain
|
Commercial Times |
| 2026-03-08 |
Pharmasaga to List on Emerging Stock Market: Targeting Diabetes Reversal with PS1
|
Economic Daily News |
| 2026-03-08 |
Visco Vision Forecasts Positive Q1 2025 Growth Following Capacity Expansion
|
Commercial Times |
| 2026-03-08 |
Chi Mei Medical Center and Cisco Launch Strategic AI Healthcare Partnership
|
Investor |
| 2026-03-08 |
Qisda Medical Sector Charges Forward: 2025 Revenue Projected to Surpass NT$30 Billion
|
Economic Daily News |
| 2026-03-08 |
Taipei Veterans General Hospital Outperforms Japan in Heavy Ion Therapy for Pancreatic Cancer
|
United Daily News (Taiwan) |
| 2026-03-08 |
Lotus Pharmaceutical Receives Regulatory Approval for Alvogen US Acquisition
|
Investor |
| 2026-03-08 |
TaiDoc Targets 5-10% Growth in 2026, Fueled by CGM and Multi-Parameter Monitors
|
Investor |
| 2026-03-08 |
Everbright Biofund: Catalyzing Research Commercialization with Initial Focus on AI Drug Discovery
|
Commercial Times |
| 2026-03-08 |
CHC Healthcare Group Breaks Ground on Integrated Long-Term Care Park
|
Commercial Times |
| 2026-03-08 |
HanchorBio: Aiming for Innovation Board Listing in Q2 2025 with Lead CD47 Candidate
|
Commercial Times |
| 2026-03-08 |
Obigen Pharma to Join Emerging Stock Market: Targeting the Global Botulinum Toxin Market
|
Commercial Times |
| 2026-03-08 |
AlleyPin and Weleader Biomedical: Redefining Clinic-Based Diagnostics
|
Commercial Times |
| 2026-03-08 |
Handa Pharmaceuticals to List on Main Board: Target for 505(b)(2) Oncology Drug Approval in 2025
|
Economic Daily News |
| 2026-03-08 |
Global Biomedical Outlook: The Golden Age of AI Drug Discovery
|
Commercial Times |
| 2026-03-08 |
Bridging Biotech Innovation to Global Ecosystems: Taiwan’s Strategy in the AI Healthcare Race
|
Commercial Times |
| 2026-01-15 |
Looking Ahead to Global Biomedical Innovation: Six Major Biotech Investment Giants Gather at MEDTEX
|
Commercial Times |
| 2026-01-15 |
Looking Ahead at Global Biomedical Innovation: The Next Biomedical Breakthrough: Microscopic Medical Robots Open a New Era of Non-Invasive Medicine
|
Commercial Times |
| 2026-01-15 |
PharmaEssentia’s ET Drug Set for Market Launch Next Year; Following Taiwan Plant, Company to Invest Over NT$15 Billion in New U.S. Facility in the First Half of Next Year
|
Economic Daily News |
| 2026-01-15 |
SHAREHOPE MEDICINE Fully Advances Healthy Taiwan Initiative, Building Operational Momentum for Next Year
|
China Times |
| 2026-01-15 |
PharmaEngine’s First-Line Pancreatic Cancer Therapy and GNTbm’s New Breast Cancer Drug Approved for NHI Reimbursement, Effective Next Month
|
Investor |
| 2026-01-15 |
Elixiron Immunotherapeutics Targets Emerging Stock Market Listing by Year-End, to Launch Phase II Vitiligo Trial in the Second Half
|
Investor |
| 2026-01-15 |
Startup Update | Chronic Disease AI Smart Healthcare Platform Health2Sync to List on the Emerging Stock Market Today
|
National Innovation Award |
| 2026-01-15 |
Jensen Huang Has Also Invested in It: AI Drug Discovery Startup Iambic Shares Proprietary Technology at the Asia Medical Technology Innovation Forum
|
Commercial Times |
| 2026-01-15 |
LAGIS to List on the TPEx in Mid-December, Multiple Growth Engines Target Double-Digit Growth Next Year
|
Investor |
| 2026-01-15 |
GNTbm’s Breast Cancer Drug Kepida Granted National Health Insurance Reimbursement, Effective December 1
|
Money-link |
| 2026-01-15 |
Genomics Wins Nine LDT Approvals in One Go, Targeting the US$100 Billion Genetic Testing Market
|
Economic Daily News |
| 2026-01-15 |
MedTex 2025 to Debut on December 3, Bringing Six Global Capital Giants and Ten Leading International Biotech Startups to Taiwan
|
Economic Daily News |
| 2026-01-14 |
Foresee Pharmaceuticals Grants Global Exclusive License of MMP-12 to Related Party QPS, with Total Deal Value and Milestones Up to US$584 Million
|
Investor |
| 2026-01-14 |
Biotech Stocks Post First-Three-Quarter Earnings; Top 10 Rankings See Major Shake-Up, with This Stock Retaining EPS Crown at NT$21.34
|
Commercial Times |
| 2026-01-14 |
OBI Pharma’s New Drug Granted Orphan Drug Designation in the U.S.
|
Economic Daily News |
| 2026-01-14 |
DR.WU SKINCARE Posts Q3 EPS of NT$2.47 as Non-Operating Income Rebounds, Returning to Profitability for the Quarter
|
Economic Daily News |
| 2026-01-04 |
Global Pharmaceutical Supply Chain Reshaped: Adimmune Chairman Highlights Industry Resilience and Accelerates International GMP Capacity Expansion
|
Investor |
| 2026-01-04 |
TCI Launches Biotech 2.0 Plan with Asset-Light, Distributed Strategy
|
Commercial Times |
| 2026-01-04 |
CDIB Capital Group’s Biotech Fund CEO Wu Hsin-Fang: Strategic Alliances Key to Seizing Opportunities
|
Economic Daily News |
| 2026-01-04 |
Bora Pharmaceuticals Reports Q3 EPS of NT$5.09; Board Approves Share Buyback
|
Economic Daily News |
| 2026-01-04 |
Tanvex BioPharma Narrows Loss in First Three Quarters; Q3 Revenue Hits Record with Boost from Biosimilars Launch
|
Commercial Times |
| 2026-01-04 |
Senhwa Biosciences Teams Up with CancerFree Biotech to Leverage Tumor Avatar Platform for New Drug Development
|
MoneyDJ |
| 2026-01-04 |
DARWIN PRECISIONS and AUO Partner with Tungs' Taichung Metroharbor Hospital to Launch a New Era of Smart Elderly Rehabilitation
|
Economic Daily News |
| 2026-01-04 |
EirGenix Strikes Second Breast Cancer Biosimilar Deal with Sandoz, Total Signing and Milestone Payments Reach US$152 Million
|
Investor |
| 2026-01-04 |
Synmosa Biopharma Reports EPS of NT$1.28 for First Three Quarters of 2025
|
Economic Daily News |
| 2026-01-04 |
Silicone Hydrogel Products Drive Growth, PEGAVISION Expands Capacity—Daxi Plant to Target 30 Million Units per Month Next Year
|
Investor |
| 2026-01-04 |
BONRAYBIO Surpasses Last Year’s Full-Year Profit in First Three Quarters, EPS 2.93, 2026 Outlook Remains Strong
|
Investor |
| 2026-01-04 |
Foresee Pharmaceuticals’ CAMCEVI Hits Record Sales, Multiple Clinical Programs Progress
|
Commercial Times |
| 2026-01-04 |
Smart Healthcare Takes Off! FAR EAST MEDICAL ELECTRONICS TECHNOLOGY to List on TPEx’s Emerging Stock Board, AI Strength Expands into Medical Cloud and Telehealth
|
anue |
| 2026-01-04 |
Lotus Pharmaceutical’s Blood Cancer Drug Hits Annual Sales Peak; October Revenue Reaches Second-Highest Record
|
Investor |
| 2026-01-04 |
WeLeader Biomedical Infuses New Momentum in Q3; Quarterly Revenue Hits Record, Driving Profit Growth
|
Economic Daily News |
| 2026-01-04 |
Bora Pharmaceuticals’ Revenue Up 6.57% in First Ten Months; North American Manufacturing to Drive Future Growth
|
Commercial Times |
| 2026-01-04 |
BIOTEQUE Q3 Gross Margin Shines, EPS 1.98 Hits Yearly High, Q4 Revenue Expected to Remain Stable
|
Investor |
| 2026-01-04 |
Taiwan Biomaterial Q3 Gross Margin Rises, Core Business Profit Quadruples, EPS 0.68 Surpasses H1 Earnings
|
Investor |
| 2026-01-04 |
Multiple International Medical Institutions Form Delegations to Visit Taiwan for the First Time
|
Commercial Times |
| 2026-01-04 |
Healthcare Expo Taiwan to Spark Global Procurement Surge
|
Commercial Times |
| 2025-12-21 |
Medigen Vaccine Biologics Corporation Plans NT$870 Million Expansion of Vaccine Production Lines and Fundraising to Target Global Markets
|
Commercial Times |
| 2025-12-21 |
CHLITINA HOLDING LIMITED Reports 30% Profit Growth in Q3, Strong Momentum Heading Into Year-End Peak Season
|
Commercial Times |
| 2025-12-21 |
HanchorBio Appoints Alvin Ying-Ming Luk as President and Chief Medical Officer to Accelerate Global Development and BD Licensing of Innovative Therapies
|
Economic Daily News |
| 2025-12-21 |
PharmaEssentia to Advance Five New Drug Candidates into Clinical Trials in 2026; Partners with TBMC to Enter the Cell Therapy Field
|
Anue |
| 2025-12-21 |
Dual Growth Engines: Anxo Pharmaceutical Targets 85 New Drug Approvals Over the Next Five Years
|
Commercial Times |
| 2025-12-21 |
Medimaging Integrated Solution Licenses Disposable Bronchoscope to U.S. Medical Distributor; Product Officially Launched in the United States
|
Investor |
| 2025-12-21 |
Andros Pharmaceuticals Completes NT$170 Million Capital Increase to Accelerate Clinical Trials and Business Development
|
Commercial Times |
| 2025-12-21 |
SHUI-MU International Advances Dual Growth Strategy in Health Promotion and Better Living; Aims to Lift High-Margin Service Contribution
|
MoneyDJ |
| 2025-12-21 |
Pharmosa Biopharm’s Long-Acting Inhaled Therapy L606 Reports Positive Phase III Results, Accelerating Entry Into a NT$100 Billion Market
|
China Times |
| 2025-12-16 |
PharmaEssentia Reports Record-High Operating Profit, Net Income, and EPS in Q3; First Three Quarters’ Earnings Nearly One Full Share Capital
|
Economic Daily News |
| 2025-12-16 |
StemCyte Launches World’s First “Cord Blood Assurance Service” in Partnership with Taiwan Life Insurance, Pioneering a New Regenerative Medicine Model
|
Commercial Times |
| 2025-12-16 |
PEGAVISION Posts Double Growth in October Revenue, Surpasses NT$702 Million, Ranking Third Highest in History
|
Investor |
| 2025-12-16 |
PharmaEngine Posts Q3 Profit High for the Year as Proprietary Anti-Cancer Drugs Progress in Clinical Trials
|
MoneyDJ |
| 2025-12-16 |
Ever Supreme Posts NT$111.13 Million Revenue in October, Up 22% Month-on-Month and 12% Year-on-Year, Setting Historical High for the Period
|
Economic Daily News |
| 2025-12-16 |
AI Wearable Devices Combined with Telemedicine Enable Real-Time Health Monitoring in Long-Term Care Centers
|
China Times |
| 2025-12-13 |
[RBMP/IBMI Commentary] The Structural Loophole in Shorting Biotech Stocks: When Financial Tools Trump Innovation Value
|
IBMI |
| 2025-12-13 |
DARWIN PRECISIONS’ New Factory Goes into Mass Production, Biomedical Business Set to Take Off Next Year
|
Commercial Times |
| 2025-12-13 |
PharmaEssentia’s Ropeg Files for US ET Approval, Targeting 2026 Authorization
|
Commercial Times |
| 2025-12-13 |
Lin BioScience’s Belite Gains UK Approval to Submit Conditional Marketing Authorization Based on Interim Analysis Results
|
Investor |
| 2025-12-13 |
AI-Assisted Precision Triage Supports Emergency Department Flow, Ministry of Health Pushes for Integrated Health Data
|
United Daily News (Taiwan) |
| 2025-12-13 |
Acer Subsidiary Altos Partners with Repurgenesis to Build High-Performance AI Drug Development Platform
|
MoneyDJ |
| 2025-12-13 |
TAHO Pharmaceuticals’ TAH3311 Officially Submits European Drug Application, First Orally Dissolvable Apixaban Film Targets Global Anticoagulant Market
|
Commercial Times |
| 2025-12-13 |
Fubon-Backed StemCyte Aims for IPO, First Foreign Company Filing for Taiwan Listing This Year
|
Economic Daily News |
| 2025-12-13 |
Mobisnet Technology: From Tax Systems to Smart Hospitals, 100% Taiwanese Robots Go Global
|
IBMI |
| 2025-12-13 |
Anxo Pharmaceutical Licenses ADHD Drug to South Korea’s WhanIn Pharm to Capture $60 Million Market Opportunity
|
Economic Daily News |
| 2025-12-13 |
AnHorn Medicines’ AI-Designed Drug AH-001 Completes U.S. Phase I Trial, Demonstrates Excellent Safety and Tolerability
|
Research Center for Biotechnology and Medicine Policy, RBMP |
| 2025-12-13 |
Tanvex BioPharma Targets Year-End Revenue as Cipla Expands Market Share
|
MoneyDJ |
| 2025-12-13 |
Chang Gung Memorial Hospital Completes 339 Fecal Microbiota Transplant Treatments, Launches “Gut Microbiome Whole-Genome Analysis” Technology
|
TechNews |
| 2025-12-13 |
PEGAVISION Reports Q3 EPS of NT$15.38, Order Visibility Extends to Q1 2026 with Positive Outlook
|
Economic Daily News |
| 2025-12-13 |
Pharmosa Biopharm’s L606 Achieves Positive Long-Term Phase III Data in the U.S.; Global PH-ILD Phase III Trial to Commence
|
Investor |
| 2025-12-13 |
Hospital Builds Its Own Nursing Robot! China Medical University Leads × EverBot Technology Develops “Healthcare Sovereignty AI”
|
IBMI |
| 2025-12-13 |
PuriBlood Medical Partners with Utah Medical to Upgrade Pet Healthcare and Expand Global Reach
|
Commercial Times |
| 2025-12-13 |
Acer Medical × FIG × Fujitsu Launch AI Exercise Assessment App to Promote Health-Oriented Insurance
|
Commercial Times |
| 2025-12-13 |
Primo Biotechnology Partners with GE Healthcare to Develop Radiopharmaceuticals
|
Commercial Times |
| 2025-12-13 |
Bora Pharmaceuticals Achieves Milestone as U.S. Injectable Facility Enters Commercial Production
|
Economic Daily News |
| 2025-12-09 |
Anxo Pharmaceutical’s Oral ARA Achieves Taiwan’s First Generic Approval, Set for Market Launch in H1 2026
|
Investor |
| 2025-12-09 |
Hon Hai Advances Smart Healthcare in Partnership with Taipei Veterans General Hospital
|
Commercial Times |
| 2025-12-09 |
3D GLOBAL BIOTECH Establishes Cell GMP Facility in the U.S., Launching Taiwan-U.S. Dual-Core Strategy
|
Commercial Times |
| 2025-12-09 |
“Taiwan Medical Shield” Sparks Multi-Billion-Dollar Opportunity, Boosting Local Vaccine and Diagnostic Industries
|
Economic Daily News |
| 2025-12-09 |
Emergency Room’s New Hero Assistant: Robot Dog – MacKay Memorial Hospital Teams Up with Ubitus to Deploy AI in Complex Medical Settings
|
IBMI |
| 2025-12-09 |
AnnJi Pharmaceutical’s Rare Disease Drug AJ201 Granted Fast Track Designation by U.S. FDA
|
Commercial Times |
| 2025-12-09 |
HERON NEUTRON MEDICAL Launches Taiwan–Japan BNCT Collaboration with University of Tsukuba
|
Commercial Times |
| 2025-12-09 |
SYSCOM COMPUTER ENGINEERING Teams Up with ASIA OPTICAL to Launch Fully MIT-Made Intelligent Nursing Robot
|
The Liberty Times |
| 2025-12-09 |
WHO Lists Adimmune’s AdimFlu-S Influenza Vaccine, Tetanus Vaccine, and Enimmune’s Enterovirus Vaccine in Its Full Vaccine Product List
|
Economic Daily News |
| 2025-12-09 |
Medimaging Integrated Solution Sees Strong Q4 Outlook as Cystoscope Shipments Gain Momentum as a Second Growth Driver
|
Investor |
| 2025-12-08 |
RiTdisplay Enters the Biomedical Sector, Launches Low-Temperature Plasma Platform to Lead Medical Manufacturing
|
Commercial Times |
| 2025-12-08 |
Taiwan University Launches AI and Advanced Biomedical Research Centers to Integrate Industry–Academia Resources and Strengthen Global Collaboration
|
United Daily News (Taiwan) |
| 2025-12-08 |
Hon Hai Invests NT$3 Billion in Computing Power to Build a Nursing Robot: A 3+3+3 Strategy Beginning at the Nursing Station
|
IBMI |
| 2025-12-08 |
UNIVERSAL CEMENT Enters AI Robotics Electronic Skin Market with U.S. Tekscan Acquisition via Subsidiary
|
Economic Daily News |
| 2025-12-05 |
YUNG ZIP CHEMICAL Expects H2 Recovery Amid U.S. Tariff Spillover and Short-Term Competitive Pressure
|
Investor |
| 2025-12-05 |
U.S. Manufacturing, Regenerative Medicine, and Booming Aesthetic Market Boost Bora, Lotus, and Other Biotech Stocks
|
Commercial Times |
| 2025-12-05 |
Qisda Completes Capital Reduction; Continues M&A to Expand European Presence
|
MoneyDJ |
| 2025-12-05 |
TaiMed Biologics Scores in Saudi Arabia as HIV Drug Receives Orphan Drug Designation
|
Investor |
| 2025-12-05 |
Lin BioScience’s Subsidiary Belite’s New Drug for Stargardt Disease Granted NMPA Priority Review
|
Commercial Times |
| 2025-12-05 |
AmCad BioMed Expands into Turkey, Extends Cardiology Applications, Signs Exclusive Distribution Agreement
|
NOWNEWS |
| 2025-12-05 |
Trump Raises Acetaminophen Safety Concerns; SINEW PHARMA’s SafeTynadol Targets New Market for Pain Relief During Pregnancy
|
Commercial Times |
| 2025-12-05 |
TWi Biotechnology’s Postpartum Depression Drug to Read Out Phase II This Quarter; Receives U.S. FDA Type C Meeting Minutes
|
anue |
| 2025-12-01 |
KIM FOREST ENTERPRISE Partners with GeneASIC and Israel’s Geneyx to Usher in the “45-Minute Genetic Health Scan” Era
|
Investor |
| 2025-12-01 |
Lin BioScience Subsidiary Belite Receives Approval to Submit NDA in China Following Positive Interim Results for STGD1 Trial
|
Investor |
| 2025-12-01 |
Asia University Signs MOU with NucleicAI to Build AI-Powered Health Data Ecosystem
|
Commercial Times |
| 2025-12-01 |
Great Tree and Protect Animal Health Form Alliance to Capture Taiwan’s Pet Market Worth Hundreds of Billions
|
Commercial Times |
| 2025-12-01 |
HanchorBio’s Anti-Cancer Drug HCB101 Shows Promising Clinical Data, Targets International Licensing and Innovation Board Listing Next Year
|
Economic Daily News |
| 2025-12-01 |
PharmaEssentia Completes Pen Injector sBLA Filing, Aims for FDA Approval by February Next Year
|
Investor |
| 2025-12-01 |
CHC Healthcare Group Posts September Revenue of NT$527 Million, Up 86% Month-on-Month and 9.1% Year-on-Year; First Three Quarters Revenue Hits Record High
|
Economic Daily News |
| 2025-12-01 |
SciVision Biotech Expands Further into Russian Aesthetics Market with Approval of Next-Generation Regenerative Injectables
|
Investor |
| 2025-12-01 |
Minister without Portfolio Shih Chung Chen: “National Infectious Disease Biobank” to Be Completed Next Year, Advancing the Three Arrows of Taiwan’s Biotech Development
|
Economic Daily News |
| 2025-12-01 |
Smart Ageing Tech Announces Major Strategic Partnership: Compal Healthcare & Technology to Merge, Accelerating Global Expansion and Capital Market Development
|
Jubo |
| 2025-11-30 |
Licensing Revenue Boosts HanchorBio’s September Revenue to NT$312 Million
|
Commercial Times |
| 2025-11-30 |
Heron Neutron Medical to Invest US$30 Million in BenQ Medical Group to Deepen Collaboration in the China Market
|
Investor |
| 2025-11-30 |
Rising CDMO Demand Spurs Expansion at Tanvex BioPharma and EirGenix
|
Commercial Times |
| 2025-11-30 |
Onyx Healthcare’s September Revenue Surges; Three-Growth Engines Drive Momentum as Q4 Targets Annual Peak
|
Investor |
| 2025-11-30 |
47 Drugs Withdrawn from Taiwan Market; TFDA Chief Chih-Kang Chiang Assures Clinical Supply Unaffected, Proposes Law Amendment to Mandate Shortage Reporting
|
United Daily News (Taiwan) |
| 2025-11-30 |
Global Pharmaceutical Market Reshuffle Brings Dual Benefits for Taiwanese Firms
|
Economic Daily News |
| 2025-11-30 |
NTU Yunlin Branch Inaugurates Organ Transplantation Medical Center, Advancing Toward Medical Center-Level Care Capacity
|
TAIWAN NEWS |
| 2025-11-30 |
Adimmune Subsidiary Enimmune Signs Exclusive Sales Agreement with Indonesia’s ETANA for Enterovirus Vaccine, Expanding Its ASEAN Presence
|
Investor |
| 2025-11-29 |
Tanvex BioPharma Reports Record September Revenue of NT$84.86 Million, a 39-Fold Year-on-Year Increase; Q3 Revenue Surpasses NT$100 Million for the First Time
|
Economic Daily News |
| 2025-11-29 |
Medeon Biodesign’s Urology Device Achieves New Milestone as Urocross Retrieval Sheath Receives U.S. FDA Clearance
|
Commercial Times |
| 2025-11-27 |
TTY Biopharm Expands Hematologic Oncology Portfolio with Selinexor, the World’s First Oral Selective Nuclear Export Inhibitor, Adding a New Growth Engine from October
|
Investor |
| 2025-11-26 |
PAHSCO’s Q3 Revenue Hits Record High, Up Over 7% Year-on-Year
|
Commercial Times |
| 2025-11-26 |
Bonraybio Reports NT$26.21 Million in September Revenue, Up 36% Year-on-Year; First Three Quarters Revenue Surges 40%, Surpassing Full-Year 2023 Total
|
Economic Daily News |
| 2025-11-26 |
HCMED INNOVATIONS and Aerogen Form Global Strategic Partnership in Nebulization Therapy
|
Economic Daily News |
| 2025-11-14 |
Mycenax Biotech Plans to Establish Joint Venture in Japan with Four Strategic Partners
|
Commercial Times |
| 2025-11-14 |
Lotus Pharmaceuticals Signs Licensing and Supply Agreement with Adalvo for GLP-1 Generic Injectable
|
MoneyDJ |
| 2025-11-14 |
PharmaEssentia Posts NT$1.32 Billion in September Revenue, Up 3.4% MoM and 41% YoY; First Nine-Month Revenue Surpasses NT$10 Billion
|
Economic Daily News |
| 2025-11-14 |
Pei-Zen Chang Appointed as Next President of Industrial Technology Research Institute
|
The Liberty Times |
| 2025-11-14 |
Silicon Photonics Won’t Be Limited to AI: Taiwan Equipment Makers Eye Potential Opportunities in Network Communications
|
WEALTH MAGAZINE Biweekly |
| 2025-11-14 |
FSC Chairman Jin-Lung Peng to Announce Taiwan’s “Asian Nasdaq” Plan on October 20
|
United Daily News (Taiwan) |
| 2025-11-14 |
Cheng Hsin General Hospital Introduces Photon-Counting CT to Address Four Major Cardiac CT Diagnostic Challenges, Advancing Smart Healthcare
|
United Daily News (Taiwan) |
| 2025-11-01 |
Ever Supreme Bio Technology Completes $1.7 Billion Acquisition of Shine Out Biotechnology to Enter Exosome Drug Development
|
Economic Daily News |
| 2025-11-01 |
Genovate Biotechnology Launches Private Placement to Introduce Strategic Partners, Accelerates Three Major Projects for International Market Entry
|
Economic Daily News |
| 2025-11-01 |
TAIGEN Signs New Drug Licensing Agreement, Officially Enters Vietnam Market
|
Commercial Times |
| 2025-11-01 |
Handa Pharmaceuticals Submits FDA New Drug Application for Cancer 505(b)(2) Candidate HND-039
|
Investor |
| 2025-11-01 |
TAHO Pharmaceuticals’ New Oral Antithrombotic Film TAH3311 Files NDA in the U.S., Targeting Market Launch Next Year
|
Economic Daily News |
| 2025-11-01 |
Leading Argentine Hospital Group Controls 90% of Medical Device Procurement, Sees Strong International Competitiveness of Taiwanese Products
|
Healthcare+ Expo Taiwan |
| 2025-11-01 |
Cancer Treatment Upgraded: National Health Insurance to Cover 10 New Drugs Starting October, Benefiting Over 2,000 Patients
|
United Daily News (Taiwan) |
| 2025-11-01 |
Anxo Pharmaceutical Flags Its Pulmonary Fibrosis P4 Generic Drug in the Middle East as FDA Accepts ANDA Review
|
MoneyDJ |
| 2025-11-01 |
NTU-Derived Startup ImmunAdd Raises NT$450 Million in Oversubscribed Funding Round
|
Commercial Times |
| 2025-11-01 |
Drug Tariff Storm: Cancer Drugs Likely to Bear the Brunt
|
China Times |
| 2025-11-01 |
Pharmosa Biopharm Presents Phase I Results of L608 at European Respiratory Society, Highlighting New Opportunities for CTEPH Treatment
|
Economic Daily News |
| 2025-11-01 |
From Pharmaceuticals to Contact Lenses and ICT Biomedicine: M&A Boom Exposes Global Strategies of Lotus Pharmaceutical, Handa, and TWi Biotechnology
|
Commercial Times |
| 2025-11-01 |
Startup Breakthrough: Surface Hydrogenation Technology Addresses Pain Points in Metal Implant Market
|
National Innovation Award |
| 2025-11-01 |
NT$680 Million Capital Injection Secures Funding, HanchorBio Accelerates Multiple New Drug Developments
|
Investor |
| 2025-11-01 |
EVER FORTUNE AI TECHNOLOGY Launches Care Robot to Capture NT$50 Billion Market Opportunity
|
Commercial Times |
| 2025-11-01 |
Tanvex BioPharma’s Biosimilar Now Launched in the U.S. Market
|
Economic Daily News |
| 2025-11-01 |
PET Pharm Biotech Applies for Innovative Board Listing, Becomes Eighth Company This Year to Submit Application
|
Economic Daily News |
| 2025-11-01 |
Chunghwa Telecom Partners with Taipei Veterans General Hospital to Integrate AI Applications and Establish Next-Generation 5G Medical Network Demonstration Site
|
Economic Daily News |
| 2025-11-01 |
U.S. FDA Grants Exemption, EirGenix Terminates Phase III Trial of EG1206A
|
Economic Daily News |
| 2025-11-01 |
National Health Insurance Total Budget Hits First “Home Run” in 23 Years; Primary Care Clinics Urge More Support for Chronic Disease Prevention
|
The Liberty Times |
| 2025-11-01 |
Taichung Municipal Hospital Begins Trial Operations with Medical Center-Level Care and Affordable Registration Fees
|
The Liberty Times |
| 2025-11-01 |
Demand-Driven Products Create New Opportunities for Acer Medical
|
Commercial Times |
| 2025-11-01 |
TaiRx Launches Own Health Supplement Brand to Build a Second Revenue Stream
|
MoneyDJ |
| 2025-11-01 |
Lotus Pharmaceutical’s $20 Billion Acquisition of Alvogen US Secures Spot Among Top 20 Global Specialty Pharma Companies
|
Economic Daily News |
| 2025-10-27 |
Alar Pharmaceuticals Targets Pet Pain Medication Market, Aims for Local Drug Approval by Year-End While Pursuing Overseas Licensing
|
Investor |
| 2025-10-26 |
“Startup Dynamics” Tackles Respiratory Disease Treatment Bottlenecks: ITIH4 Protein Drug Technology Hopes to Break Through in 2025
|
National Innovation Award |
| 2025-10-26 |
REGimmune Becomes First Japanese Biotech to List in Taiwan, Targets OTC Market in First Half of Next Year
|
Commercial Times |
| 2025-10-26 |
CHLITINA-KY’s Shift from “Expansion” to “Quality Improvement” Strategy Shows Results, Optimistic Outlook for Peak Season in H2
|
Investor |
| 2025-10-26 |
Shine-On Biomedical Targets US$1 Billion Early Licensing Deals with Two Core Technology Platforms, Eyes IPO Next Year
|
Economic Daily News |
| 2025-10-26 |
Taiwanese Scientist Liang-Kung Chen Tops Global Rankings for Sixth Consecutive Year
|
United Daily News (Taiwan) |
| 2025-10-26 |
Smart Healthcare on the Rise: ICT Giants Race to Seize New Business Opportunities
|
Economic Daily News |
| 2025-10-25 |
Innovation in Endoscopy: AI-Powered Imaging Device Breaks Diagnostic Bottleneck for Colonoscopy
|
National Innovation Award |
| 2025-10-25 |
PharmaEssentia Files for Japanese Approval of Ropeg for Essential Thrombocythemia; Market Launch Expected in Q3 2026 Targeting 30,000 Patients
|
Economic Daily News |
| 2025-10-25 |
Taiwan’s Medical Device Output Reaches US$30 Billion — Tzu Hsien Tung Calls for Greater Development to Ease Semiconductor Export Pressure
|
Economic Daily News |
| 2025-10-25 |
SciVision Biotech Secures Russian Approval for Flexotron Tendon Intra-Articular Injection; Revenue Contribution Expected by Q4
|
Investor |
| 2025-10-25 |
Qisda Accelerates Expansion in Smart Healthcare Market
|
Economic Daily News |
| 2025-10-25 |
HanchorBio’s HCB101 Reaches Value Inflection Point; Mid-Dose Data in Second-Line Gastric Cancer Fuels International Licensing Momentum
|
Investor |
| 2025-10-25 |
International Integrated Systems Expands Smart Healthcare Initiatives, Accelerates Development in Primary Care and Long-Term Care Applications
|
MoneyDJ |
| 2025-10-25 |
TWi Biotechnology Completes U.S. Phase II Enrollment for Postpartum Depression Drug, to Announce Top-Line Results in Q4 2025
|
Economic Daily News |
| 2025-10-25 |
Chang Gung Medical System and Merck & Co. Expand Collaboration to Strengthen Clinical Scale Across Multiple Therapeutic Areas
|
Economic Daily News |
| 2025-10-23 |
Senhwa Biosciences’ CX-5461 Partners with Global Pharma Giants’ PD-1 Drug, Entering the $100 Billion Immunotherapy Market
|
Investor |
| 2025-10-23 |
National Mental Health Department Promotes Policies from Early Prevention to Recovery-Oriented Care to Enhance Taiwan’s Overall Mental Health System
|
United Daily News (Taiwan) |
| 2025-10-23 |
Shuttle Launches New AI PC; Medical Device Subsidiary Carilex Expands into Global Markets
|
MoneyDJ |
| 2025-10-22 |
BioGend’s Bone Growth Factor Shows Positive Phase I/II Clinical Results in Taiwan and the U.S.; Phase III Trials and Global Licensing to Advance Concurrently
|
Investor |
| 2025-10-22 |
Heron Neutron Medical Lists on Taiwan Stock Exchange Under Fubon Securities’ Guidance
|
Commercial Times |
| 2025-10-22 |
Synmosa Biopharma Launches Public Tender Offer for 15–30% Stake in Genovate Biotechnology with 30% Premium, Shaking Up Taiwan’s Established Pharma Sector
|
Commercial Times |
| 2025-10-22 |
Industrial Technology Research Institute Honors Five New Fellows, Spanning Semiconductors, Healthcare, and Engineering
|
China Times |
| 2025-10-22 |
IBMI Delegation Visits 11 Key Institutions in Dubai Over Six Days to Deepen Bilateral Collaboration
|
IBMI |
| 2025-10-22 |
Formosa Biomedical Technology Leads the Formosa Group’s Drive for Innovation and Strategic Alliances
|
Commercial Times |
| 2025-10-22 |
Seven Biotech Leaders Report Breakthrough Successes Amid Favorable Regulatory Momentum
|
Commercial Times |
| 2025-10-22 |
ScinoPharm Taiwan Reports Record-High August Revenue Driven by Alzheimer’s Drug Manufacturing Orders
|
Investor |
| 2025-09-20 |
Taiwan’s Top Medical Experts Impress Dubai, Meet DHA to Explore Collaboration Models
|
IBMI |
| 2025-09-20 |
SciVision Biotech Expands into Russia, Reports Strong Progress
|
Commercial Times |
| 2025-09-20 |
PHARMOSA BIOPHARM Partner Liquidia Announces Full-Scale Development of L606, Targeting Dual Indication Approval
|
Investor |
| 2025-09-20 |
Shine-On BioMedical Licenses Exosome Drug Technology to Global Biopharma ESCO for NT$200 Million Plus 5% Sales Revenue Share
|
Economic Daily News |
| 2025-09-20 |
IBMI Delegation Meets TVM Capital and Dubai Chambers, Achieves Success in WHX B2B Business Matching
|
IBMI |
| 2025-09-20 |
Bora Pharmaceuticals’ August Revenue Declines Over 20%, Generic Drug Orders Gradually Recovering
|
Investor |
| 2025-09-20 |
Lotus Pharmaceutical’s Asian Business Grows 16% in First Eight Months, Expects Double-Digit Growth for Hematologic Cancer Drugs This Year
|
Commercial Times |
| 2025-09-20 |
AI-Driven Smart Healthcare: ASUS and Chang Gung Launch New “Healthy Taiwan” Engine
|
anue |
| 2025-09-20 |
Jonney Shih: ASUS AI Brain to Power Multi-Modal Robots
|
Commercial Times |
| 2025-09-20 |
Lin BioScience Subsidiary Belite Completes LBS-008 STGD1 Phase III Trial, Secures NT$8.4 Billion Private Placement
|
Economic Daily News |
| 2025-09-20 |
Camcevi Milestone Boosts Foresee Pharmaceuticals’ August Revenue to NT$142 Million, Second-Highest on Record
|
Commercial Times |
| 2025-09-20 |
Gongwin Biopharm’s China Market Penetration Boosts August Revenue; PTS302 Targets Expanded Indications
|
Investor |
| 2025-09-20 |
IBMI Delegation Arrives in Dubai to Engage Leading Middle Eastern Hospitals and Venture Capital, Opening New Bilateral Collaboration Opportunities
|
IBMI |
| 2025-09-20 |
A New Era in Life-Saving Care! AIoT-Powered Integrated Critical Care System Gives Taipei Ambulances a Golden 6-Minute Advantage
|
China Times |
| 2025-09-20 |
Daiken Biomedical Lists on the Stock Exchange on September 9, Targets Japanese Market Next Year
|
Economic Daily News |
| 2025-09-20 |
ADIMMUNE Production Lines Running at Full Capacity, Partnering with Sanofi and Korean Pharma to Expand Global Markets
|
Commercial Times |
| 2025-09-20 |
Taiwanese Traditional Chinese Medicine Goes Global: Exclusive Interview with Yi-Chang Su on “Leading Medicine with Therapeutics, Driving Agriculture with Medicine”
|
IBMI |
| 2025-09-20 |
PharmaEssentia Records Second-Highest August Revenue, Submits Taiwan ET Indication Application for Ropeg
|
Investor |
| 2025-09-20 |
EirGenix’s Breast Cancer Biosimilar Receives EMA Approval for Post-Marketing Manufacturing Site Change
|
Economic Daily News |
| 2025-09-20 |
Senhwa Biosciences’ CX-5461 to Launch Phase 1b/2 Clinical Trial for MYC-Abnormal Lymphomas with NCI Support
|
Commercial Times |
| 2025-09-19 |
President Lai: NT$10 Billion Investment in Smart Healthcare to Encourage Corporate Innovation and R&D
|
Economic Daily News |
| 2025-09-19 |
Orient Pharma Successfully Challenges Pfizer Patent; Tofacitinib Generic Expected to Launch in U.S. by 2026
|
Commercial Times |
| 2025-09-19 |
Faster Lifesaving Access: Five Key Strategies Driving “Healthy Taiwan”
|
The Liberty Times |
| 2025-09-19 |
TSH Biopharm Launches Taiwan’s First Generic Smoking Cessation Drug to Fill Market Gap, Expected to Hit Market in Q1 2026
|
Investor |
| 2025-09-18 |
Acer Accelerates Healthcare AI Push as Acer Medical Unveils aiMed at IFA
|
Economic Daily News |
| 2025-09-18 |
Innovative Platform and Intelligent Collaboration to Build a National Team for Medical AI
|
Economic Daily News |
| 2025-09-18 |
UTHR’s Nebulized Tyvaso Achieves Success in Expanding to Third Indication, PHARMOSA BIOPHARM’s L606 Poised to Benefit
|
Investor |
| 2025-09-18 |
Advanced Connection Technology Expands into Biomedical Cell Testing, Plans to Develop Exosome-Based Cancer Screening
|
MoneyDJ |
| 2025-09-18 |
BRIM Biotechnology Invests NT$150 Million in Compass Bioinformatics to Seize Precision Medicine Opportunities
|
Commercial Times |
| 2025-09-18 |
Maywufa Group Joint Investor Conference Highlights Diverse Growth Driven by Consumer Products, New Drugs, and Smart Healthcare
|
Economic Daily News |
| 2025-09-18 |
Alar Pharmaceuticals Advances Multiple Pipeline Programs; Pet Osteoarthritis Study and Treatment-Resistant Depression Phase 1 Trial Target Year-End Completion
|
Investor |
| 2025-09-18 |
Panion & BF Biotech Expands Capacity with New Plant; Advances Novel Formulation Drug Pipeline
|
MoneyDJ |
| 2025-09-18 |
Ever Supreme Bio Technology Posts Record August Revenue; Eight-Month Revenue Up 14.3% Year-on-Year
|
Commercial Times |
| 2025-09-18 |
Enimmune’s Enterovirus Vaccine Approved for Process Scale-Up, Strengthening Southeast Asia Market Entry
|
Investor |
| 2025-09-18 |
VIZIONFOCUS’ Multi-Market Expansion Drives H2 Revenue Growth, Full-Year Increase Projected at 10–15%
|
Investor |
| 2025-09-18 |
OBI Pharma Executes 50% Capital Reduction to Offset Losses, Focuses Future on ADC Development
|
Economic Daily News |
| 2025-09-18 |
Biomedical Startups Spark Funding Wave, Eight Companies Raise Over NT$4 Billion
|
Commercial Times |
| 2025-09-11 |
Taiwan’s Big Three Telecom Operators Push into Telemedicine
|
Economic Daily News |
| 2025-09-11 |
Taipei Veterans General Hospital and Gilead Sciences Taiwan Launch Collaboration to Accelerate Innovation in Virology, Inflammatory Diseases, and Oncology
|
United Daily News (Taiwan) |
| 2025-09-11 |
Microsoft Taiwan and Chung Shan Medical University Hospital Launch Generative AI Platform “MedPoint”
|
Commercial Times |
| 2025-09-11 |
UnicoCell Biomed Expands into South Korea’s Regenerative Medicine Market
|
Commercial Times |
| 2025-09-11 |
“Health2Sync’s 8-Week CGM Weight-Loss Program Pioneers Personalized Metabolic Management with Blood Glucose Data”
|
National Innovation Award |
| 2025-09-11 |
Oneness Biotech Reports Strong Weight-Loss Drug Data, Phase I Clinical Trial Planned for Q4
|
Economic Daily News |
| 2025-09-11 |
AI “New Ten Major Infrastructure Projects” Launched with NT$30 Billion in First-Year Funding
|
Commercial Times |
| 2025-09-11 |
Shih Chung-liang Appointed Minister of Health and Welfare, Known for Driving NHI Reforms During Tenure as Director-General
|
United Daily News (Taiwan) |
| 2025-09-11 |
BRIM Biotechnology Advances Four Ophthalmology Drug Candidates as Planned, New Collaboration Deal Expected Soon
|
Investor |
| 2025-09-11 |
TFBS Bioscience Secures Double Win: Virus Manufacturing Order from Korea’s artiCure and Technology Partnership with Japan’s U-medico
|
Commercial Times |
| 2025-09-11 |
ICARES MEDICUS Deepens European Expansion, Targets Doubling Revenue Within 3–5 Years
|
Investor |
| 2025-09-11 |
Heron Neutron Medical Secures First Major Order for BNCT Accelerator System, Sells NT$1.68 Billion Center to Nanjing BenQ Hospital
|
Economic Daily News |
| 2025-09-10 |
Foresee Pharmaceuticals’ Three-Month Prostate Cancer Therapy CAMCEVI Secures FDA Approval
|
Commercial Times |
| 2025-09-10 |
Adimmune Corporation Secures Brazil GMP Certification Again, Paving the Way for Influenza Vaccine Market Entry in the Southern Hemisphere
|
Adimmune Corporation announced yesterday (26th) that it has received official notification from Brazil’s National Health Surveillance Agency (ANVISA) confirming Good Manufacturing Practice (GMP) certification. The company stated that this certification marks a significant milestone in advancing its influenza vaccine registration process in Brazil. Adimmune expects to obtain regulatory approval for its influenza vaccine in Brazil by the end of 2026, enabling its formal entry into the Southern Hemisphere market. |
| 2025-09-10 |
OBI Pharma’s Subsidiary OBIGEN Pharma Reports Positive Phase II Trial Results for Next-Generation Botulinum Toxin; Plans Taiwan Emerging Stock Board Listing by Year-End
|
OBIGEN Pharma, a subsidiary of Taiwan-based OBI Pharma, announced on the 26th that its independently developed next-generation botulinum toxin, OBI-858, has successfully met the primary efficacy endpoint with statistical significance in its first human Phase II clinical trial (OBI-858-002). Two pivotal Phase III trials for OBI-858 have recently been approved by the Taiwan Food and Drug Administration (TFDA). To support international expansion, OBIGEN plans to launch a cash capital increase in the fourth quarter of this year and aims to apply for listing on Taiwan’s Emerging Stock Board before year-end. |
| 2025-09-10 |
BioGend Turns Profit in July; Bone Growth Factor Clinical Trial Results to Be Unblinded in Q3
|
At the corporate briefing on the 25th, BioGend Therapeutics Chairman Te-Li Chen announced that the company’s operations are experiencing rapid growth, with several core technologies entering the harvest stage. Among them, results from the bone growth factor clinical trial will be unblinded in the third quarter, while licensing negotiations for RevoCart are expected to be completed within the year. |
| 2025-09-10 |
Gongwin Biopharm Holdings’ New Lung Cancer Drug Pirotinib (Proxanib) Passes Preliminary Review for China’s “Dual Reimbursement” Drug List
|
Gongwin Biopharm Holdings’ new lung cancer drug Proxanib (PTS-302, Toluene Sulfonyl Urethane Injection) has taken another step forward in entering the Chinese market. On the 25th, the drug successfully passed the preliminary formal review for inclusion in the 2025 National Basic Medical Insurance Drug List in China. Notably, it is among the few drugs that also passed the preliminary formal review for the Commercial Health Insurance Innovative Drug List (“Commercial Insurance List”). According to the company, if the subsequent expert evaluations, negotiation, and pricing discussions proceed smoothly, Proxanib will be formally included in the “dual reimbursement” system, enabling rapid market expansion and potentially driving a significant surge in revenue. |
| 2025-09-10 |
Enimmune’s Kawasaki Disease Diagnostic Software Aims for Market Launch by End of 2026
|
Enimmune Corporation yesterday (25) announced that its AI-powered Kawasaki disease risk assessment software, PEKAN, has successfully completed clinical performance studies at two major medical centers in Taiwan. Results showed that PEKAN demonstrated stable and highly accurate clinical differentiation, with an accuracy rate reaching 90%, laying a solid foundation for AI-based medical device applications in pediatrics. The company is now preparing for regulatory approval under Taiwan’s Medical Device Act as a Class II medical device, with the goal of securing TFDA registration and launching by the end of 2026. Enimmune also plans to accelerate international expansion, initially targeting Asian markets through clinical collaborations and licensing partnerships. |
| 2025-09-10 |
Government to Launch Health Data Service Company with Backing from Tech Giants and Major Medical Centers
|
Wu, Cheng-Wen, Minister without Portfolio of the Executive Yuan, announced yesterday (25) that the government will follow through on the recommendations made during last year’s Biotechnology Industry Strategy and Advisory Council (BTC) meeting and establish a Health Data Service Company this year. This national-level company, combining artificial intelligence (AI) with health data, has already secured support from leading technology firms such as Quanta, Wistron, Catcher Technology, Delta Electronics, Elan Microelectronics, as well as from major medical centers including National Taiwan University Hospital, National Cheng Kung University Hospital, Taipei Veterans General Hospital, and Kaohsiung Medical University Hospital. |
| 2025-09-10 |
TaiMed Biologics Driven by Three Growth Engines; CEO: Major Business Transformation Expected by 2026
|
TaiMed Biologics CEO Jin-Mei Chang said on August 22 that the company is focused on three major growth drivers: rising sales of Trogarzo and expanding CDMO revenues, accelerated Phase II clinical development and licensing of its next-generation HIV therapies TMB-365/TMB-380, and advances in its antibody-drug conjugate (ADC) platform. He projected that 2026 will mark a turning point for the company’s operations. |
| 2025-09-10 |
ABC-KY Posts NT$1 Loss Per Share in H1; New Diagnostic Target Expected to Enter Major Clients by Year-End
|
Applied Biocode Corp. (ABC-KY) reported nearly 30% year-on-year revenue growth in the first half of 2025 but still posted a net loss of NT$103 million, equivalent to a loss of NT$1 per share. Management noted that a leading U.S. molecular diagnostics laboratory will begin adopting more of the company’s flagship products in the second half, alongside phased purchases of multiple MDx3000 fully automated molecular diagnostic systems, expected to provide significant growth momentum. Its new “STI+AMR” (Sexually Transmitted Infections plus Antimicrobial Resistance) assay is currently undergoing testing with three major clients and could enter routine clinical use before the end of the year. |
| 2025-09-10 |
Luo Lih-Fen Holding Q2 Gross Margin Surges, EPS at NT$1.38 Marks 18-Quarter High, Three Channels Drive Strong Outlook for H2
|
Beauty channel operator Luo Lih-Fen Holding (羅麗芬-KY) saw simultaneous growth across its three major sales channels in the first half of the year, driving a sharp rebound in Q2 profitability. Gross margin jumped to 69.61%, up 6 percentage points year-on-year and 9 percentage points quarter-on-quarter, boosting core earnings. Earnings per share (EPS) reached NT$1.38, the highest in 18 quarters. Looking ahead, the company is targeting e-commerce demand during the “Double 11” shopping season, launching three new products under its namesake skincare brand in Q4. Combined with the opening of more community-based stores and seasonal demand in the second half, operations are expected to outperform the first half. |
| 2025-09-10 |
Genomics BioSci & Tech. Chairman Michael Chou Rallies Partners to Drive AI-Powered Drug Development
|
The global boom in AI applications is reshaping the biotechnology and healthcare industries, with AI increasingly being used to accelerate drug discovery and development. This shift has fueled a wave of new strategic alliances. Genomics BioSci & Tech. (Genomics) entered the U.S. market in 2023 through its investment in Wyzer, and in 2024, it raised capital for its subsidiary LAI SHI TE SHENG YI, bringing in strategic investors to speed up new drug development. In July this year, Chairman Michael Chou (周孟賢) personally attended a forum announcing a strategic alliance with BIONET Corp., highlighting his determination to accelerate Genomics’ diversification and global expansion. |
| 2025-09-10 |
Core Business and Non-Operating Gains Boost CHLITINA HOLDING LIMITED’s Q2 EPS to NT$2.62, Up 285% Quarter-on-Quarter
|
CHLITINA HOLDING LIMITED (CHLITINA-KY) reported that thanks to growth in its core business and non-operating financial subsidies totaling RMB 18 million, its Q2 operating profit reached NT$147 million, up 54% quarter-on-quarter. Net profit attributable to the parent company was NT$216 million, representing a 285% quarterly increase, with earnings per share (EPS) of NT$2.62. For the first half of the year, net profit attributable to the parent company totaled NT$272 million, with an EPS of NT$3.3. |
| 2025-09-10 |
TCI’s Asset-Light Expansion Moves into Spain: New Equipment in Place, Tariff Impact Eases, H2 Performance Set to Strengthen
|
Vincent Lin, Chairman of TCI, stated yesterday (21st) that the company has successfully entered the top three global pharmaceutical companies, the top three U.S. direct selling companies, and major international internet giants, marking its transformation into a truly global enterprise operating simultaneously across the U.S., Europe, and Asia-Pacific. To support this expansion, TCI is advancing its “asset-light strategy” and is currently evaluating the establishment of a production base in Spain. |
| 2025-09-10 |
Orient Pharma Expands International Footprint with ADHD Drug Push
|
OEP Group’s biotech subsidiary Orient Pharma was listed on the Taipei Exchange on the 21st. Chairman Tsai, Cheng-Hung stated that the company will continue to capitalize on patent expirations and market gaps, leveraging its core technology platforms to build a differentiated product portfolio and enhance global competitiveness. |
| 2025-09-10 |
MAXIGEN BIOTECH Launches U.S. Investment, Targeting Opportunities in Healthy Ageing and Regenerative Medicine
|
MAXIGEN BIOTECH is accelerating its global transformation from a manufacturer to a branded company. General Manager Ching-Ting Chen stated that the company aims to increase its brand-driven revenue contribution from the current 60% to 80% by 2030. This year, it will establish a U.S. subsidiary for business operations, with medium- to long-term manufacturing also planned to move to the United States. |
| 2025-09-10 |
TTY Biopharm’s Three-Pronged Growth Strategy Continues; Second-Half Revenue Expected to Surpass First Half
|
TTY Biopharm posted record-high revenue and operating profit in the first half of 2025, with EPS at NT$2.72. At the company’s investor conference on the 20th, General Manager Sara Hou said TTY’s “three-pronged strategy” continues to advance. Its complex generic drug Lipo-AB is achieving new sales highs in the U.S., shipments of its cell-based influenza vaccine are expected to rise further, and its breast cancer hormone therapy obtained a new second-line combination CDK4/6 indication this July. The company also expects Taiwan’s first domestically developed lung cancer drug to receive approval in the fourth quarter. Over the next three years, three additional products are slated for launch. Analysts expect second-half revenue to exceed the first half, with full-year revenue growth in the high single-digit to double-digit range. |
| 2025-09-10 |
FORMOSA BIOMEDICAL TECHNOLOGY Partners with UWELL Biopharma to Build Next-Generation CAR-T Commercial Production Model
|
Formosa Biomedical Technology, a subsidiary of Formosa Plastics Group, has been diversifying its business in recent years. On the 20th, it jointly announced with UWELL Biopharma a collaboration to advance the clinical development and commercialization of next-generation CAR-T cell therapy. UWELL’s anti-CD19 CAR-T therapy candidate, UWC19, is scheduled to begin a multicenter Phase II clinical trial in the fourth quarter of this year. Formosa Biomedical Technology will leverage its strengths in drug formulation and production to support the effort, aiming to bring Taiwan’s advanced cell therapy industry onto the global stage. |
| 2025-09-10 |
Inventec Appliances Deploys Thousands of Infusion Pumps at Chi-Mei Hospital to Enhance Care Efficiency
|
Inventec Appliances, a subsidiary of the Inventec Group, announced that its SmartMed Infusion System has been officially deployed at Chi-Mei Hospital, making it the first hospital in southern Taiwan to adopt this smart infusion solution. This initiative reflects Chi-Mei Hospital’s proactive approach to smart healthcare development and underscores its strong commitment to clinical medication safety and patient care quality. |
| 2025-09-10 |
Climate Crisis Is a Health Crisis! Chih-Hung Chen: Medical Resilience Cannot Wait
|
The impact of climate disasters on Taiwan is intensifying. Since July, the island has been battered by three consecutive typhoons—Danas, Vipa, and Yangliu—with the coastal regions of Chiayi and Tainan suffering severe agricultural losses and infrastructure damage due to heavy rainfall. Experts warn that this is not only an environmental challenge but also a serious public health crisis. |
| 2025-09-08 |
Polaris Group-KY’s New Drug for Malignant Pleural Mesothelioma Enters FDA Substantive Review; U.S. Distribution Licensing to Accelerate
|
Polaris Group-KY announced that its new drug Pegargiminase (ADI-PEG 20), developed for the treatment of malignant pleural mesothelioma, has officially entered the substantive review stage with the U.S. FDA. This news drove the company’s stock to surge to its daily limit immediately after opening. If the FDA review and the planned U.S. inspection next February proceed smoothly, the drug could receive approval as early as the first half of next year, while discussions on U.S. market distribution licensing are expected to accelerate, potentially being finalized in Q1 2026. |
| 2025-09-08 |
Taipei Veterans General Hospital Breaks Ground on Boron Neutron Capture Cancer Therapy Center; NT$1.2 Billion Investment to Complete in Two Years, Achieving Comprehensive Cancer Treatment
|
Taipei Veterans General Hospital (TVGH) has officially commenced construction of its Boron Neutron Capture Therapy (BNCT) Center, scheduled for completion and operation in 2027 (Year 116 of the Republic of China calendar). Once completed, TVGH will become one of the very few medical institutions worldwide equipped with both heavy-ion therapy and BNCT, offering comprehensive, state-of-the-art radiation oncology capabilities and elevating Taiwan to the forefront of global cancer radiation treatment, education, and research. |
| 2025-09-08 |
Foxconn Technology Group Brings Smart Medical Devices to Market, Partners with NOBEL to Launch CoDoctor Eye
|
Foxconn Technology Group is taking its next step in smart healthcare. Barry Chlang, General Manager of the B Business Group, announced yesterday that the company has partnered with NOBEL Eyewear to launch the CoDoctor Eye fundus photography device. This device reduces the size of traditional 40-kg equipment to just 700 grams, successfully transforming a hospital-bound diagnostic tool into a portable digital health solution, marking a milestone for Foxconn’s smart healthcare products moving from R&D to practical application. |
| 2025-09-08 |
Bora Pharmaceuticals’ SunWay Biotech Invests NT$650 Million in Wonders Company Ltd., Acquires 30% Stake and Board Seat
|
SunWay Biotech, a subsidiary of Bora Pharmaceuticals Group, announced on the 19th that its board of directors has approved a strategic investment in Wonders Company Ltd. With a cash injection of NT$650 million, SunWay will acquire a 30% stake in the company, along with one board seat. The transaction is expected to close in September. |
| 2025-09-08 |
Syncell Partners with Thermo Fisher to Pioneer Breakthrough in Subcellular High-Resolution Spatial Proteomics
|
Biotech startup Syncell announced on the 18th that it has signed a strategic co-marketing partnership with Thermo Fisher Scientific, a global leader in scientific services, to integrate its Microscoop spatial protein purification technology with Thermo Fisher’s Orbitrap Astral mass spectrometry series. The collaboration will deliver a next-generation subcellular high-resolution spatial proteomics solution. |
| 2025-09-08 |
BioGend’s Revocart Wins Hong Kong Medical Device License
|
BioGend Therapeutics announced yesterday (18th) that its cartilage regeneration product Revocart has successfully obtained a medical device license in Hong Kong. The company will now accelerate promotion and sales in Hong Kong, Macau, and China’s Greater Bay Area (GBA). |
| 2025-09-08 |
Lotus Pharmaceutical’s Multiple Growth Engines in Asia and Export Markets Drive Second-Half Momentum; Exchange Rates Pressure Revenue but Margins Remain Intact
|
Specialty generic drugmaker Lotus Pharmaceutical spokesperson Bjartur Shen said at the company’s earnings call on the 15th that exchange rate fluctuations will trim this year’s revenue growth target by about 2–3 percentage points, but margins will remain unaffected. The second-quarter gross margin decline reflected the timing of revenue recognition for the blood cancer drug Lenalidomide, while this year’s peak sales are expected in the fourth quarter. Exports of addiction treatment drugs are likely to rise in the second half due to supply disruptions among competitors. New products such as Nintedanib will begin contributing this year, with larger volumes expected next year. Coupled with successful business integration and M&A progress in Asian markets, the company remains optimistic for the second half. |
| 2025-09-08 |
Injectables/CDMO Becoming Growth Driver, Formosa Laboratories Poised for New Revenue Momentum
|
Formosa Laboratories, a pharmaceutical company that has expanded from active pharmaceutical ingredients (APIs) into injectables, saw its net income after tax turn negative in the first half of the year due to financial asset losses and foreign exchange impacts. However, institutional investors remain optimistic about the company’s tangible benefits from CDMO business expansion and recent certification of its injectable plant. Revenue in New Taiwan dollars is still expected to remain stable year-on-year in 2024, with hopes that, in the medium term, income from CDMO services and injectables will replace APIs as the main growth engine. |
| 2025-09-08 |
Ascension Medical Biotechnology Secures Strategic Investment from Qisda Group, Enters New Growth Phase
|
On August 15, Ascension Medical Biotechnology announced that it has received a strategic investment from Qisda Group. This investment will accelerate the commercialization of Ascension’s technologies, strengthen channel integration through collaboration with Qisda, deepen its footprint in the medical industry, and propel the company into a new stage of growth. |
| 2025-09-08 |
2024 Startup Fundraising Surpasses $100 Million, National Development Fund Aims for NT$150 Billion by 2027
|
The National Development Fund (NDF), leveraging an inter-ministerial integration platform, is actively coordinating with the Ministry of Economic Affairs, the National Science and Technology Council (NSTC), and other agencies to promote innovation and entrepreneurship in Taiwan through three key strategies: “activating capital,” “expanding targets,” and “increasing success rates.” In 2024, Taiwan’s startup fundraising reached US$3.34 billion, surpassing the NT$100 billion mark, with NDF investments accounting for approximately 13.2% of total investment. The NDF aims to achieve NT$150 billion in startup fundraising by 2027. |
| 2025-09-08 |
Foreign Exchange Losses Sweep Through Biotech Sector, but 15 Companies Ride the Wave—Analysts Optimistic One Will Earn More Than Its Entire Share Capital This Year
|
The biotech industry faced widespread profit declines in the first half of the year due to foreign exchange losses. However, 15 companies—including Bora Pharmaceuticals, Sunmax Biotechnology, PharmaEssentia, Visco Vision, and Ever Supreme Bio Technology—defied the trend and posted record-high profits for the same period. Notably, Bioray Biotech and 3D GLOBAL BIOTECH turned losses into gains. |
| 2025-09-08 |
President Lai: Build Sovereign AI with Healthcare as a Priority Industry
|
President Lai Ching-te stated yesterday (17th) at the "Taiwan Climate and Health Alliance – Deans’ Sustainability Forum" that the government plans to invest NT$900 billion by 2030 in net-zero transformation. He also emphasized accelerating the development of sovereign AI, with healthcare identified as a priority sector, aiming to enhance the competitiveness of Taiwan’s medical industry. |
| 2025-09-08 |
BioGend Therapeutics Advances OIF Toward Phase III; RevoCart Expands Hospital Adoption
|
BioGend Therapeutics reported a significant increase in monthly procedures for its single-use autologous cartilage repair product, RevoCart, and achieved profitability in July. Looking ahead to the second half of the year, the company expects to receive the full report of its Osteogenic Inductive Factor (OIF) Phase II clinical data in August. Following this, BioGend plans to communicate with regulatory authorities regarding its Phase III clinical trial program, with an anticipated official launch in the second half of next year. Meanwhile, RevoCart is scheduled to be introduced to four major teaching hospitals in the latter half of the year. Combined with reduced impact from antibiotic production line maintenance, revenue contributions from both products are expected to achieve double-digit growth next year. |
| 2025-09-08 |
Qisda Sees Growth Across All Businesses in Q2, Healthcare and Smart Solutions Drive Steady Expansion
|
Qisda’s businesses warmed up in the second quarter compared with Q1, with both its healthcare segment and smart solutions business hitting record highs. Healthcare revenue surpassed NT$7 billion for the third consecutive quarter, while smart solutions reached NT$9.5 billion for the first time. Looking ahead to Q3, despite uncertainties from tariffs and exchange rates, healthcare and smart solutions are expected to continue stable growth. |
| 2025-09-08 |
PharmaEssentia Targets Sequential Revenue Growth with Global Expansion of Ropeg in PV; Applies for NCCN Inclusion as Recommended Therapy
|
PharmaEssentia’s novel therapy Ropeginterferon alfa-2b (Ropeg) for polycythemia vera (PV) continues to drive global sales growth, with second-quarter operating profit surging 147.57% year-over-year and earnings per share (EPS) reaching NT$2.50. At an investor conference on August 14, the management team noted that revenue is expected to keep rising quarter by quarter in the second half of the year. Ropeg is also advancing international market penetration, with regulatory approval in Mexico anticipated this year for PV, while simultaneously moving into the essential thrombocythemia (ET) market. PharmaEssentia has applied for Ropeg to be included in the U.S. National Comprehensive Cancer Network (NCCN) treatment guidelines, a move that would improve clinical accessibility, expand coverage, and potentially accelerate regulatory reviews. |
| 2025-09-08 |
HanchorBio Completes First Patient Dosing of Novel Drug HCB101 in Taiwan Head and Neck Cancer Trial, Advancing Clinical Development
|
HanchorBio, a global clinical-stage biopharmaceutical company, announced on August 13 that the first patient has been successfully dosed in an investigator-initiated trial (IIT) led by Dr. Chia-Hsun Hsieh of the Oncology Department at Linkou Chang Gung Memorial Hospital. The study is designed to evaluate HCB101 in combination with the immunotherapy pembrolizumab (Keytruda®) in patients with recurrent or metastatic head and neck cancer who are unresponsive to platinum-based chemotherapy, with the primary focus on safety and preliminary efficacy. |
| 2025-09-08 |
Foresee’s Three-Month Formulation of Camcevi Awaits U.S. FDA Approval, Targeting August 29 PDUFA Date
|
Foresee Pharmaceuticals recently announced consolidated revenue of NT$8.85 million in July, representing a month-on-month decline of 77.2% and a year-on-year decrease of 75.2%. The company attributed the drop primarily to the absence of product supply to distributors during the month, coupled with changes in distributor customer mix. Looking ahead, Foresee expects growth in the second half of the year, supported by milestone payments upon anticipated U.S. FDA approval of Camcevi’s three-month formulation on the target date of August 29. |
| 2025-09-08 |
Pilatus Biosciences and Roche Enter Clinical Collaboration on PLT012: Targeting Next-Generation Combination Therapy for Hepatocellular Carcinoma
|
Pilatus Biosciences, Inc., a biotech startup dedicated to developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced a clinical trial collaboration with Roche. Under the agreement, Roche will provide its anti–PD-L1 therapy Atezolizumab (Tecentriq®) to support Pilatus’ upcoming first-in-human Phase I trial evaluating the safety and tolerability of PLT012 in combination with Atezolizumab for patients with hepatocellular carcinoma (HCC). |
| 2025-09-08 |
Licensing Partner Expected to Announce Phase III Data for L606 in September–October; Pharmosa Biopharm Optimistic
|
Pharmosa Biopharm announced on the 13th that its licensing partner Liquidia Corporation (LQDA) plans to host an R&D Day in September–October this year to release the latest results from the open-label Phase III clinical trial of L606, an investigational therapy for pulmonary arterial hypertension (PAH, WHO Group I). The company expressed optimism about the upcoming milestone. |
| 2025-09-08 |
Heavy Ion Therapy for Pancreatic Cancer: Taipei Veterans General Hospital and NYU Langone Health Form Strategic Partnership for Patient Referral and Research
|
In a landmark Taiwan–U.S. medical collaboration, Taipei Veterans General Hospital (Taipei VGH) President Dr. Wei-Ming Chen led a delegation to visit NYU Langone Health, where both institutions signed a formal research agreement with a focus on pancreatic cancer treatment. The collaboration will prioritize heavy ion therapy, patient referral, and sharing of research outcomes. |
| 2025-09-08 |
United Orthopedic Reports Record July Revenue; H1 EPS NT$2.46, Japan and U.S. Drive Growth
|
United Orthopedic Corporation (UOC) announced its first-half financial results and July revenue performance. In the second quarter, exchange rate fluctuations and product mix impacted profitability, with both gross margin and operating margin declining by three percentage points from the prior quarter. Non-operating losses from foreign exchange further weighed on results, bringing quarterly net income after tax down to NT$46.57 million, or earnings per share (EPS) of NT$0.48. Cumulative EPS for the first half reached NT$2.46. |
| 2025-09-08 |
Medeon Biodesign’s Aortic Arch Repair Device Duett Receives FDA Approval for Phase II Clinical Trial
|
Medeon Biodesign announced yesterday that its subsidiary, Aquedeon Medical, Inc., has received approval from the U.S. Food and Drug Administration (FDA) to initiate a pivotal Phase II clinical trial for Duett, its aortic arch repair device. Building on the 35 cases previously approved, the expanded study will now enroll between 72 and 90 patients. The trial aims to validate Duett’s clinical value at scale, marking another critical step toward securing FDA market clearance. |
| 2025-09-03 |
Taiwan Bio Therapeutics Acquires TRACT Therapeutics to Expand Transplant Rejection and Autoimmune Disease Markets
|
Taiwan Bio Therapeutics announced on the 13th that it has signed a merger agreement with its partner, TRACT Therapeutics, Inc. Through its wholly owned U.S. subsidiary, Taiwan Bio Holding LLC, the company will acquire 100% equity in TRACT for US$3.5 million in cash. The transaction will be completed following approval by relevant authorities, officially bringing TRACT under the Taiwan Bio Therapeutics Group. |
| 2025-09-03 |
Bora Pharmaceuticals Responds to Section 232 Tariffs with Two Strategies
|
Bora Pharmaceuticals announced at its investor conference on the 12th that it will adopt two strategies to counter potential Section 232 tariffs: a “manufactured-to-market” model and the establishment of an offshore capital pool (BlockGoogle). Chairman Bobby Sheng expressed optimism that operations in the second half of the year will outperform the first half. The company’s acquisition targets remain unchanged, with several promising prospects under evaluation, though developments under Trump’s administration are still being closely monitored. |
| 2025-09-03 |
General Biologicals Advances on Three Fronts with Multiple CLIA Reagents Securing TFDA Approval
|
General Biologicals announced that its chemiluminescence immunoassay (CLIA) technology platform is achieving successive milestones. Following the approval of its fully automated chemiluminescence immunoassay analyzer by Taiwan’s Food and Drug Administration (TFDA) for special medical device manufacturing and licensing, the company has now obtained five TFDA medical device licenses for CLIA reagents. An additional 20 reagent applications are currently under review. Several hospitals have already begun testing, and collaborations have been launched with three clinical laboratories in Taiwan, while discussions are ongoing with other hospitals and labs, helping to expand momentum in the precision medicine sector. |
| 2025-09-03 |
SunWay Biotech’s Probiotic Strain Receives U.S. FDA GRAS Certification, Opening Export Opportunities
|
SunWay Biotech announced that its best-selling probiotic strain, Lactobacillus paracasei NTU 101, has received the U.S. Food and Drug Administration (FDA) “Generally Recognized As Safe” (GRAS, GRN001232) certification. This milestone not only paves the way for SunWay to expand its export opportunities but also marks the first Lactobacillus paracasei strain in Taiwan to obtain this recognition, underscoring the company’s strong research capabilities and strategic business vision. |
| 2025-09-03 |
Pan-Chyr Yang, Chairman of DIAMOND BIOFUND: Unleashing Three Forces to Propel Taiwan’s Biotech Industry Globally
|
Pan-Chyr Yang, Chairman of DIAMOND BIOFUND, stated yesterday (11) that the global biotech sector is at a pivotal intersection of multiple innovations, including AI applications, precision medicine, and cell therapy. Taiwan, with its comprehensive clinical and translational capabilities, must accelerate the integration of R&D, capital, and international market access. He emphasized that through the combined forces of long-term funding, institutional design, and global alignment, Taiwan’s biotech industry can be guided toward global leadership. |
| 2025-09-03 |
Asia-Pacific Biotechnology Investment Forum Kicks Off Executive Yuan Secretary-General Ming-Hsin Kung: Three Key Strategies to Strengthen Global Links in Biotech Industry
|
The 2025 Asia-Pacific Biotechnology Investment Forum opened yesterday (11). Executive Yuan Secretary-General Ming-Hsin Kung emphasized that with the integration of AI, ICT industries, and clinical applications, Taiwan’s biotech sector is not merely focused on manufacturing medical products but is redefining the future of healthcare. The government will implement three key strategies: supporting the transformation and upgrading of traditional industries, encouraging innovative R&D, and accelerating market adoption while strengthening local supply chains to connect with global markets. |
| 2025-09-02 |
Healthy Ageing Tech Show: NTU and Taipei Veterans General Hospital Showcase Smart Healthcare Achievements
|
The second “Healthy Ageing Tech Show” opened on the 8th at Taipei World Trade Center Exhibition Hall 1 under the theme “Rejuvenation.” The three-day event attracted more than 350 exhibitors and 1,200 booths, highlighting health promotion, smart technology, and age-friendly environments in response to an ageing society. The National Taiwan University (NTU) Healthcare System and the Taipei Veterans General Hospital (Taipei VGH) System both joined the showcase, presenting their results and innovations in elderly care and smart healthcare. |
| 2025-09-02 |
Healthy Ageing Tech Show Opens, Kaohsiung Pavilion Showcases AI Smart City for Aging-in-Place
|
The 2025 Healthy Ageing Tech Show opened on August 8 at the Taipei World Trade Center Hall 1 and runs through August 10. The Kaohsiung City Government, together with its Health, Social Affairs, Education, Sports Development, Transportation, Public Works, Labor, and Tourism bureaus, collaborated with industry partners to set up the Kaohsiung Pavilion under the theme “Ageless Enjoyment, Happy Kaohsiung.” The pavilion features smart healthcare, social care, sports and wellness, and lifelong learning for seniors, demonstrating how technology can accompany older adults toward healthy aging. |
| 2025-09-02 |
Industry and Government Join Forces to Shape the Capital’s Vision! Taipei Pavilion Debuts at the Healthy Ageing Tech Show to Build an Age-Friendly City
|
The second Healthy Ageing Tech Show was held from August 8 to 10 at the Taipei World Trade Center Exhibition Hall 1. With the theme “Ageing Well Together, Walking with Taipei,” the Taipei City Government set up the “Taipei Pavilion” at Booth A432c. The pavilion integrated three core elements—interactive experiences, age-friendly design, and senior services—highlighting the city’s diverse achievements in ageing policies. By collaborating with local innovative enterprises, the city presented its vision of creating an intelligent, resilient, and inclusive age-friendly capital, inviting citizens to join in the event. |
| 2025-09-02 |
Healthy Ageing Tech Show Opens — President Lai: Three Major Policies to Create an Age-Friendly Environment and Unlock Business Opportunities
|
The second Healthy Ageing Tech Show held its opening ceremony on the 8th. In his remarks, President Lai Ching-te stated that, in response to the advent of a super-aged society, the government has introduced three major policies to create an age-friendly environment and open up new business opportunities, aiming to make Taiwan a model of happiness among aging nations worldwide. The market scale for the ageing sector is expected to reach NT$3.6 trillion by 2025. |
| 2025-09-01 |
From Smart Care to Active Ageing: Healthy Ageing Tech Show Highlights Urban Innovation
|
As Taiwan’s ageing population grows rapidly, cities and counties are rolling out innovative strategies to address the diverse needs of older adults in daily living, healthcare, and lifelong learning. At this year’s Healthy Ageing Tech Show, the Age-Friendly Cities Pavilion drew significant attention, showcasing interactive exhibits, smart technology applications, and local service achievements that reflect Taiwan’s efforts to build an elder-friendly society. From smart healthcare and long-term care innovation to active ageing learning and lifestyle experiences, the exhibition demonstrated how cities are taking forward-looking actions to support ageing well. |
| 2025-09-01 |
Andros Pharmaceuticals Partners with Yung Shin Pharmaceutical to Enter the Topical Dermatology Market
|
Andros Pharmaceuticals announced on the 7th that it has signed a co-development and licensing agreement with Yung Shin Pharmaceutical Industrial, establishing a long-term strategic partnership. Initially, the two companies will collaborate to develop a high-value, high-margin niche generic drug, with Taiwan as the first target market, and will subsequently explore opportunities to expand into international markets. |
| 2025-09-01 |
Lin BioScience’s Subsidiary Belite Secures Additional US$15 Million Investment from Major International Fund
|
Belite, a subsidiary of Lin BioScience, announced that it has received an additional US$15 million investment (approximately NT$450 million) from the same major international fund. The financing was executed through the issuance of one American Depositary Share (ADS) and one unit of warrants per package, at US$65 per ADS (approximately NT$1,933 per share). Each warrant allows the purchase of one ADS at the same exercise price of US$65. The proceeds will be used to strengthen working capital and for general corporate purposes. |
| 2025-09-01 |
Healthy Ageing Tech Show Opens a Journey of Renewed Youth
|
Taipei World Trade Center Hall 1 Hosts Six Themes and Six Signature Events, Creating a Future of Longevity Without Long-Term Care |
| 2025-09-01 |
VIZIONFOCUS to Launch Two New Production Lines in September, Monthly Output to Reach 57 Million Lenses
|
VIZIONFOCUS, a contact lens manufacturer, announced that its consolidated revenue for July 2025 was NT$280 million, representing a 6.38% decline from the previous month but an increase of 20.82% compared to the same period last year. The month-on-month decrease was primarily due to cooling demand after the “618 Shopping Festival.” For the first seven months of 2025, cumulative consolidated revenue reached NT$1.97 billion, a 13.50% year-on-year increase. |
| 2025-08-28 |
Cardio Ring’s Next-Generation Blood Pressure Monitoring System ArteVu Secures U.S. FDA Clearance, Ushering in a New Era of Medical Monitoring
|
Cardio Ring, a U.S.-based medtech company founded by a Taiwanese team in Silicon Valley, has successfully developed ArteVu, an innovative blood pressure monitoring device capable of continuous measurement without the need for a cuff. On July 30, 2025, ArteVu received U.S. FDA clearance, marking another milestone for Taiwan’s smart healthcare technology on the global stage. |
| 2025-08-28 |
CHC Healthcare Reports NT$49.09 Million in First-Half Profit, Nearly Quadrupling QoQ; Growth to Continue Each Quarter in H2
|
CHC Healthcare Group announced its first-half financial results on the 6th, posting a net profit after tax of NT$49.098 million, up 61.4% year-on-year, with earnings per share (EPS) of NT$0.28. Second-quarter net profit after tax reached NT$40.696 million, a 3.84-fold surge compared to NT$8.402 million in the first quarter. |
| 2025-08-28 |
Acer Medical’s AI Healthcare Software Adopted by Over 500 Medical Institutions Worldwide
|
Acer Medical, a subsidiary of Acer, announced yesterday (6th) that its artificial intelligence (AI) healthcare software solutions have been successfully implemented in more than 500 medical institutions worldwide, including clinics, major hospitals, and diagnostic centers. The deployments span across Taiwan, Japan, Southeast Asia, Central America, and Europe, marking a significant milestone that highlights Acer Medical’s expertise in advancing AI applications for clinical decision support and early disease screening, as well as the strong global demand for smart healthcare solutions. |
| 2025-08-28 |
PharmaEssentia’s July Revenue Surges Past NT$1.3 Billion, Setting New Record
|
PharmaEssentia’s rare blood cancer drug Ropeg continued to deliver strong sales performance in the U.S. and global markets, driving the company’s July revenue to NT$1.3 billion, a historic monthly high, representing an 8.76% increase from June and a 48.01% increase year-on-year. Cumulative revenue for January through July reached NT$8.16 billion, up 68.65% year-on-year. |
| 2025-08-28 |
New Drug Licensing to Bear Fruit in Q4: AP Biosciences, Oneness Biotech, and TAHO Pharmaceuticals Gain International Attention
|
Taiwan’s new drug licensing momentum is accelerating, with several companies expected to see results next quarter. The biotech sector has recently attracted significant capital inflows, with companies such as OBI Pharma’s AP Biosciences, MICROBIO Group’s Oneness Biotech, and TAHO Pharmaceuticals gaining attention as their pipeline products move closer to licensing milestones, with positive developments anticipated in the coming quarter. |
| 2025-08-28 |
ALA-1000 to Enter Phase III in Q1 Next Year, Alar Pharmaceuticals Poised for New Milestone Payments
|
Alar Pharmaceuticals’ licensing partner Indivior reported second-quarter revenue and profit that exceeded expectations, which industry observers interpret as validation of its new management team’s focus on addiction-treatment drugs. This also means more resources are available to advance ALA-1000 (INDV-6001) into a Phase III clinical trial, set to begin no later than the first quarter of 2026. With trial enrollment underway, Alar is expected to receive a new wave of milestone payments, boosting profitability. |
| 2025-08-28 |
MegaPro Biomedical’s Dual Technology Platforms Drive Progress, Two Products Targeting NDA Filings by 2028
|
MegaPro Biomedical announced on the 5th that its dual technology platforms are gaining momentum. The company plans to submit a Pre-IND application for its MRI contrast agent MPB-1523 by the end of this year, paving the way for a formal 505(b)(1) NDA submission in 2028. At the same time, its reformulated oncology drug MPB-1734 will advance to bioequivalence testing following successful process scale-up, with a 505(b)(2) NDA submission also expected in 2028. |
| 2025-08-28 |
New Leadership at NTU Hospital Hsinchu Branch: Kuan-Yu Hung Returns as Superintendent, While Chong-Jen Yu Takes the Helm of the Main Hospital
|
On the afternoon of the 1st, the Hsinchu Branch of National Taiwan University Hospital (NTUH) held a handover ceremony at its Zhubei campus. The event was personally overseen by Ming-Shiang Wu, Dean of the NTU College of Medicine. During the ceremony, newly appointed NTUH Superintendent Chong-Jen Yu formally passed the seal of office to Kuan-Yu Hung, officially completing the transition. |
| 2025-08-28 |
Anbogen Therapeutics Reaches New Milestone: FDA Clears ABT-301 Triple Combination Therapy Targeting Advanced Colorectal Cancer “Cold Tumors”
|
Anbogen Therapeutics (ABT), a precision medicine biotech company, announced a major breakthrough today with the U.S. FDA’s approval to initiate Phase I/II clinical trials for its small-molecule drug ABT-301, in combination with an immune checkpoint inhibitor and an anti-angiogenic inhibitor. This triple-combination therapy will target advanced metastatic colorectal cancer (mCRC), particularly “cold tumors” that account for 90% of patients who respond poorly to current immunotherapies, offering renewed hope for this underserved population. |
| 2025-08-28 |
Taiwan Bio Therapeutics: Phase II Osteoarthritis Trial Meets Secondary Endpoint, Paving Way to Accelerate Phase III
|
Cell therapy developer Taiwan Bio Therapeutics announced results from its Phase IIb clinical trial for osteoarthritis (OA). While the primary pain reduction endpoint did not show statistically significant improvement compared to the hyaluronic acid control group, the study revealed notable efficacy in secondary endpoints, particularly in joint structure improvement—a result rarely seen among competing products. This outcome has become a major highlight, and the company now intends, together with its Singapore licensing partner, to accelerate the launch of Phase III trials, aiming to begin patient enrollment both domestically and internationally by the end of this year, though overseas enrollment may be slightly lower than initially projected. |
| 2025-08-27 |
Healthy Ageing Tech Show to Open on August 8
|
Targeting the trillion-dollar global silver economy, the “2025 Healthy Ageing Tech Show,” co-hosted by the Institute for Biotechnology and Medicine Industry (IBMI), the Research Center for Biotechnology and Medicine Policy, the Department of Industrial Development (DID), Ministry of Economic Affairs (MOEA), and the National Health Research Institutes (NHRI), will take place from August 8 to 10. This year’s event brings together 350 leading exhibitors across 1,200 booths, setting a new record in scale. |
| 2025-08-27 |
Silver Economy Emerging as New Blue Ocean: Top 10 Senior-Friendly Innovative Technologies Announced
|
As Taiwan enters a super-aged society, the silver economy is booming with unprecedented business opportunities. The latest selection of the “Top 10 Senior-Friendly Technology Products” has been unveiled, highlighting innovative solutions such as National Taiwan University Hospital Yunlin Branch’s Smart Indoor Positioning System, UGYM Technology’s Pain Relief Electrotherapy Device, imedtac’s Automated Bathing Machine, and CTBC Bank’s Senior-Friendly ATM with AI-powered fraud prevention. Industry experts believe these innovations not only showcase Taiwan’s strong R&D capabilities but also demonstrate international competitiveness, serving as important indicators for investment and industrial transformation. |
| 2025-08-27 |
Formosa Biomedical Technology and Rohto Pharmaceutical Sign Strategic Partnership to Expand Regenerative Medicine Market in Taiwan and Japan
|
Formosa Biomedical Technology announced on August 1 that, on behalf of Formosa Plastics Group’s regenerative medicine ecosystem—including IVY LIFE SCIENCE—the company signed a strategic partnership agreement with Japan’s globally renowned Rohto Pharmaceutical Co., Ltd. on July 22, marking the beginning of a deep collaboration in regenerative medicine between Taiwan and Japan. |
| 2025-08-27 |
Protect Animal Health Incorporation to Debut on Emerging Stock Board August 4 at NT$33 per Share, Targeting the Billion-Dollar Senior Pet Medicine Market
|
Protect Animal Health Incorporation, an innovative veterinary drug developer, is set to debut on Taiwan’s Emerging Stock Board on August 4 with a broker-underwritten reference price of NT$33 per share. Leveraging its “Moneyball Strategy,” platform-based incubation capabilities, and global partnerships, Protect is advancing three high-value therapeutic areas: cancer immunotherapy vaccines, gene therapy for heart disease, and an antibody drug platform. Together, these markets are valued at nearly NT$20 billion (approximately US$660 million). Its lead candidate, PT001, a novel melanoma vaccine, has already filed for field trials and will first be developed in Taiwan before expanding to global markets. |
| 2025-08-12 |
UnicoCell Biomed Advances Main Board Listing Plans, Focusing on Irreversible Diseases in Regenerative Medicine
|
UnicoCell Biomed, a key player in the field of regenerative medicine, has officially launched its plan to transfer its listing to Taiwan’s main board. The company is currently focused on regenerative treatments for irreversible diseases. Among its core pipelines, the chronic kidney disease (CKD) therapy is expected to file for a Phase III clinical trial in Taiwan next year, while overseas licensing discussions are also underway. In addition, patient enrollment for its Phase III clinical trial targeting knee osteoarthritis is anticipated to be completed by the end of this year. Meanwhile, UnicoCell is expanding the scientific data surrounding its exosome technology for both aesthetic and therapeutic applications, broadening the scope of its raw material offerings. |
| 2025-08-12 |
New Power Joins Taiwan’s Vaccine National Team: NHRI Spin-Off "TaiU Biotech" Secures NT$60 Million in Seed Funding Led by Mosaic Seed Fund
|
A new force has joined Taiwan’s vaccine national team. TaiU Biotech, a startup spun off from the National Health Research Institutes (NHRI), announced yesterday (July 31) that it has successfully closed a NT$60 million seed funding round with support from Mosaic Venture Lab. The round was led by the Mosaic Seed Fund, and with assistance from the Small and Medium Enterprise and Startup Administration of the Ministry of Economic Affairs and the National Innovation and Entrepreneurship Association, TaiU also secured co-investment from the National Development Fund. |
| 2025-08-12 |
BIONET Therapeutics’ UCMSC Exosome Drug Substance Receives FDA DMF Type II Registration Approval
|
BIONET Therapeutics, a subsidiary of BIONET Corp., announced that it has received notification from the U.S. Food and Drug Administration (FDA) approving the Drug Master File (DMF) Type II registration for its proprietary umbilical cord mesenchymal stem cell (UCMSC) exosome drug substance. |
| 2025-08-12 |
Foresee Pharmaceuticals Files for CAMCEVI Launch in Singapore
|
Foresee Pharmaceuticals announced that its licensing partner, Changchun GeneScience Pharmaceutical, has submitted a marketing application to Singapore’s Health Sciences Authority (HSA) for CAMCEVI 42mg, a new formulation developed for the treatment of prostate cancer. |
| 2025-08-12 |
KMUH Achieves HIMSS EMRAM Stage 7 Certification
|
In response to the digital wave driven by big data and artificial intelligence (AI), Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) has achieved Stage 7 of the Electronic Medical Record Adoption Model (EMRAM) certification by the Healthcare Information and Management Systems Society (HIMSS)—the highest international recognition in medical information management systems. KMUH is the first medical institution in southern Taiwan to receive this prestigious honor. |
| 2025-08-12 |
Biomedica Corporation Secures Thai Medical Certification in Just Eight Months—Reveals Three Core Strategies for Market Entry
|
Biomedica Corporation, which has actively expanded into international markets in recent years, has achieved notable success in Thailand. During the “New Southbound Healthcare Market Expansion Experience Sharing Session,” Biomedica’s Founder and Chief Marketing Officer, Ming-Hsiang Lin, shared how the company successfully obtained TFDA (Thai Food and Drug Administration) certification in just eight months. He also revealed for the first time the company’s three core strategies for entering the Thai market—offering valuable insights for medical startups targeting Southeast Asia. |
| 2025-08-12 |
Blueprint for a Super-Aged Future City: Experts Share Insights at the “Age-Friendly Cities Forum”
|
“I came to confess on July 30—our urban planning has fallen behind, because we had no prior experience with such longevity!” joked LIN, CHIEN YUAN, Professor at the Graduate Institute of Building and Planning, National Taiwan University. His comment, though made with a touch of humor, rang a serious alarm: it’s time for everyone to address the realities of a super-aged society. |
| 2025-08-12 |
Bora Pharmaceuticals’ Q2 Gross Margin Expected to Outperform Q1; Dual Growth Engines to Boost Second-Half Performance
|
Bora Pharmaceuticals reported second-quarter revenue of NT$5.18 billion, slightly below market expectations, mainly due to the appreciation of the New Taiwan dollar and production delays at its sterile injectable plant in Maryland, USA. With the shutdown impact from the first quarter now resolved, the company’s Q2 gross margin is expected to surpass that of Q1. Looking ahead to the second half of the year, the market expansion of the pediatric epilepsy oral solution VIGAFYDE and increasing CDMO orders—totaling US$138 million in new orders during the first half—are anticipated to steadily boost performance. Analysts are optimistic that these dual engines will drive a significant rebound in gross and operating margins in the latter half of the year. |
| 2025-08-12 |
Orient Europharma Group Maintains Steady Growth, Eyes Drug License Acquisitions and M&A in Southeast Asia to Accelerate Expansion
|
Orient Europharma Group is advancing its dual-track strategy, and General Manager Calvin Tsai stated that the company will continue launching new products to expand its reach across all age demographics while actively expanding into Southeast Asian markets. In the future, the company plans to partner with Orient Pharma to enter markets such as the United States and even the Middle East. This year’s revenue is expected to achieve single-digit growth. With ample cash from asset disposals, the company will continue seeking suitable targets to enrich its product portfolio. In addition to equity-based partnerships, it does not rule out acquiring drug licenses or companies to accelerate its Southeast Asia expansion. |
| 2025-08-12 |
ACRO Biomedical Signs Licensing Agreement with Vietnam’s CT Group to Market Regenerative Eye Implant Across ASEAN
|
ACRO Biomedical has officially signed a licensing agreement with Vietnam’s CT Group to market its regenerative corneal implant—the “Apis Cor Collagen Corneal Matrix”—across ASEAN countries. The product has already received medical device certification from Taiwan’s Ministry of Health and Welfare and has been gaining momentum internationally. Following a prior agreement with Australia’s Oculus Biomed Pty Ltd (OBM) to conduct clinical trials, obtain regulatory approval, and commercialize the product, this new partnership with CT Group not only boosts ACRO Biomedical’s revenue but also showcases Taiwan’s regenerative medicine capabilities while offering new hope to patients in Southeast Asia. |
| 2025-08-12 |
Exclusive Interview with Mobisnet Technology: MIT Medical Robots Target the Smart Care Market
|
Entering the era of smart healthcare, what kind of enterprise can truly deliver flexible, clinically relevant solutions to medical institutions? The answer might surprise you — a software company originally focused on developing government tax systems. |
| 2025-08-12 |
Phison’s aiDAPTIV+ Enters Medical Field in Partnership with Hsinchu MacKay Memorial Hospital
|
Phison Electronics and Hsinchu MacKay Memorial Hospital held a press conference on the 28th to unveil the results of their collaboration, officially launching an on-premise generative AI system. This marks the hospital as one of the first medical institutions in Taiwan to deploy and operate a large language model (LLM) trained and inferenced entirely in-house. The event featured a live demonstration of the system generating real-time patient consultation records, with plans to gradually roll it out across the entire MacKay healthcare network. |
| 2025-08-12 |
Exclusive Interview with Brain Navi: Secures U.S. 510(k) Clearance, Countdown to IPO Begins
|
Following the successful attainment of U.S. FDA 510(k) clearance for its brain surgery robot in May 2025, Taiwanese startup Brain Navi officially launches its countdown to IPO, aiming to list on the capital market in 2026. This will mark Brain Navi as Taiwan’s first company to enter the advanced surgical robot field with an independent brand. |
| 2025-08-12 |
Orient Europharma Group’s Subsidiary Orient Pharma Set to List on OTC, Plans to Launch New Alzheimer’s Drug
|
Orient Europharma Group’s promising subsidiary Orient Pharma is scheduled to be listed on the Taipei OTC market in late August, with a tentative underwriting price of NT$28.04. Orient Pharma held a pre-OTC performance briefing on July 29. General Manager Chun-Tung Huang stated on July 28 that Orient Pharma focuses on three major technology platforms and is actively investing in core areas such as cardiovascular and central nervous system diseases. The company currently has three marketed drugs and plans to launch four new products, including an anti-Alzheimer’s drug, over the next four years starting this year. |
| 2025-08-12 |
HCMED INNOVATIONS Reaches Breakthrough Milestone with FDA Approval for Innovative Breath-Activated Nebulizer
|
HCMED INNOVATIONS, specializing in inhalation drug-device combination CDMO products, announced that its breath-activated nebulizer AdheResp has recently received U.S. FDA 510(k) clearance. AdheResp is the world’s first FDA-cleared breath-activated nebulizer with built-in connectivity, and currently the only advanced nebulizer device with mass production capacity to support pharmaceutical clients’ clinical trials. |
| 2025-08-12 |
Tanvex BioPharma’s Biosimilar Drug Enters U.S. Market
|
Tanvex BioPharma-KY announced yesterday (25th) that since forming a strategic alliance with the Bora Group in January this year, it will now operate under the CDMO business brand “Bora Biologics” starting this week. Tanvex Chairman Bobby Sheng stated that the company’s first biosimilar drug, NYPOZ (reference original drug: Neupogen, a leukocyte growth factor), is set to officially launch in the U.S. market in the second half of this year. Additionally, the newly added 2,000-liter production line at the San Diego facility is scheduled to begin operations in the first quarter of next year. |
| 2025-08-12 |
Elixiron Immunotherapeutics’ New Drug EI-1071 Gains International Recognition
|
Refusing to let foreign pharmaceutical companies take the lead, Elixiron Immunotherapeutics is developing Enrupatinib (code-named EI-1071), a microglia-modulating drug that targets brain immune regulation, primarily for treating Alzheimer’s disease. This novel drug has been recognized by the Global Neurodegeneration Proteomics Consortium, founded by Bill Gates, and has currently advanced into Phase II clinical trials. |
| 2025-08-12 |
CRDMO National Team’s New Factory to Mass Produce 13 Million mRNA Vaccine Doses Annually
|
The government-initiated CRDMO (Contract Research, Development, and Manufacturing Organization) national team—Taiwan Bio-Manufacturing Corporation (TBMC)—announced on the 25th that its GMP facility in Zhubei is expected to be completed by the end of this year. The factory will undergo validation in the first quarter of next year and begin production in the second quarter, with an annual capacity of 13 million mRNA vaccine doses. This supports the government’s “National Security Vaccine Resilience” plan and aims to establish Asia’s most advanced nucleic acid drug manufacturing hub. |
| 2025-08-12 |
BioPhoenix Secures U.S. Up Therapeutics License to Develop Novel Proteasome Inhibitor Against Cancer
|
BioPhoenix, a subsidiary of San Fu Chemical’s San Fu Biotech, announced on the 24th that it has signed a licensing agreement with U.S.-based innovative drug developer Up Therapeutics. BioPhoenix has acquired global development, manufacturing, and commercialization rights for Up284, a first-in-class small molecule drug targeting solid tumors such as ovarian cancer. Both parties plan to submit an IND application and initiate Phase 1 clinical trials within the next 18 months. |
| 2025-08-12 |
Asia Pathogenomics Expands into Japan, Marking Global Milestone for Taiwan’s Leading Infectious Disease Diagnostics Company
|
Asia Pathogenomics Co., Ltd. has officially established a Japanese subsidiary, APGアジア準訳ジャパン株式会社, in Tokyo as a key stepping stone for its expansion into the broader Asian market. The move aims to bring the company closer to Japan’s clinical needs while accelerating the application of metagenomic next-generation sequencing (mNGS) in infectious disease diagnostics, and deepening partnerships across both the medical and industrial sectors. |
| 2025-08-12 |
CH BIOTECH R&D Secures NT$1.2 Billion Order as New Product Heads to Indonesia
|
CH BIOTECH R&D, a leading agricultural biotechnology company, announced yesterday the global launch of its next-generation product, “Endurance Enhancer.” The company also signed a distribution agreement worth USD 42 million (approximately NT$1.2 billion) with its Indonesian partner, PT MAJU MAKMUR UTOMO (M2U). The product is expected to begin contributing to revenue starting in August. |
| 2025-08-12 |
Inventec’s Smart Healthcare Arm GOOD FUTURE BIOMEDICAL Reports Strong Progress
|
Inventec has been actively expanding into high-margin product lines such as smart healthcare in recent years. Its subsidiary, GOOD FUTURE BIOMEDICAL, has secured a firm foothold in the smart health and medical market. The company’s flagship product—its circulating tumor cell (CTC) detection system—is now being promoted in partnership with Malaysian firm Wellspring Solutions Sdn Bhd, aiming to obtain Malaysia’s Medical Device Authority (MDA) registration. Certification is expected within the year, which will further strengthen collaborations with local healthcare institutions. |
| 2025-08-11 |
Bora Pharmaceuticals Strengthens U.S. Supply Chain as Iowa Governor Visits Operations
|
Bora Pharmaceuticals announced on the 23rd that Iowa Governor Kim Reynolds successfully led a delegation to visit its manufacturing site in Maple Grove, Minnesota, as well as its U.S. pharmaceutical sales subsidiary, Upsher-Smith Laboratories. During the visit, the governor participated in a roundtable discussion and toured the facilities, focusing on the theme of “localizing pharmaceutical manufacturing” and regional supply chain integration in the U.S. Midwest. |
| 2025-08-11 |
Chi Mei Hospital Leads in Healthcare Quality with ISO 7101 Certification
|
Amid the challenges posed by an aging population, rising chronic diseases, and accelerating digital transformation, healthcare quality management is facing unprecedented pressures. Once again taking the lead in medical innovation, Chi Mei Medical Center, operated by the Chi Mei Medical Foundation, officially obtained ISO 7101 certification—the world’s first international standard dedicated to healthcare quality management—in July this year. It is now the first medical center in Taiwan to achieve this milestone, marking a new chapter in aligning Taiwan’s healthcare quality with international standards. |
| 2025-08-11 |
Taipei Veterans General Hospital’s Electronic Medical Record System Achieves U.S. Certification
|
On July 11, Taipei Veterans General Hospital (TVGH) officially passed the Stage 6 certification of the Electronic Medical Record Adoption Model (EMRAM) developed by the Healthcare Information and Management Systems Society (HIMSS). This milestone reflects the hospital’s attainment of globally advanced standards in key areas such as EMR system functionality, clinical decision support, and information security—demonstrating TVGH’s strong capabilities and tangible achievements in the realm of smart healthcare. |
| 2025-08-11 |
AlleyPin Partners with Global Pharma Data Leader IQVIA to Accelerate Digital Health Transformation in Taiwan Clinics
|
AlleyPin has officially announced a strategic partnership with IQVIA, a global leader in pharmaceutical data and technology services. The two companies will jointly promote clinic-centric digital health innovation, introducing forward-looking data applications and tech-enabled service models to Taiwan’s primary care sector. |
| 2025-08-11 |
Syncell Inc. Raises NT$750 Million in Series A Funding to Build Taiwan’s International-Class Biotech High-End Instrument Brand
|
Taiwan innovative biotech instrument company Syncell Inc. today announced the successful completion of a NT$750 million Series A funding round, led by Taiwania Capital. The round also saw participation from heavyweight investors including Everbright Biofund, National Development Fund, Abico Group, Himalaya Venture Fund, Ta Ya Venture Capital, BE Health, Isaiah Capital, Hua Nan Venture Capital, First Venture Capital, Dongan Investment, ITIC, and Taiwan Cooperative Venture Capital. The capital raised will be used to accelerate international market expansion and technology development, positioning Syncell as a leading Taiwanese biotech company creating internationally recognized high-end instruments. |
| 2025-08-11 |
HanchorBio’s Anti-Cancer Drug HCB101 to Complete International Licensing as Early as Q4 This Year, Plans to List in Q1 Next Year
|
HanchorBio-KY, a biotech company listed on the OTC market, held an investor conference on the 22nd, during which Chairman Liu Shigao shared the latest clinical progress and future outlook for its investigational anti-cancer biologic HCB101. Liu expressed optimism that HCB101 will complete overseas market licensing between Q4 this year and Q3 next year, with a projected valuation of US$1.8 billion to $2.5 billion by year-end. The company aims for a successful listing on the stock market in Q1 of next year. |
| 2025-08-11 |
BenQ Materials Advances in Medical Business, Reports Positive Results
|
BenQ Materials, a leading polarizer manufacturer, has been actively expanding its medical business in recent years. In the last quarter, revenue from its medical segment is expected to exceed 30% of total sales, helping to optimize the product mix and improve gross margin performance. |
| 2025-08-11 |
SunWay Biotech Expands Hospital Portfolio with Distribution Rights for Four Dr. Reddy’s Drugs in Taiwan
|
Bora Health, the pharmaceutical distribution arm of SunWay Biotech, has signed a collaboration agreement with global pharmaceutical leader Dr. Reddy’s Laboratories Ltd. (Dr. Reddy’s), securing exclusive distribution rights in Taiwan for four of its products. These drugs focus on therapeutic areas including infectious diseases, central nervous system (CNS) disorders, and rare diseases, significantly enhancing Bora Health’s product lineup in the hospital channel. |
| 2025-08-11 |
APN LifeSciences Secures Strategic Investment from ADDF
|
Taiwan's biotech innovation gains global recognition. APN LifeSciences has announced a strategic investment from the Alzheimer’s Drug Discovery Foundation (ADDF). Founded by the family behind global beauty giant Estée Lauder, the ADDF’s backing will accelerate the development of APN 1607. |
| 2025-08-11 |
Migraine Diagnosis with a Single Drop of Blood Becomes Reality: Taiwan Team Led by Taipei Veterans General Hospital Develops Predictive Model with 90% Accuracy Over Five Years
|
Migraine is one of the most common neurological disorders globally, affecting an estimated 15% of the population, with over 1 billion sufferers worldwide—three times more common in women than in men. According to the Global Burden of Disease Study, migraine is the second leading cause of disability among individuals aged 15 to 49, severely impacting work, education, and quality of life. In Taiwan, approximately 2 million people experience migraine attacks each year. |
| 2025-08-11 |
GlycoNex Advances Targeted Gastric Cancer Antibody Drug GNX1021, Aiming to Launch Phase I Clinical Trial in Q2 2026
|
GlycoNex, a Taiwan-based biopharmaceutical company, announced that its antibody-drug conjugate (ADC) GNX1021, developed in collaboration with OP NanoPharma, has successfully completed pre-fill testing for clinical trial use. The results confirmed process stability and product quality in accordance with international standards. In July, GLP toxicology studies in rats and cynomolgus monkeys were also initiated, with completion expected by the fourth quarter of this year. The company plans to submit clinical trial applications to the health authorities in Taiwan and Japan in the first quarter of 2026, with the goal of launching a Phase I clinical trial in the second quarter of 2026. |
| 2025-08-11 |
Libo Pharma Completes NT$850 Million Fundraising to Accelerate Global Development of Immunotherapy Drug NM-IL-12, Targeting Q4 Emerging Stock Board Listing
|
On July 21, Libo Pharma announced the successful completion of a NT$850 million fundraising round. In addition to continued support from its parent company LIH PAO GROUP, original venture capital shareholders Beiley Biofund, Zhongjia Investment, and President International Development, this round also attracted several new investors, including Taishin Venture Capital, CDIB Healthcare II Venture Fund, Capital Venture Management, CTBC Venture Capital, and Qisda Group. Despite global economic uncertainties and tariff concerns, the company achieved this fundraising against the odds, underscoring the market’s strong confidence in Libo Pharma’s R&D capabilities and future potential. |
| 2025-08-11 |
Oneness Biotech’s New Drug “Fespixon” Receives Marketing Approval from Indonesia’s National Agency of Drug and Food Control
|
On July 18, Oneness Biotech announced that its new drug Fespixon, developed for the treatment of diabetic foot ulcers, has been granted marketing authorization by Indonesia’s National Agency of Drug and Food Control (BPOM).
The company stated that it received notification from its Indonesian consulting firm that the drug registration for Fespixon had been approved by BPOM. Following the commercial launch of this new drug in Indonesia, Oneness Biotech will pay a sales royalty to the licensor in accordance with the terms of their licensing agreement. |
| 2025-08-11 |
EirGenix Debuts on TWSE Today, Forms ADC Alliance with TTY Biopharm
|
EirGenix (Taiwan Biotech Co., Ltd.) is officially transitioning to the Taiwan Stock Exchange (TWSE) today (21st). Chairman Dr. Lee-Cheng Liu announced that in addition to the continued momentum of its CDMO business, the company has entered a strategic alliance with TTY Biopharm for the development of ADCs (antibody-drug conjugates) that combine large-molecule biologics with small-molecule drugs. Furthermore, the company’s first biosimilar for breast cancer, EG12014, has already obtained two drug licenses, which are expected to further boost its growth trajectory. |
| 2025-08-11 |
PharmaEssentia's New Drug Ropeg Applies for Regulatory Approval in Canada, Expanding Its Global PV Market Footprint
|
Last Friday (the 18th), PharmaEssentia announced a major development: the company has submitted a New Drug Submission (NDS) in Canada for its proprietary therapy BESREMi (Ropeginterferon alfa-2b, referred to as Ropeg or P1101) for the treatment of polycythemia vera (PV), marking its official entry into the Canadian market. |
| 2025-08-11 |
Enimmune Submits Marketing Authorization Application for EV71 Vaccine in Vietnam
|
Emerging biotech stock Enimmune announced on the 20th that its independently developed enterovirus 71 (EV71) vaccine, EnVAX-A71, has been officially submitted for marketing authorization in Vietnam. The submission was made on July 18 by its local partner, the Vietnamese state-owned company VABIOTECH, to the Drug Administration of Vietnam (DAV) under the Ministry of Health. |
| 2025-08-07 |
Collaborative Breakthrough by NCKU Cancer-Cardiology Team: New Drug Proven Effective in Preventing Cardiotoxicity from Cancer Treatments
|
The Cardiology Department, Division of Medical Oncology, and Breast Surgery Department at National Cheng Kung University Hospital (NCKU Hospital) have successfully completed the world’s first Phase II clinical trial using a next-generation heart failure drug—Angiotensin Receptor-Neprilysin Inhibitor (ARNI)—to prevent cancer therapy-related cardiac dysfunction (CTRCD). This collaborative research marks a major step forward in achieving safer and more effective integrative care for cancer patients. |
| 2025-08-07 |
Locus Cell's Order Book Extends Through End of 2025
|
Locus Cell’s large-scale CDMO facility for cell therapy in Zhubei is nearing completion and gearing up for production. The company announced yesterday (17th) that the construction of the Zhubei plant, built with an investment exceeding NT$900 million, will be completed in August this year. An additional NT$547 million will be invested in interior construction, with the goal of officially beginning production in the first quarter of next year. |
| 2025-08-06 |
HanchorBio’s HCB101 Achieves High-Dose Milestone in Clinical Development
|
HanchorBio’s novel immunotherapy drug candidate HCB101 has reached a significant milestone in its Phase I clinical trial. Three patients with advanced solid tumors received a high intravenous dose of 18 mg/kg, and no dose-limiting toxicities or serious adverse events were observed during the monitoring period, demonstrating favorable tolerability. This result was unanimously approved by the Clinical Safety Review Committee at 8:00 PM Taiwan time on July 14, laying a critical foundation for further dose escalation and broader clinical application. |
| 2025-08-06 |
EirGenix Gains Momentum from Contract Fulfillment and CDMO Growth to Boost Second-Half Performance
|
At its investor conference on the 15th, EirGenix announced positive momentum for 2024. Senior Vice President Chang Chih-Jung noted that the number of contracts signed so far this year has already surpassed that of 2023. As these contracts begin to be executed in the third and fourth quarters, along with contributions from the CDMO business, the company expects significant support for its operations in the second half of the year. |
| 2025-08-06 |
Genetics Generation Advancement Builds Smart Laboratory
|
Genetics Generation Advancement (GGA) announced yesterday (16th) that it has signed a strategic cooperation agreement with Lightest Biomedical, a subsidiary of Genomics BioSci & Tech. (GBT), to jointly establish a smart laboratory with AI scalability and compliance management capabilities. This initiative aims to accelerate the development of Lightest Biomedical’s new antibiotics and novel drugs for Parkinson’s disease, with an Investigational New Drug (IND) application to the U.S. expected by 2026. |
| 2025-08-06 |
Gongwin Biopharm's Lung Cancer Drug PTS302 Expands into Malaysia and Taiwan, Accelerating Development in the Asia-Pacific Market
|
Gongwin Biopharm (Gongwin-KY) announced yesterday (16th) that its subsidiary, Gongwin Biopharm Taiwan, has secured two key licensing deals for its lung cancer drug PTS302. |
| 2025-08-06 |
Senhwa Biosciences’ New Drug Program Sponsored by U.S. NCI: First Monotherapy Clinical Trial Begins Patient Enrollment
|
Senhwa Biosciences announced yesterday (July 16) that its investigational new drug Pidnarulex (CX-5461) has been selected for a five-year cancer treatment program sponsored by the U.S. National Cancer Institute (NCI). The first clinical trial under this program—evaluating Pidnarulex as a monotherapy for advanced solid tumors—has successfully enrolled its first patient at the NIH Clinical Center in Bethesda, Maryland, USA. The NCI will fund the clinical trial with an estimated budget of USD 4.8 million, significantly reducing Senhwa's R&D burden and accelerating drug development. |
| 2025-08-06 |
Acer’s Medical Spinoff Develops New AI Healthcare Application
|
Acer Medical, a spinoff of Acer focusing on AI in healthcare, has achieved another milestone in its AI strategy. On July 16, the company announced a partnership with Japan’s Fujitsu to co-develop a new solution named “aiGait powered by UvanceAI.” The solution utilizes Fujitsu’s high-precision AI skeletal recognition technology to analyze patients’ physical movements and gait abnormalities, helping healthcare professionals detect early signs of dementia and Parkinson’s disease, thereby improving clinical diagnosis and intervention efficiency. Acer Medical plans to roll out the solution across elderly care institutions and primary clinics in Taiwan by the end of this year. |
| 2025-08-06 |
Preventing Hospital-Acquired Infections: TYGH and NHRI Jointly Develop “Blind-Spot-Free” Hand Hygiene Monitoring System
|
Hand hygiene is a key measure in preventing infections—especially critical within hospital settings. During the COVID-19 pandemic, Taoyuan General Hospital, Ministry of Health and Welfare (TYGH), experienced a major nosocomial outbreak that led to a 42-day shutdown. In response, the hospital collaborated with the Institute of Biomedical Engineering and Nanomedicine at the National Health Research Institutes (NHRI) to develop the world’s first non-camera, de-identified hand hygiene monitoring system. This innovative system was validated in the hospital’s intensive care units (ICUs) with an accuracy rate of 70% and was featured on the cover of the international journal Global Challenges in December last year. |
| 2025-08-06 |
Ministry of Digital Affairs to Launch Taiwan Sovereign AI Corpus in Q4
|
The Ministry of Digital Affairs has proposed the “Data Innovation and Utilization Promotion Act” and held a briefing on July 15 to explain key aspects of the draft legislation. Among the highlights is the plan to build Taiwan’s sovereign AI corpus by establishing standard licensing terms and conducting data inventories across government agencies. The corpus is scheduled to launch in the fourth quarter. |
| 2025-08-06 |
Leadtek Biomed Chairman Appointed: ADATA Takes 41% Stake, K.S. Lu to Serve as CEO and Drive IPO Efforts
|
Leadtek Biomed, a biotech subsidiary of Leadtek, recently raised NT$100 million in capital and brought in high-profile strategic partners. Memory giant ADATA acquired a 41% stake, becoming the largest shareholder. ADATA Chairman Simon Chen has taken over as Chairman of Leadtek Biomed from Leadtek’s Chairman K.S. Lu. The company registration update was completed at the end of June. |
| 2025-08-06 |
Government Policy Fully Backing Taiwan Innovation Board’s Push Toward Becoming the “Nasdaq of Asia”
|
Chairman of the Taiwan Stock Exchange (TWSE), Lin Hsiu-Ming, stated on the 15th that the Exchange will continue to refine the Innovation Board's framework and dedicate more resources to realizing its goal of becoming the “Nasdaq of Asia” and a cradle for the next wave of unicorns. These efforts are aimed at fostering a globally competitive, flexible, and innovation-friendly regulatory environment, positioning Taiwan as a rising hub for emerging industries and international investors. |
| 2025-08-06 |
China Medical University Launches AI Medical Robotics Initiative
|
AI-powered robots are booming, and major medical institutions are pushing for widespread adoption. Chang-Hai Tsai, Chairman of China Medical University and Healthcare System, stated that the CMU system will focus on the development of intelligent medical robots, including care robots, companion robots, disinfection robots, and nursing robots. The university will continue to collaborate with leading technology companies and innovation teams to jointly develop a new generation of smart robots. |
| 2025-08-06 |
Acepodia Biotechnologies Eyes ADC Market Boom, Plans to Spin Off New Company and Attract U.S. and European Investment
|
Targeting the booming antibody-drug conjugate (ADC) market, Acepodia Biotechnologies Chairman Sonny Hsiao announced on the 14th that the company plans to spin off its bispecific antibody dual-drug conjugation platform into a new entity, contributing the technology as capital. The new company aims to attract American investors, with the goal of completing the setup by the end of this year and raising $50–60 million USD to accelerate development of the platform technology. |
| 2025-08-06 |
Sinphar Advances Global Expansion with Multiple International Partnership Agreements
|
On July 14, Sinphar Pharmaceutical announced a major step forward in its internationalization efforts. During the Interphex Japan exhibition held this July, Sinphar’s General Manager, Yu-Liang Pei, personally led a team to Japan, where the company successfully signed several cross-border cooperation agreements. The team also held in-depth discussions regarding pharmaceutical contract manufacturing and import sales, further strengthening its market presence in Taiwan and across Asia. |
| 2025-08-06 |
Flat Medical Accelerates Global Expansion with Continued Breakthroughs in Anesthesia and Pain Localization Technology
|
Taiwanese medical technology company Flat Medical has been steadily advancing both technologically and commercially in the global anesthesia and pain management sector in recent years. Since entering mass production and sales in 2023, its flagship product, the EpiFaith® smart locator, has experienced rapid growth with an annual increase of 3 to 4 times in sales volume. Cumulative shipments have surpassed tens of thousands of units, establishing a solid presence across key markets including Europe, the United States, Japan, South Korea, and Taiwan. |
| 2025-08-06 |
Brighten Optix Reports June Revenue of NT$48.68 Million, Up 4.8% Month-on-Month; First Half Revenue Grows 3.1% Driven by Two Key Factors
|
Brighten Optix announced on the 10th that its consolidated revenue for June reached NT$48.68 million, a 4.81% increase compared to the same period last year. The company’s consolidated revenue for the first half of the year totaled NT$368 million, up 3.1% year-on-year, primarily benefiting from strong growth in emerging markets across the Asia-Pacific region and continued strong sales of its three-in-one myopia control kit. |
| 2025-08-06 |
Darwin Precisions Corporation Expands into Diverse Fields
|
Michael Tsai, Chairman of Darwin Precisions Corporation, stated that the company is no longer just a display manufacturer but now provides comprehensive solutions that truly address customer needs. With new applications gradually coming to fruition, Darwin is actively expanding into multiple fields, embarking on a new phase of growth. |
| 2025-08-06 |
Dual Engines Drive Growth: GeneReach Biotechnology’s June Revenue Up 66% Year-on-Year
|
GeneReach Biotechnology announced consolidated revenue of NT$17.31 million for June 2025, a 3.26% month-on-month decrease but a 65.54% increase compared to the same period last year. The company’s cumulative revenue for the first half of the year reached NT$107 million, representing a 20.10% year-on-year growth. GeneReach stated that in the second half of the year, it will further strengthen its global market presence, deepen penetration in existing markets, and continue to explore emerging market potential in South America, focusing on Ecuador and Paraguay, aiming to inject steady operational momentum. |
| 2025-08-06 |
Breakthrough in Pulmonary Hypertension Diagnosis: Results in 10 Minutes
|
Pulmonary hypertension is a highly fatal cardiopulmonary disease that often suffers from delayed diagnosis due to subtle early symptoms, increasing patient mortality risk. Taipei Veterans General Hospital recently announced a major research breakthrough, completing the world’s first multinational and multicenter validation of an "ECG-Based Pulmonary Hypertension Detection System." This system can automatically analyze electrocardiograms within 10 minutes and instantly transmit positive high-risk patient results to clinicians, assisting in timely scheduling of further examinations such as echocardiography, thereby improving survival rates. |
| 2025-08-06 |
Bora Pharmaceuticals Reports H1 Revenue Surpassing NT$10 Billion, Up 26.9%, Setting Historical Record
|
Bora Pharmaceuticals announced on the 10th that its preliminary consolidated revenue for June reached NT$1.65 billion, a 2.7% decrease compared to the same period last year. When measured in U.S. dollars, however, June revenue grew 10.3% from May and increased 3.4% year-over-year. The main factor for this discrepancy was the appreciation of the New Taiwan dollar. For the first half of this year, Bora’s cumulative revenue exceeded NT$10 billion, representing a 26.9% year-on-year increase and setting a new historical record for the period. Overall operations continue to show steady growth. |
| 2025-08-06 |
Gongwin Biopharm’s U.S. Subsidiary to Receive $50 Million Investment from Fund A for Clinical Trials in the U.S.
|
Gongwin-KY announced on the evening of July 10 that its subsidiary, Gongwin Biopharm, received a letter of intent (LOI) from Fund A on July 9. Fund A plans to participate in the establishment of Gongwin’s U.S. subsidiary and intends to invest up to $50 million USD (approximately NT$1.462 billion), representing about half of the Series A fundraising target of $100 million USD. This round of fundraising is expected to release approximately 20% to 25% of the equity. |
| 2025-08-06 |
Daiken Biomedical’s June Revenue Soars Over 90% Year-on-Year with Seven Strategic Engines for Expansion
|
Daiken Biomedical announced that its consolidated revenue for June reached NT$175 million, a 93.35% increase compared to the same period last year. The company’s cumulative revenue from January to June grew 50.57% year-on-year. Concurrently, Daiken unveiled its “Seven Strategic Engines” international expansion blueprint, aiming to establish itself as Asia’s most promising health technology brand. |
| 2025-08-06 |
SYNMOSA Reports 5.7 Billion NTD Consolidated Revenue in June, Up 51.5% Year-on-Year
|
SYNMOSA saw its consolidated revenue reach 575 million NTD in June, representing a 51.5% increase compared to the same period last year and an 8% rise from May. The accumulated consolidated revenue for the first half of the year totaled 3.062 billion NTD, up 16.9% year-on-year. |
| 2025-08-06 |
Import Drug Tariffs at 200% Prompt Bora Pharmaceuticals and Lotus Pharmaceutical to Boost U.S. Manufacturing
|
U.S. President Donald Trump announced plans to impose a 200% tariff on imported drugs, allowing the industry a one-year grace period to relocate production lines to the United States. In response, Taiwan’s two major export-focused pharmaceutical companies, Bora Pharmaceuticals and Lotus Pharmaceutical, recently confirmed they have increased the proportion of drug production on their U.S. manufacturing lines. |
| 2025-08-06 |
Ever Fortune’s Hair Growth Cap Receives TFDA Medical Device Certification, Targets Hair Loss Treatment Market
|
Ever Fortune announced on the 9th that its subsidiary, Ever Wynn Technology, jointly developed the Reness Hair Growth Cap, which has received medical device certification from Taiwan’s TFDA. The company plans to apply next for U.S. FDA approval, aiming to enter the international market with its hair growth technology. |
| 2025-08-06 |
TaiHao Medical Inc. Launches AI Medical Devices in Southeast Asia
|
Taiwanese AI medical imaging leader TaiHao Medical Inc. announced multiple major international developments on July 10, demonstrating its technological strength and commercial progress in the global healthcare market. |
| 2025-08-06 |
Foresee Pharmaceuticals Reports June Revenue of NT$38.86 Million, Up 179% Month-on-Month; H1 Revenue Reaches NT$222 Million, Growing 12% Year-on-Year
|
Foresee Pharmaceuticals announced on the 9th that its consolidated revenue for June was approximately NT$38.86 million, representing a 179% increase from May and a 22% rise year-on-year. The cumulative consolidated revenue for the first half of this year reached about NT$222 million, marking a 12% year-on-year growth. |
| 2025-07-29 |
Tanvex’s June Consolidated Revenue Soars 997% Year-on-Year, Setting New Record; CDMO Revenue Surges
|
Tanvex-KY announced on the 8th that its preliminary consolidated revenue for June reached NT$26.56 million, up approximately 127% from the previous month and soaring 997.56% year-on-year, marking consecutive monthly growth and a new record for the same period. The preliminary consolidated revenue for Q2 totaled NT$46.82 million. Although exchange rate fluctuations caused a slight 6% decrease in NT dollar terms compared to the previous quarter, when measured in functional currency USD, Tanvex Biotech’s Q2 revenue reached about US$1.56 million, representing a 3% increase quarter-on-quarter. |
| 2025-07-29 |
CHLITINA HOLDING LIMITED’s Q2 Profit Boosted by RMB 18 Million Government Subsidy
|
CHLITINA HOLDING LIMITED (麗豐-KY) saw a significant profit boost in the second quarter, benefiting from a RMB 18 million (approximately NT$72.96 million) government subsidy recognized in its accounts. This subsidy contributed NT$0.88 to earnings per share (EPS), substantially higher than the Q1 EPS of NT$0.68. Coupled with a sales upturn in the Chinese mainland market following new product launches, analysts are optimistic about a strong quarterly profit performance, with potential for sustained momentum in the second half of the year. |
| 2025-07-29 |
Grape King Bio Maintains Full-Year Business Outlook
|
Grape King Bio reported a consolidated revenue of NT$4.82 billion for the first half of the year, a year-on-year decrease of 5.57%, due to weakened overall consumer spending. Revenue in June reached NT$880 million, representing a 6.79% increase from the previous month and remaining flat compared to the same period last year. The company anticipates that revenue in the second half will be boosted by the launch of new products, continuing its historical trend of stronger performance in the latter half of the year. All operational plans are proceeding as scheduled, and the company maintains its full-year growth target for consolidated performance. |
| 2025-07-29 |
HeXun Biosciences Reports NT$151 Million in Revenue for the First Half of the Year, Up 13.60% Year-on-Year
|
Driven by the strong momentum of its two core growth engines—CDMO/CMO clinical development and high-quality exosome raw materials—HeXun Biosciences posted revenue of NT$26.78 million in June. Cumulative revenue for the first half of the year reached NT$151 million, marking a 13.60% year-on-year increase. |
| 2025-07-29 |
Protect Biotech Targets Emerging Stock Board Listing in Early August, Focusing on Three Innovative Pet Drug Categories for Global Market Expansion
|
Protect Biotech, a company specializing in the development of new veterinary drugs, announced on July 7 that it has submitted its application earlier this month and aims to list on the Emerging Stock Board in early August. General Manager Haolin Sung stated that the company is focusing on three major categories of pet medications—cancer treatment, heart disease treatment, and autoimmune therapies. Its lead development product, PT001, which targets melanoma, is currently undergoing field trial application. Following its launch in Taiwan, the company plans to expand into international markets. |
| 2025-07-29 |
Health Supplement Industry Expands Aggressively Overseas
|
As global awareness of health and wellness continues to rise, Taiwanese health supplement companies are accelerating their expansion into international markets in search of new growth drivers. Recently, three companies—TCI Co., SHINY BRS GROUP, and Jia Jie Biomedical—have simultaneously advanced into overseas markets, launching full-scale efforts across Europe, the U.S., Japan, Southeast Asia, and Mainland China to capture international revenue growth opportunities. |
| 2025-07-29 |
TaiMed Biologics' Trogarzo Partner TH Acquired by Future Pak; TaiMed Confirms Ongoing Collaboration and Enhanced Synergy
|
TaiMed Biologics announced that its exclusive U.S. partner for the HIV drug Trogarzo, Theratechnologies (TH), has signed a definitive agreement with CB Biotechnology, an affiliate of Future Pak. Under the agreement, TH will be acquired for US$3.01 per share in cash, along with a contingent value right (CVR) of up to US$1.19 per share, bringing the total potential transaction value to US$254 million. The acquisition is expected to close in Q4 2025, pending shareholder and court approval. |
| 2025-07-29 |
KIM FOREST and Chang Hua Hospital, MOHW Collaborate to Establish Taiwan’s First “1-Ping Automated Laboratory 2.0”
|
Biotech-listed company KIM FOREST has partnered with Chang Hua Hospital, Ministry of Health and Welfare (MOHW), to successfully launch a new “Laboratory 2.0” model. The project features the implementation of Roche Diagnostics’ most advanced fully automated testing systems, creating a highly efficient and intelligent testing workflow within a limited space, and setting a new benchmark for smart healthcare in Taiwan. |
| 2025-07-29 |
Biotech M&A Heats Up: Acquiring Drug Licenses and Technologies Becomes the New Strategy—Lotus Pharm, Handa, and Taiwan Bio Therapeutics Lead the Charge
|
The wave of mergers and acquisitions in the biotech industry continues to intensify. Beyond traditional company takeovers, the acquisition of drug licenses and cutting-edge technologies—aimed at rapidly boosting revenues and enhancing R&D capabilities—has emerged as a new and increasingly strategic approach. Lotus Pharmaceutical alone acquired six drug licenses from international pharmaceutical companies in the first half of this year to expand its presence in Southeast Asia. Earlier this year, Handa Pharmaceuticals invested USD 30 million to acquire the blood cancer drug Phyrago (Dasatinib), while Taiwan Bio Therapeutics obtained the patent rights to the TregCel regulatory T cell (Treg) platform from U.S.-based TRACT for USD 3.5 million, strengthening its position in cell therapy. |
| 2025-07-29 |
Foxconn and Kawasaki Heavy Industries Testing “Nursing Robot” in Taiwan; Japanese Media: Commercial Launch Set for 2026
|
According to Nikkei Asia, Foxconn Technology and Japanese robotics giant Kawasaki Heavy Industries have jointly developed a humanoid nursing robot, which is currently undergoing testing at a hospital in Taiwan. The robot is expected to be officially launched in the Taiwanese market in fiscal year 2026, with a sales target of 200 units by fiscal year 2027. |
| 2025-07-29 |
PharmaEssentia Reports Double-Digit Growth in June Revenue; Q2 Marks Ninth Consecutive Record-High, H1 Revenue Up 73.23% Year-on-Year
|
PharmaEssentia announced that its revenue for June reached NT$1.2 billion, marking a 1.51% month-on-month increase and a 41.09% year-on-year growth. The revenue was primarily driven by steady sales growth of its novel rare blood cancer treatment, Ropeginterferon alfa-2b (Ropeg, also known as P1101), in the U.S. market. Despite the recent strength of the New Taiwan Dollar, the company still posted both monthly and yearly revenue gains, supporting continued revenue growth. |
| 2025-07-29 |
Orient Europharma Introduces Photoimmunotherapy, Aiming for Taiwan Drug Approval Next Year
|
Orient Europharma recently announced that it has secured the commercial rights to Rakuten Medical’s Alluminox platform-based photoimmunotherapy products in Taiwan, Singapore, Malaysia, and the Philippines. This therapy was approved by Japan’s Ministry of Health, Labour and Welfare in 2021 and has since been used in nearly 1,000 treatment sessions. Currently undergoing Phase III clinical trials in Taiwan, Orient Europharma aims to obtain regulatory approval locally by next year. |
| 2025-07-15 |
ApexBio Sees Q3 Revenue Dip, Eyes Rebound in Q4; CGM Clinical Submission Targeted by Year-End
|
Medical device company ApexBio reported strong performance in the first half of the year, with revenue reaching NT$924 million for the January–May period, marking a 25.5% year-on-year increase. The company stated that due to ongoing uncertainty surrounding U.S. tariffs, it will temporarily shift focus toward the European and other markets. While third-quarter demand is expected to soften due to the summer holiday season, shipment momentum is projected to strengthen in the fourth quarter. As for its continuous glucose monitoring (CGM) product, ApexBio aims to complete development and submit a clinical trial application by the end of the year, with certification efforts to follow in 2025. |
| 2025-07-15 |
TCI Co. Pursues Asset-Light Global Expansion to Mitigate Tariff Risks
|
In response to the growing trend of localized manufacturing triggered by Trump-era tariffs, TCI Co. announced the launch of its "asset-light global expansion strategy." In addition to its existing facilities in Taiwan, China, and the United States, the company has completed production line setup at its India plant this year and is actively evaluating the establishment of a liquid pouch production line in Europe. Further expansions into other regions are also planned to strengthen its global footprint. |
| 2025-07-15 |
Acer Medical’s “VeriOsteo OP” Obtains Regulatory Approval in Singapore
|
Acer Medical, the smart healthcare subsidiary of Acer Group, continues to expand its footprint in Southeast Asia. On July 3, the company announced that its AI-assisted diagnostic software for bone density abnormalities, VeriOsteo OP, has officially received marketing authorization from Singapore’s Health Sciences Authority (HSA). |
| 2025-07-15 |
Taipei Veterans General Hospital Reaches 500 Cases of Carbon Ion Therapy, With Pancreatic Cancer Leading and Drawing Patients from Southeast Asia
|
Taipei Veterans General Hospital (TVGH) has reached a significant milestone at its Heavy Particle Therapy Center, treating its 500th cancer patient. To mark the occasion, the medical team prepared a special farewell for the patient before his return home, celebrating the successful completion of his treatment. According to Dr. Yu-Ming Liu, Director of the Center for Heavy Particle and Radiation Oncology at TVGH, 90% of patients receiving this advanced therapy are from Taiwan, while the remaining 10% are international patients—primarily from Southeast Asia. Among the treated cancers, pancreatic cancer, known for its treatment difficulty, accounts for the largest share. |
| 2025-07-15 |
Yoda Therapeutics-KY’s Phase II MSA Clinical Trial Approved by Japan’s PMDA, Targeting Completion by 2026
|
Yoda Therapeutics-KY announced on the 2nd that its subsidiary’s application for a Phase II clinical trial of YA-101, a new drug candidate for the treatment of Multiple System Atrophy (MSA), has been approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). This follows previous approvals by the U.S. Food and Drug Administration (FDA) and Taiwan’s Food and Drug Administration (TFDA) last year. |
| 2025-07-15 |
Lin BioScience’s Oral Drug LBS-008 for Late-Stage Dry AMD Completes Global Phase 3 Enrollment
|
On July 2, Lin BioScience, through its subsidiary Belite Bio, Inc., announced that enrollment for the global Phase 3 clinical trial of its oral drug LBS-008 (Tinlarebant) for the treatment of geographic atrophy (GA), the advanced form of dry age-related macular degeneration (dry AMD), has been completed. A total of 500 participants were enrolled across the United States, United Kingdom, France, Czech Republic, Switzerland, mainland China, Taiwan, and Australia. Tinlarebant is positioned to become the world’s first oral treatment for GA, targeting a global market opportunity exceeding USD 20 billion. |
| 2025-07-15 |
Inventec’s AI Empowers Wound Care at Taichung Tzu Chi Hospital, Enhancing Medical Quality and Efficiency
|
On July 2, leading ODM manufacturer Inventec announced that its AI-powered medical device, “InSmart Wound Assessment Software” (TFDA Device License No. 008105), has been in service at Taichung Tzu Chi Hospital for nearly a year. The software has successfully supported the development of the hospital’s signature wound care program. From initial wound screening across the hospital to specialist nurse training applications, the software has reduced average wound assessment time by more than 40-fold. This year, Tzu Chi Medical Foundation plans to expand its use to long-term care centers, supporting home care and community-based specialist nurses in wound assessment—accelerating chronic disease care, alleviating workforce shortages, and improving long-term care quality. |
| 2025-07-15 |
Taipei Veterans General Hospital Reaches AI Diagnostic Milestone: Brain Imaging Identifies Schizophrenia with 91.7% Accuracy
|
Schizophrenia is a severe, chronic mental disorder affecting about 1% of the global population. Traditionally, diagnoses have relied primarily on behavioral assessments, and the medical community has long sought objective biological markers. Professor Chih-Chieh Yang from the Department of Psychiatry at Taipei Veterans General Hospital has led a team in developing an advanced “Smart Brain Imaging Platform” using cutting-edge medical AI technology. This platform assists in evaluating schizophrenia with an accuracy rate of 91.7%, earning a Gold Medal at the prestigious Edison Awards—known as the “Oscars of Innovation.” |
| 2025-07-15 |
Ever Supreme Bio Technology Celebrates Dual Milestones: Record-High June Revenue and Phase 2 Trial of UMSC01 Set for Q3 Launch
|
Ever Supreme Bio Technology has announced two major milestones. Thanks to sustained momentum in its cell therapy CDMO (Contract Development and Manufacturing Organization) orders, the company posted June consolidated revenue of NT$80.87 million, marking a 30% year-on-year growth and an 11% increase from the previous month—the highest June revenue in the company’s history. Cumulative revenue for the first half of the year has reached NT$398 million, and expectations for even stronger performance in the second half remain high, signaling continued positive growth momentum. |
| 2025-07-15 |
New Biomedical Player Joins the Market: LotusNine Medical Debuts on the Pioneer Stock Board, Focusing on Mobile AI Medical Devices
|
The Taipei Exchange’s Pioneer Stock Board welcomes a new addition in the biotech and healthcare category. LotusNine Medical Inc., a company integrating AI to develop innovative mobile medical devices and risk detection platforms, officially listed today (July 2). |
| 2025-07-15 |
Primo Biotechnology Completes Series A Funding, Targets Emerging Stock Board Listing by 2026
|
As global pharmaceutical giants Eli Lilly, AstraZeneca, and Novartis aggressively expand into the radiopharmaceutical market, Taiwan-based startup Primo Biotechnology Co., Ltd. is gaining momentum, announcing the successful completion of its Series A funding round. |
| 2025-07-15 |
Immunwork’s Long-Acting Octreotide Drug TE-8214 Shows Promising Results in Phase 1 Clinical Trial
|
Immunwork, founded by renowned immunologist Tse Wen Chang, announced on July 1 that its independently developed long-acting octreotide candidate TE-8214 has successfully completed its Phase 1 clinical trial in Australia. The results demonstrated good safety and tolerability, with the drug achieving its intended pharmacological mechanism. Additionally, subcutaneous injection was well tolerated and did not cause any injection-site reactions. |
| 2025-07-15 |
HanchorBio Licenses Immuno-Oncology Drug HCB101 to Shanghai Henlius in a Deal Worth Up to USD 202 Million
|
HanchorBio, a Taiwan-based biotech company specializing in innovative immuno-oncology therapies, announced on June 30 that it has entered into an exclusive regional licensing agreement with Shanghai Henlius Biotech, Inc. The deal includes a $10 million upfront payment and up to $192 million in milestone payments, for a total potential value of $202 million. The agreement covers the development and commercialization of HCB101 across Mainland China, Hong Kong, Macau, selected Southeast Asian countries, and the entire MENA region (Middle East and North Africa). This collaboration marks a significant milestone for Taiwan’s homegrown oncology drug development on the international stage. |
| 2025-07-15 |
Tanvex BioPharma Breaks into U.S. Market with First Biosimilar, Licensed for 2025 Launch
|
Tanvex BioPharma, a subsidiary of the Bora Group, announced yesterday (June 30) that it has licensed its biosimilar NYPOZI to U.S.-based pharmaceutical company Invagen for commercial sales in the United States. Industry insiders note that this marks a new chapter for Tanvex, as it officially enters the global market with product launches expected to generate revenue, royalties, milestone payments, and profit-sharing income. |
| 2025-07-15 |
PURIBLOOD MEDICAL to Establish Domestic Blood Bag Supply Chain as Product Gains Strategic Material Status
|
PURIBLOOD MEDICAL, the only domestic manufacturer of blood bags and leukocyte reduction filters in Taiwan, announced on June 30 that it is ready to begin production at the nation’s first blood bag manufacturing facility in Shulin, built in collaboration with Nan Ya Plastics through a technology transfer. The facility has an initial production capacity of 8 million blood bags and 2.8 million sets of blood bag filter kits. Once the in-line filter kit product receives certification, it will be immediately available to meet national demand. |
| 2025-07-15 |
CHLITINA-KY Targets Steady Quarterly Growth in 2025 through Brand Expansion, Product Innovation, and New Customer Acquisition
|
CHLITINA Holding Limited (CHLITINA-KY) is aligning its operations with the growing demand in the premium anti-aging market, while actively responding to the rise of new retail and evolving consumer behaviors. In addition to launching multiple new products, the company is strengthening its live commerce strategy through official livestreams, in-house broadcasting teams, and collaborations with key opinion leaders (KOLs) to boost product visibility and conversion. In 2025, CHLITINA aims to drive growth by expanding its brand portfolio, introducing new products, and acquiring new customers. With supportive policies under China’s “seeking progress while maintaining stability” approach, the company expects revenue to grow steadily, achieving its goal of quarter-over-quarter improvement. |
| 2025-07-14 |
OBI Pharma Focuses on ADC as Core Growth Strategy
|
At the shareholders’ meeting on the 27th, OBI Pharma CEO Heidi Wang announced that following the termination of the Globo H program, the company has realigned its strategy to concentrate on antibody-drug conjugate (ADC) products and platform technology licensing as its primary growth driver moving forward. |
| 2025-07-14 |
TCM BIOTECH Continues New Drug and Innovative Medical Device Development; 2025 Operations Expected to Surpass Last Year
|
At its shareholders’ meeting on the 27th, TCM BIOTECH approved the 2024 financial statements and dividend distribution plan, proposing a cash dividend of NT$0.35 per share. Chairman Huan-Ching Hsu stated that although revenue declined last year due to adjustments in production and sales structure, overall profitability still grew. For 2025, cumulative consolidated revenue through May decreased by 2.17% year-on-year; however, May alone showed strong growth with monthly revenue up 34.65% and year-on-year growth of 22.08%, reflecting robust double-digit monthly and yearly increases. With continued benefits from product mix adjustments, second-half performance is expected to surpass the first half. |
| 2025-07-14 |
TaiRx Advances Dual Track of New Drugs and Health Products with Comprehensive International Collaboration
|
TaiRx, a biopharmaceutical company, is progressing on two fronts: new drug development and health products. Following the U.S. FDA orphan drug designation granted to its small-molecule anticancer drug CVM-1118, the company has attracted multiple international pharmaceutical companies for partnership discussions. The next step involves initiating multinational, multi-center clinical trials targeting neuroendocrine tumors (NET) in collaboration with major industry players. Meanwhile, the selenium injection and health supplement businesses continue to expand, with a flagship health product scheduled for a major launch in mid-August and a high-dose packaging version of the selenium injection “Xiningte” planned for release next year. |
| 2025-07-13 |
SG Biomedical Advances Innovative Plasma Medical Technology, Setting New Milestones in Healthcare Industry
|
SG Biomedical specializes in innovative plasma medical technology, pioneering the use of plasma treatment for chronic wounds in surgical care. With over 18 years of clinical evidence from hospitals in Germany, the UK, and the European Union, its efficacy has been validated by more than 82 professional medical journals worldwide. The technology is applicable to various types of wound care, including acute and chronic large wounds, diabetic foot ulcers, surgical wound infections, and burn infections. |
| 2025-07-06 |
TBMC to Build Taiwan’s First GMP Facility for Nucleic Acid Drugs, Targeting Launch in First Half of 2026
|
Taiwan Bio-Manufacturing Corporation (TBMC) held a groundbreaking ceremony on the 26th for its new GMP facility in Zhubei, marking the official launch of the nation’s first GMP-compliant manufacturing base for mRNA nucleic acid drugs and vaccines. The facility is slated for operation in the first half of 2026. Chairman Patrick Y. Yang stated that this represents a key milestone in TBMC’s journey toward becoming a world-class pharmaceutical CDMO. |
| 2025-07-06 |
Andros Pharmaceuticals Reports Positive Phase II Results for APC201, Initiates Global Licensing
|
On June 26, Andros Pharmaceuticals announced on behalf of its subsidiary that the Phase I/IIa clinical trial for its novel drug APC201—designed to treat localized knee osteoarthritis pain—has yielded positive Phase II results in Australia. Both primary and secondary efficacy endpoints were met, indicating good overall safety and tolerability, with preliminary data showing a trend toward pain reduction in study participants. |
| 2025-07-06 |
APRINOIA Therapeutics Targets Early Diagnosis Market for Dementia
|
APRINOIA Therapeutics is advancing into the early diagnosis market for dementia. On June 25, company founder Ming-Kuei Jang stated that the presence of Tau protein is highly correlated with neurodegeneration and disease progression, making it a gold standard for early diagnosis. APRINOIA’s lead imaging agent, APN-1607, enables visualization of Tau protein deposition in the brain and is currently undergoing regulatory review in Taiwan, China, the United States, and Japan. Taiwan may become the first market to approve the product. |
| 2025-07-06 |
Sunfun Info Pursues Triple-Growth Strategy in 2025; Subsidiary Daiken Biomedical Gains Listing Approval
|
Sunfun Info held its annual shareholders’ meeting on June 26, chaired by Chairman Chia-Ming Chang, where it approved a fourth-quarter 2024 dividend distribution of NT$0.2036 per share in cash. To strengthen working capital and support future investments in new ventures—particularly in AI and the beauty & housing sectors—the company plans to issue both cash and stock dividends in parallel. Meanwhile, on June 25, its subsidiary Daiken Biomedical received formal approval for its initial public offering from the Taiwan Stock Exchange Board of Directors. |
| 2025-07-06 |
Orient EuroPharma Introduces Cancer-Fighting Photoimmunotherapy in Collaboration with Japan’s Rakuten Medical
|
A new breakthrough in cancer treatment is on the horizon. Orient EuroPharma (OEP) Group has announced that it has secured the commercial rights to Rakuten Medical’s photoimmunotherapy platform in Taiwan, Singapore, Malaysia, and the Philippines. This marks Rakuten Medical’s first licensing agreement with a Taiwanese pharmaceutical company. The therapy is currently undergoing Phase III clinical trials in Taiwan, with the goal of obtaining local regulatory approval next year. Rakuten Medical also plans to consolidate clinical data from Taiwan, the U.S., and Japan to pursue FDA approval in the U.S., further expanding the reach of this innovative treatment. |
| 2025-07-06 |
Sofiva Genomics Advances Precision Medicine with Strategic Focus on Cancer, Dementia, and Reproductive Health
|
At its institutional investor conference on the 25th, Sofiva Genomics outlined its three major strategic priorities, with Chairman Yi-Ning Su personally presenting the company’s vision: integration into Taiwan’s NGS (next-generation sequencing) national health insurance coverage, active expansion into cancer and Alzheimer’s genetic screening markets, and growth in PGT-A applications in assisted reproduction. As the scope of its products and services continues to expand, Sofiva Genomics is poised for a new wave of growth. |
| 2025-07-06 |
EpiSonica Secures Medical Device Approvals in Indonesia and Thailand, Accelerates Southeast Asia Expansion
|
EpiSonica’s flagship product, the ArcBlate MRgHIFU—an image-guided focused ultrasound surgical system—has received market clearance from the Thai Food and Drug Administration, following its approval by Indonesia’s Ministry of Health in late August last year. The device is approved for the treatment of adenomyosis and uterine fibroids. |
| 2025-07-02 |
3D Global Biotech to Launch IPO Application in Q3, Eyes Growth with Pediatric Myopia Control Products
|
3D Global Biotech is set to initiate its IPO process, with plans to submit an application for listing on the Taiwan Innovation Board or over-the-counter (OTC) market as early as the third quarter. Targeting opportunities in the ocular health market, the company leverages its proprietary nano-surface functional crosslinking technology to enhance the water content and moisture retention of contact lenses. Following its initial shipments of adult contact lenses to clients in China at the end of last year, 3D Global Biotech will also introduce orthokeratology lenses for pediatric myopia control, with shipments to China expected in the second half of the year. |
| 2025-07-02 |
Pharmosa Biopharm Announces EU Orphan Drug Designation for Investigational Drug L608
|
Pharmosa Biopharm announced on June 24 that it has received official written notification from the European Commission, confirming that its investigational drug L608 has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for the treatment of systemic scleroderma (SSc). |
| 2025-07-02 |
Ever Fortune.AI Projects 20–30% Revenue Growth This Year, Teams Up with Phison to Debut AI Healthcare Robot Prototype by Year-End
|
Ever Fortune.AI is targeting the growing burden on frontline healthcare workers by developing an AI-powered medical care robot through its joint venture with Phison Electronics. Their co-founded company, EverBot Technology, is expected to unveil a prototype in the third quarter and make its public debut at a medical technology exhibition by the end of the year. Supported by the ramp-up of its Medical AI product line and continued strong sales of health supplements by its subsidiary, Ever Fortune.AI anticipates a 20–30% year-over-year revenue increase in 2024. |
| 2025-07-02 |
Three Gynecological Drugs to Be Withdrawn: No Benefit in Preventing Preterm Birth and Potential Cancer Risk in Male Offspring
|
Taiwan’s Food and Drug Administration (TFDA) announced that medications containing hydroxyprogesterone caproate will have their licenses revoked by January 2026, following a re-evaluation of their clinical benefits and risks. These drugs are commonly prescribed for gynecological conditions such as dysmenorrhea, irregular menstruation, and recurrent miscarriage. Starting next January, patients and healthcare providers will need to switch to alternative treatments. |
| 2025-07-02 |
New Alzheimer’s Drug May Be Covered by NHI by Year-End? Minister Tai-Yuan Chiu: Subject to HTA Evaluation
|
Far Eastern Memorial Hospital and Easeful Clinic had originally scheduled to administer the new Alzheimer’s drug Kisunla on June 18, but due to flight delays, the medication finally arrived in Taiwan on June 19 and cleared customs smoothly. The first dose in Taiwan is expected to be administered on the morning of June 23. Given that a one-year course of treatment costs over one million NTD, the National Health Insurance Administration (NHIA) plans to discuss by the end of the year whether to include it under coverage. Minister of Health and Welfare Tai-Yuan Chiu stated that the decision will first undergo a formal Health Technology Assessment (HTA) to ensure rational resource allocation. |
| 2025-07-02 |
Heron Neutron Medical Aims to Go Public by Year-End, Pushing Taiwan-Made BNCT onto the Global Stage
|
Heron Neutron Medical, a subsidiary of the Hermes Technology Group, is accelerating its efforts to commercialize its accelerator-based boron neutron capture therapy (AB-BNCT). The company obtained medical device approval for its AB-BNCT system in 2024, and its companion drug B10 L-BPA for head and neck cancer is currently in Phase II clinical trials, with patient enrollment expected to be completed by the end of this year. General Manager Shen Leo emphasized that BNCT is Taiwan’s only domestically developed large-scale medical device, and with supportive government policy, it has the potential to represent Taiwan on the global stage—not only by advancing from late-line to second-line treatment locally, but also by facilitating international deployment through whole-plant exports. |
| 2025-07-02 |
Onyx Healthcare Builds Third Growth Engine, High-Margin Projects to Continue Shipping in H2 with Positive Outlook for the Year
|
Onyx Healthcare is developing a third growth engine, according to General Manager Fu-Chun Chuang. The company’s two core businesses continue to advance steadily, while its new full-scale medical device contract manufacturing (CM) business is set to launch following GMP (now QMS) certification. This initiative focuses on mass production of existing, already-approved devices, aiming to begin contributing to revenue within four to six months. Although gross margin faced headwinds in the first quarter, high-margin project clients remain stable, with shipments expected in the second half of the year, supporting a cautiously optimistic full-year outlook. |
| 2025-07-02 |
UNICOCELL BIOMED Submits Listing Application, Eyes Board Transition in Q4
|
UNICOCELL BIOMED has officially submitted its listing application to the Taiwan Stock Exchange, following the receipt of approval as a technology-based enterprise. With two of its allogeneic adipose-derived stem cell therapies already in mid- to late-stage clinical trials, and operations showing steady progress, the company is widely expected to complete its board transition by the fourth quarter. |
| 2025-07-02 |
Merry Life’s Alzheimer’s Drug TML-6 Receives FDA Approval for Global Phase II Clinical Trial
|
Merry Life Biomedical announced on the 23rd that its investigational new drug for Alzheimer’s disease (AD), TML-6, has received FDA approval to initiate a global Phase II clinical trial. Following the launch of its Phase I trial in the U.S. in June last year, the FDA formally approved Merry Life’s Phase II clinical trial protocol in May this year. The trial is scheduled to begin in the first quarter of 2026, enrolling 210 participants for a 12-month study. |
| 2025-07-02 |
EU MDR Fully Enforced by 2028: Sixteen Taiwanese Companies, Including Qisda and United Orthopedic, Secure Early Market Access
|
The European Union’s new Medical Device Regulation (MDR) is set to be fully implemented by the end of 2028. At present, only 16 Taiwanese manufacturers—including Qisda, AmCad BioMed, PACIFIC HOSPITAL SUPPLY, United Orthopedic, Avita, Wellell, and Visco Vision—have successfully obtained MDR certification, securing their entry into the EU market. Older certificates issued under the former MDD framework for invasive, moderate- to high-risk devices expired at the end of last year, posing a major challenge for companies seeking to maintain or expand their European market presence. |
| 2025-07-02 |
TaiMed Biologics Announces Phase IIb Clinical Trial of TMB-365/380, Marking a Major Milestone in Transforming HIV Treatment
|
TaiMed Biologics announced on the 22nd the official launch of its Phase IIb clinical trial for the combination therapy TMB-365/380. The trial’s primary efficacy endpoint will evaluate the proportion of participants with HIV-1 RNA below 50 copies/mL at week 48, based on the Snapshot analysis method. In addition to expanding the number of participants, the trial will also extend its geographic scope beyond the United States to include Taiwan, with a total enrollment target of 75 subjects. |
| 2025-07-01 |
CHC Healthcare Group Targets Profit Growth with Three Strategic Initiatives
|
CHC Healthcare Group is set to ramp up activity across its three major business divisions in the second half of the year. The company announced that, driven by a wave of equipment replacements at hospitals, many institutions are expanding their procurement of new medical devices, with revenue from these orders expected to be recognized starting in the third quarter. In addition, the appreciation of the New Taiwan dollar is favorable for equipment purchases, leading to a projected increase in both revenue contribution and profitability from the medical equipment segment this year. |
| 2025-07-01 |
Genomics BioSci & Tech. Targets Profitability and Launches IPO Plan for 2025
|
Genomics BioSci & Tech. (Genomics) held its annual shareholders’ meeting on the 20th, approving a cash capital increase through public offering in preparation for its initial public offering (IPO). Shareholders also agreed to waive their preemptive rights, officially initiating the company’s IPO process. Chairman Meng-Hsien Chou stated that following a strategic business realignment, the company is now focused on revenue growth and aims to achieve profitability this year. |
| 2025-07-01 |
The 2026 World Congress of Internal Medicine to Be Held in Taiwan: Ming-Shiang Wu Hopes to Showcase Taiwan's Medical Strength
|
In a major step toward elevating Taiwan’s global visibility in healthcare and realizing the vision of a “Healthy Taiwan,” the Taiwan Society of Internal Medicine has successfully secured the bid to host the 2026 World Congress of Internal Medicine. The Society announced that the event will bring together over 8,000 internists, scholars, and researchers from around the world to Taiwan. The congress will focus on the importance of preventive medicine in internal medicine, particularly the critical role of adult vaccination in enhancing public health. Through cross-sector collaboration and policy advocacy, the event aims to demonstrate Taiwan’s strong commitment to improving healthcare quality and extending healthy life expectancy. |
| 2025-07-01 |
Locus Cell Secures Another International Order, Partners with Japan’s CellFiber to Expand Global CDMO Footprint
|
On the 19th, Locus Cell announced the signing of a CDMO (Contract Development and Manufacturing Organization) agreement with CellFiber, a leading regenerative medicine company in Japan. Under the agreement, Locus Cell will support the production of clinical-grade products, with the total value estimated to exceed tens of millions of New Taiwan dollars. With the company’s fully automated GMP-compliant smart facility in Zhubei set to be completed by the end of the year, Locus Cell expects to seamlessly scale up to mass production and sees strong potential for expanding its CDMO business. |
| 2025-07-01 |
Comeback in Motion: EirGenix’s Licensing Partner Sandoz Resubmits EG12014 Biologics License Application to the FDA for Review
|
EirGenix announced on the 19th that its licensing partner, Sandoz, has resubmitted the Biologics License Application (BLA) for EG12014, a trastuzumab biosimilar lyophilized injection (150 mg), to the U.S. Food and Drug Administration (FDA) for review. |
| 2025-06-28 |
JUN ZHI Biomedical Partners with University of South Australia to Advance International Clinical Applications of Nano Mass Spectrometry
|
On the 18th, JUN ZHI Biomedical Co., Ltd. officially signed a Memorandum of Understanding (MOU) with the University of South Australia to jointly promote the clinical application and global expansion of its nano mass spectrometry diagnostic platform, bringing new momentum to the field of precision medicine worldwide. |
| 2025-06-28 |
Lotus Pharmaceutical to Acquire Five Drug Licenses in Vietnam for NT$457 Million, Accelerating ASEAN Expansion
|
On the 18th, Lotus Pharmaceutical announced that its subsidiary, Lotus International Pte. Ltd., has signed an asset purchase agreement with Vietnam’s Duy Tan Pharmaceutical Joint Stock Company. The deal involves acquiring trademarks, drug marketing approvals, and manufacturing supply agreements for five pharmaceutical products in Vietnam for a total consideration not exceeding USD 15.5 million (approximately NT$457 million). The transaction is expected to close in the third quarter. |
| 2025-06-28 |
PharmaEssentia’s New Drug Ropeg Approved in Argentina, Expanding Latin American Market After Brazil
|
PharmaEssentia announced on the 18th that its new drug Ropeginterferon alfa-2b (Ropeg) has received approval from Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) for the treatment of polycythemia vera (PV). Following its approval in Brazil earlier this March, this marks another milestone for PharmaEssentia’s expansion into the Latin American market, further advancing its global business footprint. |
| 2025-06-28 |
Sunmax Biotechnology’s New Factory Passes QMS Certification, Bulk Solution Production Begins to Contribute, Revenue Growth Expected to Strengthen This Year
|
Sunmax Biotechnology, a collagen implant manufacturer, successfully passed its earnings distribution plan at its shareholders’ meeting yesterday (18th), approving a cash dividend of NT$11.6 per share. Chairman Barry Lin said after the meeting that although the economic outlook remains weak—especially in the medical aesthetics sector—the company’s uniquely positioned products remain in short supply. While the new factory is not expected to be fully operational until the first half of 2027 at the earliest, Sunmax obtained manufacturing approval under the medical device Quality Management System (QMS) guidelines at the end of April. This will allow the company to gradually start producing bulk solution for filling at the old plant, which will contribute incrementally to performance. Lin expects revenue growth momentum to strengthen somewhat this year, though a significant jump in performance will wait until the new factory’s full-scale production begins. |
| 2024-02-20 |
Taiwan's health ministry upgrades 3 hospitals to 'medical centers'
|
Taiwan News |
| 2024-02-05 |
Taiwan biomanufacturer aims to be ‘biotech TSMC’
|
Taipei Times |
| 2024-01-23 |
Chang Gung Medical Foundation and Boehringer Ingelheim Taiwan forge strategic partnership for clinical trials
|
Nownews.com |
| 2024-01-19 |
Chang Gung Memorial Hospital to build smart ward in Malaysia
|
TSSDNEWS |
| 2024-01-04 |
Inventec to boost biomedical startup incubation
|
United Daily News |
| 2023-12-21 |
Taiwan has successfully been included in the list of third countries for APIs, indicative of the regulatory system recognized by the European Union
|
TFDA |
| 2023-12-15 |
Taiwan Bio signs pact with US-based TRACT Therapeutics
|
BioSpectrum Asia |
| 2023-11-14 |
HIMSS and Taiwan’s National Health Insurance Administration Form Agreement to Drive Digital Transformation Through International Collaboration
|
HIMSS |
| 2023-11-08 |
China Medical University Hospital achieves triple HIMSS validations
|
HealthcareIT News |
| 2023-11-06 |
ITRI Excels with Eight 2023 R&D 100 Awards, Showcasing Biotechnological Triumph
|
ITRI |
| 2023-10-13 |
Taiwanese firm TaiGen Biopharma to develop and commercialise new drug in Malaysia and Singapore
|
BioSpectrum Asia |
| 2023-10-04 |
Taiwan's medtech startup Flat Medical secures funding for global market expansion
|
BioSpectrum Asia |
| 2023-10-03 |
TFBS Bioscience opens a branch office in Japan to boost viral vector production business
|
Commercial Times |
| 2023-09-21 |
Drugs made in Taiwan snag and expect more market approvals
|
Economic Daily |
| 2023-09-21 |
EirGenix wins a long-term contract for Japanese market
|
Investors.com |
| 2023-09-06 |
Taiwan researchers make breakthrough in treating brain trauma in mice
|
Taiwan News |
| 2023-08-29 |
Novel therapeutics, medical devices do not necessarily tie with NHI coverage: Pan-Chyr Yang, VP of IBMI
|
Commercial Times |
| 2023-08-29 |
DSFederal and Taipei Medical University Forge Partnership to Promote Innovation in Data Science Tech
|
DSFederal |
| 2023-08-25 |
Digital health faces regulatory challenges: Pan-Chyr Yang, VP of IBMI
|
Economic Daily |
| 2023-08-23 |
Chung-Ho Memorial Hospital in Taiwan achieves Stage 6 EMRAM
|
HIMSS |
| 2023-08-22 |
Taiwan-based Formosa Pharma inks $86 M worth ophthalmology deal with American firm Eyenovia
|
BioSpectrum Asia |
| 2023-08-18 |
Bora acquires six US brand product licenses, rights
|
Taipei Times |
| 2023-08-10 |
Qisda ‘confident’ on Q3 sales
|
Taipei Times |
| 2023-08-02 |
AI has prospects in smart healthcare: Barry Lam
|
Economic Daily |
| 2023-08-02 |
Biomedical investor summit to be held in spring 2024 in Taiwan
|
Commercial Times |
| 2023-07-14 |
Taiwan tops ranking in Numbeo’s 'Global Health Care Index by Country'
|
Taiwan News |
| 2023-07-10 |
DKSH unveils largest automated healthcare distribution centre in Taiwan
|
BioSpectrum Asia |
| 2023-07-06 |
Taiwan attracts foreigners to come for reproductive medicine and cancer treatment
|
Liberty Times |
| 2023-06-29 |
Pharmosa announced the collaboration with Liquidia Technologies, Inc. For L606 in North America
|
Pharmosa Biopharm |
| 2023-06-16 |
Singapore's Inex Innovate buys Taiwan genomics business of Yourgene for $4 M
|
BioSpectrum Asia |
| 2023-06-13 |
Taiwan's Academia Sinica signs mRNA agreement with Moderna
|
Taiwan News |
| 2023-06-06 |
NCKU Hospital inks MOU with India's Yashoda Super Speciality Hospitals
|
twpowernews.com |
| 2023-05-26 |
Taiwan's NHIA and UK's NICE Sign Partnership Agreement to Advance Health Technology Assessment, Optimize Resource Allocation
|
NHIA |
| 2023-05-16 |
TVGH unveils first cancer center of its kind in Taiwan
|
Taipei Times |
| 2023-04-18 |
First Asian medical team departs Taiwan for Ukraine
|
Radio Taiwan International |
| 2023-04-14 |
PharmaEssentia snagged $462M, the largest overseas fundraising to Taiwan
|
Investor.com.tw |
| 2023-04-10 |
Taiwan-based Compal Electronics launches innovative therapeutic medical devices
|
BioSpectrum |
| 2023-03-23 |
Hospital touts new world-class center for surgical training
|
Taipei Times |
| 2023-03-20 |
Taiwan has the most particle therapy facilities in terms of population density
|
United Daily |
| 2023-03-09 |
Newsweek lists National Taiwan University Hospital as one of world’s best
|
Taiwan News |
| 2023-02-22 |
China Medical University Hospital ranks global third in 2022 HIMSS Digital Health Indicator
|
HIMSS |
| 2023-02-22 |
Chang Gung Memorial Hospital ranks second globally in 2022 HIMSS Digital Health Indicator
|
HIMSS |
| 2023-02-08 |
Taiwan-based Lotus Pharma launches drug for multiple myeloma in Brazilian market
|
BioSpectrum Asia |
| 2023-01-09 |
New era of smart healthcare centre established in Pulau Pinang
|
New Straits Times |
| 2022-12-12 |
Healthcare+ Expo 2022 stages digital transformation solutions and expands supply-demand footprint across markets
|
Healthcare+ Expo |
| 2022-12-12 |
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
|
Press Release |
| 2022-09-23 |
GSK transforms to improve pharmaceutical operations
|
Taipei Times |
| 2022-09-22 |
Polaris Group Announces Positive Top-Line Results from Phase 2/3 ATOMIC study in Patients with Malignant Pleural Mesothelioma to Assess ADI-PEG 20 with Pemetrexed and Cisplatin
|
Press Release |
| 2022-09-21 |
Ministry eyes US biotech cooperation
|
Taipei Times |
| 2022-09-16 |
Bora expands its CDMO capabilities as it makes landmark acquisition of TWi Pharmaceuticals
|
BioIT World |
| 2022-09-02 |
Taiwanese AI Startup AESOP Raises $3M to Tackle Medical and Billing Errors
|
Press Release |
| 2022-09-01 |
Point Robotics Receives FDA 510(k) Clearance for its POINT™ Kinguide Robotic-Assisted Surgical System to Push the Boundaries of Precision Spinal Surgeries
|
Press Release |
| 2022-08-19 |
Taiwan Excellence Pavilion to showcase 10 leading medical tech innovators at Medical Fair Asia 2022
|
BioSpectrum Asia |
| 2022-08-12 |
TTY, Everest form exclusive partnership to introduce to Taiwan a new drug for treating multiple-drug-resistant infection
|
Press Release |
| 2022-08-11 |
Taiwan and US researchers develop cancer treatment
|
Taipei Times |
| 2022-08-10 |
Formosa Pharmaceuticals And AimMax Therapeutics Announce Successful Top-Line Results From CPN-302 For The Treatment Of Inflammation And Pain After Cataract Surgery
|
Press Release |
| 2022-08-09 |
Taiwan Approves the First Autonomous Neurosurgical Navigation Robot NaoTrac
|
Press Release |
| 2022-08-04 |
Asustek AI platform to help 5G app developers
|
Taipei Times |
| 2022-08-03 |
Taiwan develops world's first commercial personalised cancer cell profile
|
BioSpectrum Asia |
| 2022-08-03 |
The National University of Asunción's Team Shared Phase III Study Data of MVC COVID-19 Vaccine
|
Press Release |
| 2022-08-01 |
SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir®
|
Press Release |
| 2022-07-28 |
JCR Pharmaceuticals invests in Mycenax Biotech, becomes largest shareholder
|
Press Release |
| 2022-07-27 |
ASUS and Tan Tock Seng Hospital co-develop an AI-based tool to improve the accuracy and efficiency of diagnosis in blood diseases
|
Press Release |
| 2022-07-25 |
NTUH develops treatment for rare deadly condition
|
Taipei Times |
| 2022-07-24 |
Chi-Huey Wong awarded Tetrahedron Prize for Creativity in Organic Synthesis
|
The Scripps Research Institute |
| 2022-07-21 |
Belite Bio Announces Start of LBS-008 Phase 3 Stargardt Disease Trial
|
Press Release |
| 2022-07-20 |
Health2Sync and AstraZeneca Taiwan to Kick off Digital Patient Management Programs for Chronic Kidney Diseases
|
Yahoo Finance |
| 2022-07-18 |
TFBS Biosciences expands state-of-the-art facility for viral vector production in Taiwan
|
BioSpectrum Asia |
| 2022-07-18 |
Hsueh Jui-yuan named Taiwan's new health minister, Victor Wang heads CECC
|
Taiwan News |
| 2022-07-15 |
Taiwan reports 1st child with cancer cured by CAR T-cell therapy
|
Taiwan News |
| 2022-07-14 |
Amaran Biotech Introduces the First Fully-Automated Robotic Aseptic Filling Line in Taiwan
|
Press Release |
| 2022-07-13 |
Flat Medical Enters the Vascular Access Medtech Domain with its Newly Acquired MDR Certification and New Medical Advisor
|
Press Release |
| 2022-07-13 |
ADC Therapeutics out-licenses Zynlonta in Taiwan and Singapore
|
The Pharma Letter |
| 2022-07-12 |
Taiwan, China joint venture to develop inhalation-type drugs
|
Taipei Times |
| 2022-07-08 |
Top research institute selects 19 new members
|
Taipei Times |
| 2022-07-08 |
A powerful investment alliance of Aztiq and Innobic acquires Alvogen’s shares in Lotus and Adalvo in a US$475m deal
|
Press Release |
| 2022-07-05 |
Taiwan startups win top prizes at SelectUSA Tech
|
Taiwan Today |
| 2022-07-01 |
IPO market advances significantly
|
Taipei Times |
| 2022-06-28 |
MBI joins TCI Alliance, Benefits of Internationalization Emerge
|
Press Release |
| 2022-06-24 |
Rakuten Medical Taiwan Announces Commencing a Phase 2 Clinical Trial for Head and Neck Squamous Cell Carcinoma Photoimmunotherapy based on the Alluminox™ platform at 5 Leading Medical Centers
|
Press Release |
| 2022-06-24 |
UnicoCell and Tzu-Chi Hospital Ophthalmology Research Center collaborate to Open New Horizons of "Vision"
|
Press Release |
| 2022-06-23 |
3 TTA Startups: FaceHeart, iStaging and ible Technology to Win Global Challenge (Coup de Coeur) at VivaTech 2022
|
Press Release |
| 2022-06-21 |
Belite Bio Receives Approval to Initiate LBS-008 Phase 3 Study at CERA Clinical Trial Site in Australia
|
Press Release |
| 2022-06-20 |
Scientists behind mRNA vaccines win Tang Prize
|
Taipei Times |
| 2022-06-16 |
Taiwan introduces digitised dialysis management system
|
BioSpectrum |
| 2022-06-15 |
Tanvex BioPharma and TaiMed Biologics form a business alliance to offer efficient CDMO services in Biologics
|
Press Release |
| 2022-06-14 |
Endo Executes Agreement With Taiwan Lipsome Company to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain
|
Press Release |
| 2022-06-14 |
Good News from Taiwan Participants in BIO 2022 - Pharmasaga and PrecisemAb Make It to the Start-Up Stadium Finalists Defeating Hundred Teams
|
Yahoo |
| 2022-06-13 |
Taiwan shortens COVID quarantine to 3 days for all arrivals
|
Taiwan News |
| 2022-06-07 |
Taiwan develops rapid test for liver function that only requires a drop of blood
|
Taiwan News |
| 2022-06-01 |
Foresee Pharmaceuticals Announces European Commission Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord Healthcare to Head the E.U. Commercialization
|
Press Release |
| 2022-06-01 |
Chunghwa Telecom and Thonburi Hospital Collaborate to Create the New Chapter of Thailand’s “Smart Hospital” Services
|
Press Release |
| 2022-05-30 |
Taiwan develops high potent immunotherapy for COVID-19 Omicron variant
|
BioSpectrum Asia |
| 2022-05-26 |
IntelliCentrics announces strategic alliance to ensure quality healthcare in Taiwan
|
BioSpectrum Asia |
| 2022-05-25 |
Tungs' Taichung MetroHarbor Hospital in Taiwan latest to achieve Stage 6 EMRAM
|
Healthcare IT News |
| 2022-05-23 |
Qisda forms gene tech partnership
|
Taipei Times |
| 2022-05-23 |
Taiwan FDA authorizes PCR test kit production by Terry Gou-backed company
|
Taiwan News |
| 2022-05-19 |
Taiwan's Medigen COVID vaccine enters WHO data analysis trial stage
|
Taiwan News |
| 2022-05-19 |
Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi®
|
Press Release |
| 2022-05-18 |
BRIM Biotechnology, Inc. and Ora, Inc. announce new partnership to accelerate the development of regenerative peptide therapy, BRM421 for Dry Eye Syndrome
|
Press Release |
| 2022-05-13 |
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery
|
Press Release |
| 2022-05-11 |
Kim Forest eyes approval for non-invasive virus test
|
Taipei Times |
| 2022-05-11 |
Bora Pharmaceuticals acquires Eden Biologics CDMO Assets Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
|
Press Release |
| 2022-05-09 |
Adimmune Supplies over 50% of Government QIV Procurement and Its International Sales Reaches New High
|
Press Release |
| 2022-05-06 |
Taiwanese enterovirus vaccine trials successful
|
Taipei Times |
| 2022-05-06 |
Taiwan's NTHU holds opening ceremony for Post-baccalaureate Programme in Medicine
|
BioSpectrum Asia |
| 2022-05-05 |
Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Disease
|
Press Release |
| 2022-05-03 |
Belite Bio Announces Pricing of $36 Million Initial Public Offering
|
Press Release |
| 2022-05-03 |
Research: Multicolor live-cell imaging identifies asynthetic fission
|
Academia Sinica |
| 2022-04-28 |
TaiMed Receives from Theratechnologies Notification of Returning Commercialization Rights for Trogarzo in European Territory
|
Press Release |
| 2022-04-28 |
iXensor Receives Strategic Investment from Rohto Pharmaceutical with A Separate Technology Licensing Agreement
|
Press Release |
| 2022-04-27 |
ITRI wins two Edison Awards
|
Taiwan News |
| 2022-04-25 |
Taiwan-developed herbal COVID drug works for kids too
|
Taiwan News |
| 2022-04-21 |
Quarantine-free entry into Taiwan possible in July: Health minister
|
Radio Taiwan International |
| 2022-04-18 |
Orient EuroPharma gains rights to Contrave for Taiwan
|
BioSpectrum Asia |
| 2022-04-18 |
Lotus received approval for Alymsys®, a biosimilar to Avastin® (bevacizumab), in Taiwan
|
Press Release |
| 2022-04-15 |
SyneuRx completes enrolment in Phase II trial of Covid-19 oral antiviral
|
Clinical Trials Arena |
| 2022-04-13 |
Biochemist Chi-Huey Wong receives US ‘Pioneer’ award
|
Taipei Times |
| 2022-04-12 |
Fifty-five drug shortages reported in first two months
|
Taipei Times |
| 2022-04-12 |
CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants
|
Press Release |
| 2022-04-11 |
Ontario Together Fund invests $1.9M in Bora Pharmaceutical Services
|
Canadian Manufacturing |
| 2022-04-11 |
OBI PHARMA ANNOUNCES POSTER PRESENTATIONS AT AACR 2022 ANNUAL MEETING FOR OBI-3424 AND GLOBO H SCIENCE
|
Press Release |
| 2022-03-30 |
Asus, Nvidia to jointly build Taiwan’s first supercomputer for medical research
|
Taiwan News |
| 2022-03-25 |
Lotus acquires Cialis® (Tadalafil) in Taiwan from Lilly
|
Press Release |
| 2022-03-23 |
EEG breakthrough - towards precision treatment in migraine
|
Press Release |
| 2022-03-21 |
Taiwan:Health ministry to increase co-payments in national health insurance scheme
|
Asia Insurance Review |
| 2022-03-17 |
TaiGen returns to black due to bonus payment
|
Taipei Times |
| 2022-03-14 |
TaiMed Expands Its Business Model from Biologic Drug Innovator to Contract Development and Manufacturing Organization (CDMO)
|
Press Release |
| 2022-03-10 |
SOPHiA GENETICS HRD Solution Adopted in Asia Pacific
|
Press Release |
| 2022-03-08 |
HCmed, Formosa Laboratories, and Formosa Pharmaceuticals Signed MoU to Form a Global CDMO for Inhalation Treatment Drugs
|
Press Release |
| 2022-03-08 |
Adimmune revenue soars 25-fold on sales abroad
|
Taipei Times |
| 2022-03-08 |
Herbal treatment shows promise in reducing virus deaths, institute says
|
Taipei Times |
| 2022-03-03 |
Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products
|
Press Release |
| 2022-03-03 |
NCCN Clinical Practice Guidelines in Oncology Update Recommends BESREMi® for the Treatment of Polycythemia Vera
|
Press Release |
| 2022-03-02 |
Lotus obtained marketing authorizations for Lenalidomide and Gefitinib in Philippines
|
Press Release |
| 2022-02-24 |
Japan order first from overseas for ITRI test kit
|
Taipei Times |
| 2022-02-24 |
Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement
|
Press Release |
| 2022-02-23 |
OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau
|
Press Release |
| 2022-02-22 |
The data of SNS812, an anti-Pan-COVID19 siRNA, co-developed by Oneness & MBS and supervised by NTU professors, were published today by EMBO Mol. Medicine
|
Press Release |
| 2022-02-21 |
Taiwan's NHRI: Survival length of biliary tract cancer patients dramatically prolonged in study of new chemotherapy regimen
|
Press Release |
| 2022-02-16 |
Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries
|
Press Release |
| 2022-02-16 |
Taiwan unveils potential mRNA vaccine for all COVID variants including Omicron
|
Taiwan News |
| 2022-02-16 |
Medigen vaccine passes Paraguay trial, earns EUA
|
Taipei Times |
| 2022-02-15 |
NaviFUS® Model 101 has been chosen for the 2022 Edison Awards Outpatient Treatment Finalist
|
Announcement |
| 2022-02-14 |
Kaohsiung surgeon first female to head ICS
|
Taipei Times |
| 2022-02-11 |
Taiwan unveils potential mRNA vaccine for all COVID variants including Omicron
|
Taiwan News |
| 2022-02-09 |
OBI Pharma announces COVID-19 vaccine clinical trials to start in 2022
|
CNA News |
| 2022-01-28 |
Senhwa’s Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations.
|
Press Release |
| 2022-01-27 |
Working with a Nobel laureate: NYCU and CiRA Foundation at Kyoto University signed a Japan–Taiwan collaborative research agreement that aims to automate various processes in iPS cell manufacturing
|
Press Release |
| 2022-01-26 |
Taiwanese researchers make world’s first chip virus reader
|
Taipei Times |
| 2022-01-25 |
Lotus Korean subsidiary received approval of Alymsys®, a biosimilar to Avastin® (bevacizumab)
|
Press Release |
| 2022-01-25 |
Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer
|
Taiwan News |
| 2022-01-22 |
Taiwanese workplace digital health platform H2U scores $8M in funding
|
Mobile Health News |
| 2022-01-19 |
Deloitte expects IPOs to double
|
Taipei Times |
| 2022-01-18 |
Advantech Implement First Smart Hospital in Vietnam
|
Press Release |
| 2022-01-17 |
Eisai to launch digital tool CogMate™ in Taiwan and Hong Kong
|
Press Release |
| 2022-01-17 |
NCKU touts diagnostic system in use worldwide
|
Taipei Times |
| 2022-01-13 |
Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000
|
Press Release |
| 2022-01-11 |
Taiwan university unveils heart arrhythmia detection app
|
CNA News |
| 2022-01-10 |
SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants
|
Press Release |
| 2022-01-07 |
Covid-19 Drug Duo Achievements: GoldenBiotech’s New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries
|
Press Release |
| 2022-01-04 |
Tax breaks for biomedical R&D pass legislature
|
Taipei Times |
| 2022-01-04 |
MediBalloon Expands Operations and Establishes Mass Production Capabilities in Taiwan's Medeologix
|
Press Release |
| 2021-12-21 |
Adimmune upbeat about flu vaccine sales in 2022
|
Taipei Times |
| 2021-12-21 |
ASUS Aims to Lead the New Digital Era with Launch of ASUS-NTU Joint Research Center
|
Press Release |
| 2021-12-20 |
Senhwa’s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma
|
Press Release |
| 2021-12-16 |
Taiwan’s Acura NanoMedicine reduces drug resistance in cancer cells
|
BioSpectrum Asia |
| 2021-12-10 |
Bora Pharmaceuticals collaborates with Taishin Holdings to launch CDMO investment and M&A plan
|
Press Release |
| 2021-12-09 |
A New Electroencephalography-Aided Diagnosis System for Rapid and Accurate Screening of Alzheimer’s Disease and Its Prodromal – Mild Cognitive Impairment.
|
Press Release |
| 2021-12-09 |
IBMI President Wong: Existing vaccines ‘might protect against Omicron’
|
Taipei Times |
| 2021-12-07 |
Wanfang Hospital develops stenosis detection device
|
Taipei Times |
| 2021-12-07 |
Kaohsiung Veterans General Hospital: New treatment for chronic migraines shows promise
|
Taipei Times |
| 2021-12-07 |
Taiwan explores mix-and-match booster trial of COVID-19 vaccines
|
BioSpectrum Asia |
| 2021-11-24 |
COVID-19 nasal spray effective in animal studies
|
Taipei Times |
| 2021-11-15 |
U.S. FDA Approves BESREMi® (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera
|
Press Release |
| 2021-11-10 |
NHRI researchers make lupus breakthrough
|
Taipei Times |
| 2021-11-09 |
Acepodia Strengthens Board of Directors and Scientific Advisory Board with Key Appointments
|
Press Release |
| 2021-11-04 |
ITRI and Catcher Technology Jointly Develop the Next-Generation Integrated Electrosurgery System
|
Press Release |
| 2021-11-02 |
Intech testing new asthma inhaler with eye on US market
|
Taipei Times |
| 2021-10-27 |
Medigen’s MVC-COV1901 Selected for WHO COVID-19 Solidarity Trial Vaccines
|
Press Release |
| 2021-10-18 |
US FDA greenlights TTY Biopharm’s leukemia drug
|
Taipei Times |
| 2021-10-15 |
PharmaEssentia receives regulatory approval in South Korea for BESREMi to treat polycythemia vera
|
Press Release |
| 2021-10-07 |
TaiMed aiming to apply for US FDA authorization
|
Taipei Times |
| 2021-10-07 |
Taiwan plans to introduce antiviral drug for treating COVID
|
Taiwan News |
| 2021-10-07 |
CYTENA BPS launches microbioreactor with real-time monitoring
|
BioSpectrum Asia |
| 2021-09-27 |
Taiwan develops world's first ultrasonic vortex thrombolytic device
|
BioSpectrum Asia |
| 2021-09-24 |
Taiwanese scientists discover potential cure for diabetes
|
Taiwan News |
| 2021-09-22 |
TaiMed Biologics: The results pf phase 3 study of Trogarzo IV Push (study-302)
|
Press Release |
| 2021-09-15 |
Taiwan researchers develop breakthrough breast cancer treatment technique
|
Taiwan News |
| 2021-09-13 |
China Medical University Hospital Treats First Patient with Ethos™ Therapy in Taiwan, Expanding Access to Personalized Cancer Care
|
Press Release |
| 2021-09-13 |
Adimmune’s Next-Generation COVID-19 Vaccine Receives Clinical Trial Approval from Indonesia
|
Press Release |
| 2021-09-06 |
The data of the Phase 3 international multicenter clinical trial and the mechanism of action of Fespixon (ON101) have been published by JAMA Network Open
|
Press Release |
| 2021-09-01 |
Taiwan FDA hosting 2021 APEC Medical Devices Regulatory Science Center of Excellence (CoE) Workshop
|
BioSpectrum Asia |
| 2021-08-25 |
Cerba Research, ACT Genomics to Open Joint Lab Facility in Taiwan Cerba, ACT Genomics
|
GenomeWeb |
| 2021-08-24 |
United Biomedical seeks appeal after EUA denied
|
Taipei Times |
| 2021-08-19 |
Biomedicine eyed as chief industry of coming decade
|
Taipei Times |
| 2021-08-17 |
Senhwa's oral drug Silmitasertib for COVID-19 to conduct phase 2 trail in US
|
Press Release |
| 2021-08-16 |
Elderly care startup Jubo Health secures TWD$195M, eyes North America
|
IBMI |
| 2021-08-12 |
Adimmune boosts productivity of vaccine, adding another 80 million doses
|
IBMI |
| 2021-08-11 |
Genovate Biotechnology unveils three growth strategies
|
IBMI |
| 2021-08-11 |
PharmaEngine expects pancreatic cancer drug sales to top $272M
|
IBMI |
| 2021-08-10 |
Taiwan FDA excels at international regulatory harmonization of medical devices
|
BioSpectrum |
| 2021-08-09 |
Taiwan’s biopharmaceutical sector embraces onshore manufacturing
|
IBMI |
| 2021-08-06 |
KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to Manufacture Generic Product for Filing in Japan
|
Press Release |
| 2021-08-06 |
API manufacture Formosa Laboratories profits TWD181M in H1
|
IBMI |
| 2021-08-06 |
TSTBio’s iProtin system receives CE mark
|
IBMI |
| 2021-08-06 |
NaviFUS Receives Approval of Focused Ultrasound Trial to Enhance Radiotherapy
|
Press Release |
| 2021-08-04 |
Lumosa Therapeutics Announces Positive Result from LT3001 Phase 2A Clinical Trial in Acute Ischemic Stroke
|
Press Release |
| 2021-08-04 |
Precision Medicine and Genomics Center opens, targeting cancer and inherited disease
|
IBMI |
| 2021-08-04 |
Lotus confirms ANDA filing and patent challenge for generic RYDAPT®
|
Press Release |
| 2021-08-03 |
QPS Supports COVID-19 Vaccine Development In Taiwan
|
Press Release |
| 2021-08-03 |
Tanvex submits BLA for TX05 (Herceptin Biosimilar) to FDA
|
IBMI |
| 2021-08-02 |
Taiwan’s biotechnology and pharmaceutical sectors join hands in the post-COVID economy
|
IBMI |
| 2021-07-30 |
Formosa Plastics commits $390m to medical supplies
|
IBMI |
| 2021-07-28 |
Taiwan brings hope for breast cancer patients with new epigenetic drug
|
BioSpectrum |
| 2021-07-26 |
Taiwan sees rapid growth of clinical trials in cell therapies
|
IBMI |
| 2021-07-23 |
Qualcomm announces new accelerator program in renewed push against Apple Watch
|
Mint India |
| 2021-07-22 |
EirGenix Achieves the Fourth Milestone of Its Trastuzumab Biosimilar Licensing Agreement
|
Press Release |
| 2021-07-21 |
Taiwan’s photonics industry hits TWD$800bn, biomedical photonics thrives
|
IBMI |
| 2021-07-20 |
DKSH partners with life science innovator Nicoya in Asia
|
Press Release |
| 2021-07-19 |
Device taps brain waves to help paralyzed man communicate
|
Taiwan News |
| 2021-07-19 |
Meridigen announces compassionate use of new stem cell drug
|
IBMI |
| 2021-07-19 |
Lotus Pharmaceutical overseas drug sales spike in Q1 & Q2
|
IBMI |
| 2021-07-19 |
Olive and ASUS Partner, Bringing AI-Assisted Coding to 775+ Hospitals
|
Press Release |
| 2021-07-15 |
Center Ventures disposes of Jacobio shares with returns of $820 million
|
IBMI |
| 2021-07-13 |
GlycoNex announces Phase I trial of osteoporosis biosimilar in Japan
|
Press Release |
| 2021-07-13 |
TCI Bio inks manufacturing deal with US company
|
Taipei Times |
| 2021-07-12 |
Orient Pharma enters licensing agreement with Jingxin Pharmaceutical for cholesterol medication
|
IBMI |
| 2021-07-09 |
Vaccine developer Adimmune sets up manufacturing site in Indonesia
|
IBMI |
| 2021-07-07 |
Medical device developer MiiS’ AI-DR granted Class II clearance by TFDA
|
IBMI |
| 2021-07-06 |
ACT Genomics Completes Acquisition of MC Diagnostics
|
Press Release |
| 2021-07-06 |
Bora Group's subsidiary Yuta Health becomes Bora Health
|
Press Release |
| 2021-07-06 |
TLC Announces Details of Stock Swap Transactions
|
Press Release |
| 2021-07-05 |
A new drug for diabetic foot ulcer launched in Taiwan, aims at global markets by 2030
|
IBMI |
| 2021-07-02 |
IC company Sunplus ventures into endoscope cameras
|
IBMI |
| 2021-07-02 |
TLC and Endo Enter Commercialization Agreement
|
Press Release |
| 2021-06-30 |
EpiFaith® Expanding to U.S. Military Hospitals After a Newly Awarded Agreement by the Defense Logistics Agency
|
Press Release |
| 2021-06-30 |
Acer makes headway in SEA markets with VeriSee DR (Diabetic Retinopathy) medical software
|
IBMI |
| 2021-06-29 |
Inmagene and TWIB Partner to Develop AC-1101 for Multiple Dermatological Immunological Diseases
|
Press Release |
| 2021-06-24 |
Lumosa and DONGWHA Enter Exclusive Distributorship Agreement for LT1001 in Korea
|
Press Release |
| 2021-06-24 |
Drug maker SyneuRx raises TWD400m for CNS and COVID drugs
|
IBMI |
| 2021-06-24 |
Some COVID-19 shots may be linked to rare heart problems in teens, CDC says
|
CBS News |
| 2021-06-24 |
Applied BioCode expands in diagnostic tests and licensing
|
IBMI |
| 2021-06-24 |
AmCham launches initiative to facilitate Taiwan-U.S. trade agreement
|
CNA News |
| 2021-06-23 |
Taiwanese mobile health firm iXensor gets CE mark for its COVID-19 digital point-of-care test
|
Mobile Health News |
| 2021-06-22 |
Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus
|
PR Newswire |
| 2021-06-22 |
Taiwanese firm UBI-Asia inks COVID-19 vaccine deal with Paraguay
|
BioSpectrum Asia |
| 2021-06-22 |
Covid: Asthma drug 'speeds up recovery at home'
|
BBC |
| 2021-06-22 |
Taiwan experts do not recommend mixing AstraZeneca and Moderna
|
Taiwan News |
| 2021-06-21 |
Could a Nasal Spray of Designer Antibodies Help to Beat COVID-19?
|
NIH Director's Blog |
| 2021-06-21 |
Amendments to the Act for the Recruitment and Employment of Foreign Professionals Approved
|
National Development Council |
| 2021-06-21 |
WHO says delta is becoming the dominant Covid variant globally
|
CNBC |
| 2021-06-21 |
Jacobio Earns $20M AbbVie Milestone
|
Contract Pharma |
| 2021-06-21 |
Taiwan/ Medigen touts enterovirus vaccine trials
|
Taipei Times |
| 2021-06-18 |
Bristol-Myers, Eisai in up to $3.1 bln deal to develop cancer drug candidate
|
REUTERS |
| 2021-06-18 |
US to spend $3.2B on treatments for COVID-19, other viruses
|
ABC News |
| 2021-06-18 |
CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy
|
REUTERS |
| 2021-06-17 |
Amazon selling its own COVID-19 test kits for $39.99
|
FOX Business |
| 2021-06-17 |
CureVac may pick Korea as Asian base for COVID vaccine production
|
The Korea Economic Daily |
| 2021-06-16 |
GSK pays iTeos $625M upfront to join Merck, Roche and the rest in TIGIT immuno-oncology race
|
Fierce Biotech |
| 2021-06-16 |
Vietnam likely to license Nanocovax for emergency use
|
Hanoi Times |
| 2021-06-16 |
AstraZeneca hits snag in COVID-19 drug development
|
Channel News Asia |
| 2021-06-15 |
Celltrion says trial shows antibody COVID-19 treatment to be safe and effective
|
REUTERS |
| 2021-06-15 |
Novavax COVID-19 vaccine more than 90% effective in U.S. trial
|
REUTERS |
| 2021-06-10 |
Taiwanese COVID vaccine developer to present clinical trial results
|
Taiwan News |
| 2021-06-03 |
The preliminary result of EMA inspection of Trogarzo production in SBL
|
TaiMed Biologics |
| 2021-05-31 |
Acepodia Presents Data on its Allogeneic Natural Killer-Like Gamma-Delta T Cell Therapy, ACE1831, in Development for Hematological Cancers
|
Acepodia USA |
| 2021-05-28 |
Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer
|
Foresee |
| 2021-05-26 |
TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India
|
TLC |
| 2021-05-19 |
Taiwan-developed Chinese medicine for COVID-19 nearing approval
|
CNA news |
| 2021-05-14 |
CMIC and DCB Signed MOU for Cooperation Partnership
|
DCB |
| 2020-06-01 |
Taiwan Food and Drug Administration approves Remdesivir to treat patients with severe COVID-19 disease
|
TFDA |
